

(19)



(11)

EP 1 497 440 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
20.08.2008 Bulletin 2008/34

(21) Application number: **03753569.7**

(22) Date of filing: **24.04.2003**

(51) Int Cl.:
C12N 15/861 (2006.01)

(86) International application number:
PCT/EP2003/050126

(87) International publication number:
WO 2004/001032 (31.12.2003 Gazette 2004/01)

(54) STABLE ADENOVIRAL VECTORS AND METHODS FOR PROPAGATION THEREOF

STABILE ADENOVIRALE VEKTOREN UND METHODEN FÜR DEREN VERMEHRUNG

VECTEURS ADENOVIRAUX STABLES ET TECHNIQUES DE PROPAGATION DE CES VECTEURS

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**
Designated Extension States:
AL LT LV MK

(30) Priority: **25.04.2002 PCT/NL02/00281**
15.10.2002 PCT/NL02/00656
25.11.2002 EP 02102631

(43) Date of publication of application:
19.01.2005 Bulletin 2005/03

(73) Proprietor: **Crucell Holland B.V.**
2333 CN Leiden (NL)

(72) Inventors:
• **VOGELS, Ronald**
NL-3461 HW Linschoten (NL)
• **HAVENGA, Menzo, Jans, Emco**
NL-2401 KG Alphen aan den Rijn (NL)
• **ZUIJDGEEST, David, Adrianus, Theodorus**
NL-2565 VH Den Haag (NL)

(74) Representative: **Verhage, Richard Abraham et al**
Crucell Holland B.V.
P.O. Box 2048
2301 CA Leiden (NL)

(56) References cited:
EP-A- 1 149 916 WO-A-00/70071
WO-A-02/22800 WO-A-02/40665

- **BABISS L E ET AL: "PROMOTER OF THE ADENOVIRUS POLYPEPTIDE IX GENE: SIMILARITY TO E1B AND INACTIVATION BY SUBSTITUTION OF THE SIMIAN VIRUS 40 TATA ELEMENT" JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 65, no. 2, February 1991 (1991-02), pages 598-605, XP002943494 ISSN: 0022-538X**
- **CARAVOKYRI C ET AL: "CONSTITUTIVE EPISOMAL EXPRESSION OF POLYPEPTIDE IX (PIX) IN A 293-BASED CELL LINE COMPLEMENTS THE DEFICIENCY OF PIX MUTANT ADENOVIRUS TYPE 5" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 11, 1 November 1995 (1995-11-01), pages 6627-6633, XP000561195 ISSN: 0022-538X**
- **GHOSH-COUDHURY G ET AL: "PROTEIN IX, A MINOR COMPONENT OF THE HUMAN ADENOVIRUS CAPSID, IS ESSENTIAL FOR THE PACKAGING OF FULL LENGTH GENOMES" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 6, no. 6, 1987, pages 1733-1739, XP001041974 ISSN: 0261-4189**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**FIELD OF THE INVENTION**

[0001] The invention relates to the field of medicine, more in particular the invention relates to recombinant adenoviral vectors and the use thereof.

BACKGROUND OF THE INVENTION

[0002] Human adenoviruses are non-enveloped icosahedral particles of 60-90 nM size. To date 51 serotypes have been identified that are subdivided into 6 subgroups based on hemagglutination properties and sequence homology (Francki et al., 1991). The genome has a length of 34 to 36 kb and is flanked on both sites by inverted terminal repeat sequences (ITR). The virus infectious cycle is divided into an early and a late phase. In the early phase (6-8 hours after infection) the virus is uncoated and the genome transported to the nucleus after which the early gene regions E1-E4 become transcriptionally active.

[0003] The early region-1 (E1) contains two transcription regions named E1A and E1B. The E1A region encodes two major proteins that are involved in modification of the host cell cycle and activation of the other viral transcription regions (reviewed by Russell, 2000). The E1B region encodes two major proteins, 19K and 55K, that prevent, via different routes, the induction of apoptosis resulting from the activity of the E1A proteins (Rao et al., 1992; Yew and Berk, 1992; reviewed in Shenk, 1996). In addition, the E1B-55K protein is required in the late phase for selective viral mRNA transport and inhibition of host protein expression (Pilder et al., 1986).

[0004] An intermediate protein, pIX, is part of the capsid and is known to stabilize the hexon-hexon interactions (Furcinitti et al., 1989). In addition, pIX has been described to transactivate TATA containing promoters like the E1A promoter and MLP (Lutz et al., 1997).

[0005] Due to the extensive knowledge of the viral biology and the high efficiency of nuclear delivery after entry into cells, adenoviruses have become popular tools for gene delivery into human cells. In addition, adenoviral vectors are stable and can be produced relatively easy at large scale. In most cases vectors are deleted for at least the E1 region, which renders them replication deficient. Production of E1-deleted vectors based on subgroup C serotypes Ad5 or Ad2 is achieved in E1 complementing cell lines such as 293 (Graham et al., 1970), 911 (Fallaux et al., 1996) and PER.C6TM (Fallaux et al., 1998). As disclosed in US patent 5,994,128 vectors and cell line need to be carefully matched to avoid generation of replication competent adenoviruses through homologous recombination between adenovirus sequences in the cell line and the vector. Thus, PER.C6TM cells and matched adenoviral vectors provide a preferred system for the production of group C adenoviral vectors (Fallaux et al., 1998). The deletion of E1 sequences provides space for the introduction of foreign genes in the viral vector. Since the maximum size of Ad5 genomes that can be incorporated into virions is limited to about 105% of the wt length, E1-deleted viruses can accommodate approximately 4.8 kb of foreign DNA (Bett et al., 1993).

[0006] The maximum packaging capacity in virions that lack pIX is reduced to approximately 95% of the normal genome length (Ghosh-Choudhury et al., 1987). This is most likely caused by the reduced stability of pIX- ("pIX-minus") virions. The deficiency in pIX-minus mutant Ad5 can be complemented by episomal expression of pIX in a packaging cell line used for producing viruses (Caravokyri et al., 1995).

[0007] Although the serotypes Ad5 and Ad2 are most commonly used as gene transfer vectors, other serotypes may have preferred characteristics that make them more useful as a therapeutic or prophylactic tool. Subgroup B viruses Ad35 and Ad11 for example are much less prone to neutralisation by human sera than Ad5 and Ad2 viruses (disclosed in WO 00/70071). Neutralisation of adenoviral transfer vectors diminishes transduction efficiency in vivo. Furthermore, the infection efficiency of antigen presenting cells, like dendritic cells, by recombinant viruses carrying the fiber of Ad35 was found to be greatly enhanced in vitro compared to Ad5 viruses (WO 00/70071, WO 02/24730). Thus, Ad35-based vectors combine highly improved infection efficiency with low neutralisation in human sera, making such vectors suitable for vaccination purposes.

[0008] Generation and propagation of fully E1-deleted Ad35-based vectors is possible (see e.g., International Patent Application PCT/EP03/50125 by Crucell Holland B.V., filed 24 April 2003, published as WO 03/104467 on 18 December 2003). However, careful analysis of a variety of recombinant Ad35-based vectors has revealed that such vectors are less stable, i.e. can contain less foreign DNA compared to the Ad5-based vectors. In the current patent application means and methods are presented to overcome this problem.

DESCRIPTION OF THE FIGURES

[0009] Fig. 1. Map of pWE.Ad35.pIX-rITRΔE3

[0010] Fig. 2. Gel analysis of PCR fragments generated on Ad35 E1-deleted viruses with and without the E3 region.

PI = plasmid control; M = marker: 1 kb plus ladder (Invitrogen); mQ = H₂O. Indicated genome lengths are in kb.

[0011] Fig. 3A. Sequence alignments of the proximal pIX upstream sequence regions of various adenoviruses generated with MEGAlign software (DNASTar) using Clustal method. Source of sequences are indicated in the text. The Sp1 site and TATA-box in Ad5 and Ad2 (as in Babiss and Vales, 1991) are boxed.

Fig. 3B. Schematic comparison of putative Sp1 - and TATA-boxes in proximal pIX regions from sequences given in 3A.

[0012] Fig. 4. Map of pAdApt535.Luc

[0013] Fig. 5. Map of pAdApt535

[0014] Fig. 6A. Gel analysis of PCR fragments generated on DNA isolated from Ad35.AdApt.Luc and Ad35.AdApt535.Luc viruses or generated on plasmid controls. M = Marker (1 kb plus ladder, Invitrogen). Each virus preparation or plasmid control is analysed with two specific PCR amplifications.

Fig. 6B. Gel analysis of PCR fragments generated on Ad35.AdApt.LacZΔE3 (35LacZ) and Ad35.AdApt535.LacZΔE3 (535LacZ) viruses or generated on plasmid controls.

[0015] Fig. 7. Map of pBr.Ad35.ΔSM.AdApt.LacZ

[0016] Fig. 8. Schematic representation of the putative promoters in the E1B promoter and 55K coding region.

[0017] Fig. 9. Schematic representation of the restriction sites in the 55K region that can be used to generate distinct fragments for identification of a putative promoter. Numbering of the sites is according to their position in wild type Ad35.

[0018] Fig. 10. Sequence alignment of the region between the polyA signals of the E1A region and of the E1B/pIX region in three different subgroup B serotypes.

[0019] Fig. 11. Schematic representation of pBr.Ad35.PRn.

[0020] Fig. 12. Schematic representation of pBr.Ad35.PRnAE3.

[0021] Fig. 13. Schematic representation of the system for producing recombinant adenoviral particles in cells such as PER.C6 through a double homologous recombination event.

[0022] Fig. 14. Alignment of Ad35 and Ad11 pIX-cDNA sequences with wt Ad35 sequence. The sequences obtained from cloned cDNA fragments as described in example 18 were aligned using SeqMan software from DNASTAR. Ad35 cDNA sequences were derived from RNAs isolated from wtAd35- or Ad35E1B+Luc-infected cultures (sequence of one out of seven clones is shown), the Ad11 cDNA sequence from RNA isolated from an wtAd11-infected culture. The sequence numbering is arbitrary. For the Ad35 wt sequence, nucleotide 3339 to nucleotide 3628 of the wt Ad35 sequence is shown. The intron sequence (seen as a gap in the cDNA sequences) is flanked by splice donor (SD) and splice acceptor (SA) sites closely matching the known consensus sequences. The SeqMan software has placed the first two nucleotides from the SD (AG) in the cDNA sequences at the 3' end of the intron sequence instead of the 5' end.

[0023] Fig. 15. Location of the pIX cap site in Ad35 viruses.

Schematic representation of the genome organization around the E1B gene and pIX sequences in Ad35; depicts the transcription start site and intron boundaries in the pIX mRNA. Nucleotide sequences are according to wt Ad35 DNA (WO 00/70071). M= MunI, B=Bsu36I, SD= splice donor and SA= splice acceptor. The transcription start site (nucl. 3339, cap site), the stop codon of 55K (TAA) and the start codon of pIX (nucl. 3484, ATG) are in bold. A dotted line indicates that sequences are not shown.

[0024] Fig. 16. Transgene PCR results from Ad35 viruses with a 166 bp 3' E1B sequence retained.

A representative example of the results of the transgene PCR assays on Ad35.AdAptBsuLuc5Orf6 (lane 1-9) and Ad35.AdAptBsuLuc viruses (lanes 10-14). M= 1kb+ marker (Invitrogen), P= pAdAptBsuLuc control plasmid.

SUMMARY OF THE INVENTION

[0025] It is shown in the present invention that a recombinant group B adenovirus that has a deletion in the E1 region up to the stopcodon of E1B 55K, can accommodate less exogenous sequences than a similar Ad5 recombinant adenovirus. It appears that this is due to a relative underexpression of the pIX gene in said group B virus in a given packaging cell, when the pIX coding region is preceded by sequences between the E1B 55K stopcodon and the pIX startcodon only. It is shown that such viruses can be rendered more stable and/or capable of accommodating more exogenous sequences when either the pIX promoter is at least partly restored by including sequences from the E1B 55K coding region into such a virus, or by using a heterologous promoter to regulate pIX, such that a normal, or even a relative overexpression, of pIX is achieved in a given packaging cell.

The present invention provides recombinant subgroup B adenoviruses, nucleic acid that upon introduction into a packaging cell constitutes the genome of such adenoviruses, methods for increasing the stability and/or packaging capacity of such adenoviruses, and packaging cells comprising such adenoviruses, according to the claims.

DETAILED DESCRIPTION OF THE INVENTION

[0026] It is one aspect of the invention to provide a method for increasing the stability and/or the packaging capacity

of a recombinant adenovirus having at least a deletion in the E1-region, comprising the step of expressing the elements necessary for production and assembly of said recombinant adenovirus into virus particles in a packaging cell in the presence of an elevated level of pIX gene product in said packaging cell, relative to the level of pIX gene product obtained when the pIX coding sequence is behind its endogenous proximal upstream sequence without E1B 55K sequences. In certain embodiments of the method of the invention, said elevated level of pIX gene product is brought about by retaining or reintroducing part of the E1B 55K sequences in said adenovirus. In other embodiments, said elevated level of pIX gene product is brought about by the expression of the pIX coding sequences under control of a heterologous promoter. The invention further provides a recombinant adenovirus comprising a functional pIX coding sequence under control of an expression sequence, said expression sequence comprising part of an E1B 55K sequence capable of increasing expression of the pIX coding sequence in a given packaging cell, relative to the expression of said pIX coding sequence behind its endogenous proximal pIX upstream sequence without the part of said E1B 55K sequence, with the proviso that said part of an E1B 55K sequence does not code for a functional E1B 55K gene product. It is shown in the present invention that pIX promoter sequences can be present in said E1B 55K sequences, and including these sequences in said expression sequence can therefore increase pIX expression. The presence of said E1B 55K sequences increases the stability and/or packaging capacity of said recombinant adenovirus, compared to the situation where said pIX coding sequence is behind its endogenous proximal pIX upstream sequence without the part of said E1B 55K sequence.

An adenovirus of serotype 35 with a deletion in the E1 region but with an intact E1B 55K coding region (pBr.Ad35.left-ITR. Δ E1A Δ 21K) has been disclosed in WO 02/40665. However, a functional 55K gene product, such as present in the disclosed vector, inhibits apoptosis, and hence it is desired to obtain recombinant adenovirus that lacks functional E1B 55K expression, e.g. by mutating the E1B 55K gene or preferably by including only part of the E1B 55K sequences, more preferably including only sequences downstream of the E1B 55K startcodon. It will be clear to the skilled person that it is beneficial to minimize the amount of E1B 55K sequences in said vector in order to generate viruses with a maximal E1 deletion to accommodate more foreign nucleic acid, while at the same time retaining sufficient E1B 55K sequences to have the benefit according to the present invention of an increased stability and/or increased packaging capacity within the recombinant adenovirus. With the teachings of the present invention, the person skilled in the art will be able to find the minimally required sequences within E1B 55K that lead to the stabilization and/or increase in packaging capacity of the recombinant adenovirus, e.g. by using standard molecular cloning techniques to obtain serial deletions within the E1B 55K region starting from the disclosed vector (pBr.Ad35.leftITR. Δ E1A Δ 21K) and determining the stability or packaging capacity. It is therefore an object of the present invention to provide a recombinant adenoviral vector according to the invention wherein said sequences encoding the E1B 55K gene product comprise about 0.7 kb or less of the adenovirus sequences that are directly upstream of the pIX open reading frame. In other embodiments, said sequences comprise not more than about 680, 600, 550, 500, 450, 400, 350, 300, 250, 200, 150, or 100 nt of the adenovirus sequences that are directly upstream of the pIX open reading frame. In one embodiment, such a recombinant adenoviral vector retains 166 bp of the 3' end of the 55K coding sequence. As will be clear to the person skilled in the art, the invention is not limited to the presence of a sequence that is found in a contiguous stretch directly upstream of the pIX coding sequences in the natural adenovirus. Instead, it will also be possible according to the invention to have sequences that are more upstream, i.e. from the E1B 55K region (e.g. a restriction or PCR fragment, see e.g. example 10 and fig. 9), fused to the more proximal pIX regulatory sequences, thereby creating an artificial combination of regulatory sequences, as long as this results in increased pIX expression in a given packaging cell, when compared to the absence of any E1B 55K sequences. Said adenovirus is a subgroup B adenovirus, preferably an Ad35 or Ad11 adenovirus. Adenoviruses of serotypes 35 or 11 have been shown to be particularly useful for administration to humans, as there are much less individuals that have neutralizing antibodies to these serotypes than to the serotype 5 hitherto most used (WO 00/70071). It is another aspect of the invention to provide the nucleic acid that can act as the genome of the adenovirus according to the present invention.

[0027] As an alternative or in addition to the presence of E1B 55K sequences that increase the expression of the pIX gene, it is also possible to overexpress pIX itself by mutating the pIX gene, preferably its promoter, to increase the stability and/or packaging capacity of a recombinant adenovirus. A modified pIX gene is a pIX gene having a different promoter and/or transcription terminator, and/or mutated coding sequences, e.g. obtained by codon optimisation, introduction of introns that stabilize RNA, and the like. A pIX gene according to the invention comprises genetic information encoding pIX, and includes nucleic acid such as the pIX gene such as found in natural adenoviruses, cDNA and information encoding mutant pIX in the form of allelic variants or nucleic acid encoding mutant pIX that has at least part of the function of pIX which may differ from normal pIX in quantitative or qualitative aspects, derived from pIX by mutation, deletion, addition, or translocation of amino acids, or combinations thereof.

[0028] If a recombinant adenovirus has a deletion of at least the E1B 55K region up to and including the stopcodon of the E1B 55K gene product, the pIX open reading frame will be preceded by sequences between the E1B 55K stopcodon and the startcodon of pIX. These sequences are herein referred to as the "endogenous proximal pIX upstream sequences" (e.g. the Ad35 pIX upstream sequence in Ad35 based recombinant adenoviral vectors, the Ad11 pIX upstream sequence in Ad11 based recombinant adenoviral vectors, etc. are referred to as endogenous in this respect; the definition includes

allelic variants that may be found in nature and which are not created in the laboratory; see Fig. 3A for some proximal pIX upstream sequences).

A "heterologous promoter" as used herein is defined as any sequence different from the sequences naturally found upstream of the pIX gene, including the sequences of the E1B 55K region and the endogenous proximal pIX upstream sequences, and being capable of acting as a promoter and thereby regulating transcription of pIX coding sequences. In one aspect, a heterologous promoter may be a sequence at least in part derived from a proximal pIX upstream sequence (i.e. the sequences between the E1B 55K stopcodon and the startcodon of pIX) from an adenovirus from another serotype than the serotype from which the recombinant adenoviral vector is derived (e.g. an Ad5 pIX upstream sequence in an Ad35 recombinant adenoviral vector). This is referred to herein as a "non-endogenous proximal pIX promoter". In one embodiment of the invention, Ad35 derived pIX expression is driven by an Ad5 non-endogenous proximal pIX promoter. Any non-endogenous proximal pIX promoter derived from the proximal pIX upstream sequence from a serotype that confers higher levels of pIX expression than the endogenous pIX proximal sequences of the adenoviral vector may be used. Identification of such non-endogenous proximal pIX promoters may be based upon sequence information, such as will be evident to the person skilled in the art from Example 4. In particular embodiments, the adenoviral vector according to the invention is derived from an adenovirus subgroup E serotype, or preferably of subgroup B serotype. In specific embodiments, said adenoviral vector is derived from an adenovirus serotype 35 (Ad35), Ad11, Ad7, or Ad4. In alternative embodiments, said non-endogenous proximal pIX promoter is at least in part derived from a proximal pIX upstream sequence of an adenovirus classified in subgroup C, A, D, or F. In particular embodiments said non-endogenous proximal pIX promoter is at least in part derived from a proximal pIX upstream sequence of an adenovirus serotype 12 (Ad12), Ad9, or Ad40, or more preferably of Ad5 or Ad2. Alternatively, sequences acting as non-endogenous proximal pIX promoter can be found empirically, by general molecular biology methods known to persons skilled in the art, such as by transcription assays wherein promoters can be routinely tested for strength. It will be clear to the skilled person that elements from a promoter may be swapped without exchanging the whole promoter, e.g. adding, deleting, or mutating known transcription factor binding sequences to a promoter may influence its strength. Mutating at least part of promoter sequences can be done by changing the sequence by mutations, such as by additions, deletions, or exchanging of one or more nucleotides, including stretches of nucleotides with a known function. Substituting promoter sequences is done by replacing part or all of these sequences by a different promoter. Such replacing can be done according to standard molecular biology techniques all well known to the person skilled in the art. Any promoter can be constructed in operable association with the pIX gene of choice, and tested for its effect.

[0029] In another aspect, a heterologous promoter is unrelated to adenoviral non-endogenous proximal pIX promoters. Therefore, heterologous promoters may also be viral promoters, including but not limited to promoters derived from Cytomegalovirus (CMV, e.g. the human CMV immediate early gene promoter, further herein referred to as the CMV promoter), Rous Sarcoma Virus (RSV, e.g. the RSV long terminal repeat promoter, further referred to herein as the RSV promoter), TK, HBV, SV40 and the like. In one embodiment, an adenoviral E1B promoter is used as a heterologous promoter. Cellular promoters can also be used as heterologous promoters, and these include but are not limited promoters from PGK, metallothionein, EF1- α , β -actin, and the like. Synthetic or hybrid promoters, comprising elements from more than one promoter, can also be used for the invention, and are all included within the scope of the term heterologous promoter. Promoters used may be constitutive or inducible. In the context of an inducible promoter a promoter is considered suitable for the invention if it gives overexpression in its induced state. Any promoter sequence resulting in overexpression of pIX according to the invention can be used as a heterologous promoter according to the invention. Besides promoter strength, one other aspect determining the usefulness of a particular promoter when present in the recombinant adenoviral vector itself is its size, as longer promoters will take up space available for the transgene. A person skilled in the art will be able to use the present invention to allow for optimising the vector experimentally with respect to promoter length and strength with regard to insert size, to find the most stable recombinant vector.

It will be clear that a heterologous promoter may still contain or include part or all of the endogenous proximal pIX upstream sequences, or alternatively wholly replace these sequences, as long as the heterologous promoter according to the invention can cause the overexpression of genetic information encoding pIX in a packaging cell of choice. It will also be clear to the person skilled in the art that when an endogenous non-pIX adenoviral promoter (e.g. the E1A, E2A, etc. promoter) or a heterologous promoter that for instance regulates the transgene is used for driving expression of pIX by use of an internal ribosome entry site (IRES) between the non-pIX adenovirus gene or the transgene and the pIX coding sequence (in either order), this is to be regarded as being within the scope of the term "heterologous promoter" according to the invention.

[0030] An elevated or increased level of pIX gene product in the invention is the result of overexpression of the pIX gene in a packaging cell of choice. Overexpression of the pIX gene as used herein is defined as an expression level of pIX, either on RNA or protein level or both, that is higher than the pIX expression level obtained when the coding region of pIX is behind the "endogenous proximal pIX upstream sequences" as defined herein, in a given packaging cell. "Overexpression" is meaningful in the context of the present invention for a particular heterologous promoter-pIX combination of an adenovirus in combination with a particular packaging cell of choice. Methods to determine expression

levels are generally well known to persons skilled in the art, and include but are not limited to RT-PCR, Northern blotting, Western blotting, and the like. For the present invention, overexpression would be measured by determining the expression levels in a recombinant adenovirus with a given insert (e.g. luciferase) in a given packaging cell of choice, wherein the genetic information encoding pIX is behind the endogenous proximal pIX upstream sequences without E1B 55K sequences, and comparing these expression levels to those in a recombinant adenovirus that is the same except that the pIX coding region is regulated by a heterologous promoter or by sequences from the endogenous E1B 55K gene (its 'natural' promoter that has been at least partly reconstituted). Overexpression of pIX is indicated by a ratio higher than 1 for the expression level obtained by the heterologous or 'natural' promoter over that obtained by the endogenous proximal pIX upstream sequences without E1B 55K sequences. The choice of a packaging cell is determined by factors such as the serotype of the elements of the recombinant adenovirus that interact with the complementing adenoviral functions in the packaging cell, product purity (such as absence of replication competent adenovirus from the generated batch), ease of use, growth characteristics, and the like. Examples of packaging cells are known to the person skilled in the art, and include 293 cells, 911 cells, and PER.C6™ cells as used herein, as well as derivatives thereof adapted for complementation of adenoviral vectors of specific serotypes, such as PER55K.

[0031] It will be clear that in all embodiments of the invention, the pIX coding sequences and regulatory sequences driving the expression of pIX can be positioned on their natural location within the adenovirus genome, as well as in different parts of the adenovirus genome, e.g. in the region that originally contained the E3 sequences.

[0032] Recombinant adenoviruses with increased stability are capable of incorporating larger genomes into virus particles (virions). Hence, increasing the stability of recombinant adenoviruses as used herein will allow the recombinant adenoviruses according to the invention to include more foreign genetic information, comprising a gene of interest. Furthermore, recombinant adenoviruses with increased stability according to the invention may be capable of being propagated for more passages without signs of instability. Stability can be measured by several methods known to people skilled in the art, including but not limited to PCR on recombinant virus to demonstrate the presence of desired recombinant adenoviral vectors. Instability will lead to by-products, which can also be visualized by PCR methods, and the like. Restriction analysis of viral DNA, determination of the relative infectivity of virus particles, determination of the thermostability of adenoviral particles also can be used to determine the stability of recombinant adenoviral vectors (Caravokyri and Leppard, 1995). Methods to determine stability/instability of recombinant adenoviral vectors are also given in Example 3 of this application. A recombinant adenovirus, also called recombinant adenoviral vector, or adenoviral vector, as used herein is derived from an adenovirus, lacks at least part of the E 1 region (comprising the E1A and E1B genes) of an adenovirus and can comprise foreign genetic information of which delivery and/or expression by said vector is desired. Exogenous (or foreign) genetic information as used herein, is any genetic information that is not naturally present in an adenovirus, and is also referred to as transgene. This includes but is not limited to genes of interest, expression cassettes, and the like. Such exogenous genetic information can fill the space in the genome that has become available by the deletion of adenoviral E1 sequences. Recombinant adenoviral vectors are useful for various purposes, such as in gene therapy applications, vaccine preparation, and the like. In addition to the E1 region deletion, also E3 sequences can be deleted from such adenoviral vectors, to increase the capacity for foreign genetic information in certain preferred embodiments. Other deletions and various combinations of part or complete deletions of E2, E3, and E4 regions combined with the E1 deletion can be used, if necessary in combination with a packaging cell comprising the genetic information lacking in the adenoviral vector, when necessary for replication of the adenoviral vector. All recombinant adenoviruses having a deletion in the E1-region combined with optionally any other deletions in the adenovirus genome, are meant to be included within the scope of the present invention. The adenoviruses of the present invention can be used in different settings such as gene therapy or prophylactic and/or therapeutic vaccination, including tumour vaccination and anti-viral vaccination. For this, the adenoviral vector functions as a gene delivery vehicle, wherein a non-native gene is incorporated into the adenoviral genome. The adenoviral particle can subsequently be targeted specifically to target cells of interest; the adenovirus binds to that specific cell either through capsid-receptor binding or through other means, and delivers the transgene. Targeting of adenoviruses can be performed in many different ways. Persons skilled in the art of adenoviral vector targeting will be aware of all the different possibilities that are applied to deliver the adenoviral vectors to the cells of interest. Such possibilities include but are not limited to capsid alterations (fiber, hexon and/or penton modifications, such as deletions, swaps between fibers of different serotypes, and additions of peptides and/or other binding moieties), wherein chimeric fibers are produced that recognize a receptor present on the cell of interest, or wherein the binding of the penton-base is utilized. Other possibilities are linking targeting moieties to the capsid proteins, wherein for instance binding peptides, known and strong binding proteins, or antibodies or parts thereof are linked to the capsid proteins to achieve specific targeting. Such vectors can all be produced using the methods and means provided by the present invention. Therefore, the present invention also discloses recombinant adenovirus vectors according to the invention, further comprising a sequence encoding a non-adenoviral protein. Such sequences can be present on different locations within the adenoviral backbone, but preferably they are located in the E1 region, which is lacking in the recombinant adenoviral vectors of the invention. The E1 region is complemented by the complementation elements present in the complementing cells. The direction of the promoter, transgene and other regulatory

sequences can be directed towards the left-, as well as to the right inverted terminal repeat.

The production of viral vectors based on adenovirus and/or on other viruses such as the Adeno-Associated Virus (AAV), wherein the combination, such as an Ad-AAV chimeric virus, can integrate into the host cell genome is also contemplated. Several methods are known in the art for generating integrating adenoviruses. Generally, the invention is also useful for the production of adenovirus forms that (specifically, or non-specifically) can integrate.

[0033] As mentioned, several non-adenoviral transgenes can be cloned into the recombinant adenoviral vectors of the present invention. These do not only include regulatory nucleic acid sequences such as enhancers, promoters (e.g. strong non-adenoviral promoters such as the cytomegalovirus promoter, the SV40 promoter and the RSV promoter) and polyadenylation signals, but also heterologous genes for therapeutic purposes. Therefore, in one aspect of the invention, recombinant adenovirus vectors according to the invention are provided, wherein said non-adenoviral protein is selected from the group consisting of: a cell-death inducing polypeptide, a tumor specific antigen, a viral protein, a hormone and a cytokine. Non-limiting examples of non-adenoviral factors, proteins, polypeptides and peptides are transcription factors, intracellular signalling proteins, phosphatases, kinases, apoptosis inhibiting factors, receptor antagonists, soluble forms of membrane-bound receptors, RNA inhibitors, anti-sense RNA's, decoy factors, ribozymes, and more specifically, thymidine kinase, erythropoietin, novel-erythropoiesis stimulating protein (NESP), IL3, ceNOS, gamma-interferon and gp100. Non-adenoviral viral proteins can be cloned into the recombinant adenoviral vectors provided by the methods and means of the present invention for vaccination purposes. Such viral proteins include, but are not limited to, gag, pol, env, nef, etc. for HIV vaccines, E6 and E7 proteins for Human Papilloma Virus vaccines, circumsporozoite proteins from Plasmodium protozoa for malaria vaccines, rotavirus components for rotavirus vaccines, ebola proteins for ebola vaccines, the F and G gene products from Respiratory syncytial virus for Respiratory Syncytial virus vaccines, HA and NA for influenza vaccines, etc.

Adenoviruses according to the invention are preferably human adenoviruses, i.e. derived from adenovirus that is capable of infecting human cells, but the invention is equally useful for non-human adenoviruses. A person skilled in the art will be aware of the fact that in addition to all human adenoviruses numerous non-human adenoviruses have been identified in the art. Obviously, also non-human adenoviruses can be applied to reach the same results as disclosed by the present invention. Non-limiting examples of non-human adenoviruses that can be produced using the methods and means of the present invention are canine-, bovine-, monkey- and avian adenoviruses. Serotypes as used herein therefore goes beyond species-restricted serotypes.

"Derived from" as used herein, means that nucleic acid sequences, genes, or proteins that are normally found in an adenovirus, are used for the generation of recombinant adenoviruses according to the invention. Methods to generate such recombinant adenoviruses are well known to persons skilled in the art, and include but are not limited to general molecular biology methods such as cloning of genetic information into desired constellations by use of restriction enzymes, and the like. "Derived from" is also meant to include the synthetic construction of genetic information based upon knowledge of such genetic information. Such methods include but are not limited to, the use of adenoviral genetic material as a template for PCR to construct a new adenoviral construct that is based upon the sequence of the template adenovirus, the construction of completely synthetic genetic information with a desired sequence e.g. by linking synthetic oligonucleotides to a desired construct, and the like. It is to be understood that 'derived from' does not necessarily mean a direct cloning of the wild type DNA. A person skilled in the art will also be aware of the possibilities of molecular biology to obtain mutant forms of a certain piece of nucleic acid. These mutations may render a different functionality, but they may also be silent in a way that certain mutations do not alter the functionality of that particular piece of DNA and its encoded protein. Therefore, the terms 'functional part, derivative and/or analogue thereof' are to be understood as equivalents of the nucleic acid they are related to. A person skilled in the art will appreciate the fact that certain deletions, swaps, (point)mutations, additions, etc. may still result in a nucleic acid that has a similar function as the original nucleic acid. It is therefore to be understood that such alterations that do not significantly alter the functionality of the proteins such as the pIX protein, E4-orf6 and E1B-55K gene product are within the scope of the present invention. It will be clear to those skilled in the art, that the method for obtaining the genetic information encoding the recombinant adenovirus can be varied without departing from the scope of the present invention. Human adenoviruses have been classified into subgroups A-F, which encompass 51 serotypes (see e.g. EP 0978566). For some applications, it can be beneficial to use adenoviral vectors derived from adenoviruses from specific subgroups or from certain serotypes that have a tissue tropism for a desired cell type, e.g. dendritic cells (WO 02/24730). The general absence of neutralizing antibodies in the population against adenovirus from certain subgroups or from a specific serotype is also an important parameter to determine the serotype of choice (WO 00/70071). Because of the similarity between the subgroup B viruses (see e.g. Examples 4 and 11) it is expected that the invention is particularly suitable for the adenoviruses of subgroup B. Hence, the present invention relates to adenoviral vectors derived from an adenovirus classified in subgroup B. Subgroup B of human adenoviruses comprises Ad3, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad35, and Ad50. Preferred embodiments of the present application relate to recombinant adenoviral vectors derived from Ad35 or Ad11 serotypes. Besides choosing for a serotype for specific applications, so-called chimeric adenoviruses can be used. These comprise parts or all of genetic sequences coding for coat proteins, such as fiber, penton, or hexon, from one or more adenoviral

serotypes linked to the remaining genetic information (the 'main' adenoviral vector part) from other serotypes, which can be used to decrease immunogenicity or change the tissue tropism of the 'main' adenoviral vector (EP 0978566). The 'main' part as used herein means that it contributes most of the genetic information to said chimeric virus, and a chimeric adenovirus will therefore be included in the serotype group of the 'main' part of such a virus. It will be clear to those skilled in the art that the present invention can also be used for such chimeric adenoviruses when these could face similar instability problems. It can for instance be expected that a chimeric adenovirus comprising Ad35 sequences as the main part and comprising a fiber that is derived from e.g. an Ad11 adenovirus may have similar instability upon propagation as is reported for the Ad35 recombinant adenoviral vectors described here. Hence, when recombinant adenoviruses are mentioned in this application, chimeric adenoviral vectors are meant to be included in the present invention.

[0034] The elements necessary for production and assembly of recombinant adenoviral vectors are well known to the person skilled in the art (described supra; US patent 5,994,128; Russell, 2000). Production of E1 deleted recombinant adenoviruses in the form of virions is done in packaging cells, also called complementing cells. Such cells provide *in trans* the genetic information of the adenovirus lacking in said recombinant adenoviruses, necessary to produce recombinant virus (recombinant virions). Well-known packaging cells are 293 cells, 911 cells and PER.C6™ cells (supra). For most purposes it is preferable to use a packaging cell and a recombinant adenoviral vector that lack overlapping sequences that would otherwise lead to homologous recombination resulting in replication competent adenovirus (US patent 5,994,128). PER.C6™, as deposited under no. 96022940 at the European Collection of Animal Cell Cultures at the Center for Applied Microbiology and Research, is therefore a very suitable packaging cell for propagating recombinant adenoviruses. Other methods to decrease the generation of replication competent adenovirus have also been envisaged and concern for instance manipulation of adenoviral sequences to reduce the homology between sequences present in the packaging cell and the vector (e.g. Hehir et al., 1996; Robert et al., 2001). Packaging cells can, besides the obligatory E1 region, comprise other adenoviral sequences to complement other adenoviral functions when these are functionally lacking in the recombinant adenovirus used, such as e.g. parts or all of E2, E4, and the like. The complementing information in packaging cells can be present either integrated in the genome, or as extrachromosomal copies, e.g. on plasmids, vectors, cosmids, and the like. Other methods make use of so-called helper viruses, which comprise genetic information lacking in the recombinant adenovirus. Recombinant adenoviral vectors are also used as so-called helper viruses used for the production of recombinant adenoviruses that contain a genome deleted for most or all adenoviral genes (gutless vectors or helper dependent adenoviruses). In the final production of such gutless adenoviruses it is necessary to avoid packaging of the helper adenovirus. A person skilled in the art is familiar with the methods to achieve this, for example using a site-specific recombinase on an engineered site in the packaging signal to delete this packaging signal. Often it is necessary to separate remaining helper virus from the desired gutless virus using CsCl-gradient separation. This is easier to achieve when the genome lengths of the helper and gutless virus differ maximally. Therefore, a large helper virus is preferred above a smaller one. As will be clear to the person skilled in the art, the present invention can equally be applied to increase the stability of the recombinant adenovirus by use of a recombinant helper virus having the increased pIX expression, which can be accomplished by the methods described in the present invention. Any cell containing genetic information that can be used to complement the recombinant adenovirus, to generate recombinant virus particles, is meant to be included in the scope of the meaning of packaging cell. It will be clear to the person skilled in the art that the advantage gained by the present invention is not dependent on the packaging cell used.

[0035] The genetic information encoding pIX can either be present on the recombinant adenoviral vector but can also be present independent from said recombinant adenoviral vector, and such extraviral genetic information can be present either integrated in the genome, or as extrachromosomal copies, e.g. on plasmids, vectors, cosmids, and the like. Introducing genetic information into a packaging cell can be done according to a variety of methods, such as transfection by lipofectamin, calcium phosphate precipitation, viral infection, and the like. Such methods are generally well known to the person skilled in the art, and the method used for introduction of genetic information is not critical for the scope of the invention. Functional pIX in expressible format as used herein means genetic information encoding pIX in operable linkage to a promoter or other regulatory sequence capable of driving expression of said genetic information encoding pIX in the packaging cell. Introduction of genetic information into the packaging cell can be done either prior to, concomitantly with, or after the introduction of the recombinant adenoviral vector. It was found that constitutive episomal expression of pIX in a 293-based packaging cell line complements the deficiency of pIX mutant adenovirus type 5 (Caravokyri and Leppard, 1995). However, for such applications special episomal plasmids containing an EBNA1 expression cassette are required, and propagation of adenoviral vectors in such cell lines suffers from the disadvantage that parts of the episome very likely will become part of the recombinant adenoviral vector. Hence, in preferred embodiments of the present invention, genetic information encoding functional pIX is present on the adenoviral vector.

In attempts to decrease the amount of recombination leading to replication competent adenovirus, some authors have used a pIX gene derived from Ad7 - a group B virus- which was driven by a mutated pIX promoter of Ad5, to diminish the overlap between the nucleic acids of the (Ad5-derived sequence containing) packaging cell and the recombinant

adenoviral vector (Robert et al., 2001). However, those experiments were not done to increase the stability of the viral vector, and this stability was not measured in those experiments. In the current application, the transcription regulating sequences of pIX in the adenoviral vector are changed with the purpose of increasing the stability of the virus and/or increasing the capacity for foreign genetic material in virions. The invention demonstrates that a recombinant adenoviral vector derived from Ad35 comprising a pIX gene under the control of an Ad5-derived proximal pIX promoter derived from Ad5 is more stable/can harbour more foreign genetic information than the corresponding virus with the endogenous (i.e. Ad35 derived) proximal pIX upstream sequences. Therefore, the present invention also provides a recombinant adenovirus comprising a functional pIX coding sequence and having at least a deletion in the E1-region, wherein the pIX coding sequence is under control of a heterologous promoter, and wherein said recombinant adenovirus is derived from an adenovirus other than an adenovirus serotype 5. In certain embodiments, said heterologous promoter is a non-endogenous proximal pIX promoter. In preferred embodiments the genetic information encoding pIX is derived from Ad35 or Ad11. In such embodiments, a preferred non-endogenous pIX promoter is an Ad5 promoter.

In another aspect, the invention provides a recombinant adenoviral vector obtainable by a method according to the invention. Such recombinant adenoviral vectors are useful, e.g. in the preparation of vaccines (WO 00/70071; WO 01/38362; WO 02/24730), as gene delivery vehicles, and the like. Choosing a desired main serotype for such recombinant adenoviral vectors can be used for obtaining vectors with an altered tissue tropism as compared to the much-used Ad5 adenoviral vectors, and/or can be used because they are less immunogenic than such Ad5 derived vectors (WO 00/70071).

For the generation of recombinant adenoviral vectors, it is convenient to clone the transgene into a plasmid (adapter plasmid), containing the left part of an adenovirus lacking E 1 sequences and having restriction enzyme sites for cloning. The recombinant adenoviral vector is then generated by homologous recombination with a cosmid comprising the right part of the adenovirus having at the 5'end overlapping sequences with the 3'end of the adapter plasmid (see examples in present application; method described in WO 99/38362). Thus it is another aspect of the present invention to provide a recombinant nucleic acid sequence comprising an adenoviral left ITR, a packaging signal, other adenoviral sequences with a deletion in the E1 region, at least part of the E1B 55K open reading frame and pIX coding sequences.

[0036] The invention further provides a recombinant adenovirus packaging cell comprising an recombinant adenovirus according to the invention. In one embodiment said recombinant adenovirus packaging cell comprises a nucleic acid capable of complementing an E1B 55K deficiency of said recombinant adenovirus and wherein said recombinant adenovirus comprises nucleic acid molecule comprising a part of the sequence encoding a E1B 55K gene product increasing the expression of the pIX gene, with the proviso that the latter recombinant nucleic acid molecule does not encode a functional E1B 55K gene product, and wherein said cell and said recombinant adenovirus do not comprise sequence overlap leading to the formation of a recombinant adenovirus comprising a nucleic acid encoding a functional E1B 55K protein. This embodiment is particularly useful for preventing the formation of recombinant adenoviruses comprising additional adenovirus function.

[0037] The invention will now be illustrated with some examples, which are not intended to limit the scope of the invention.

EXAMPLES

[0038] Standard molecular biology methods were used (e.g. Sambrook and Russel, 2001), unless otherwise indicated. Primer sequences are provided in Table IV.

Example 1. PER.C6™-based complementing cell lines for E1-deleted Ad35 viruses.

[0039] PER.C6 cells were seeded in 10 cm culture dishes at a density of 3x10⁶ cells/dish in PER.C6 culture medium (DMEM (Gibco BRL) complemented with FBS (Gibco BRL) up to 10% and 10mM MgCl₂ (4.9 M stock solution, Sigma)). Two days later, 9 dishes were transfected with 1 µg Scal linearised pIG35.55K DNA (described infra) and 9 dishes were transfected with 1.5 µg Scal linearised pIG35.55K DNA. Separate control dishes were transfected with 1 or 1.5 µg Scal linearised pAdApt35.LacZ (described in WO 00/70071) to monitor transfection efficiency and with or 1.5 µg Scal linearised pcDNA.nlsLacZ. pcDNA.nlsLacZ (described in WO99/55132) is a pcDNA3-based plasmid (Invitrogen) with the nlsLacZ gene driven by the CMV promoter. pcDNA.nlsLacZ also contains a neo^r expression cassette. As a negative control one extra dish was transfected with linearised pAdApt35.LacZ, a construct that lacks the neo^r selection gene. All transfections were performed with the LipofectAmine transfection kit (Invitrogen/Life Technologies) according to manufacturers instructions using 5 ml LipofectAmine reagent/µg DNA. Cells were incubated for 4 hrs with the transfection mixture after which the medium was replaced with PER.C6 culture medium. The next day medium was replaced with culture medium containing 0.5 mg/ml G418 (Gibco BRL) except in the two dishes that were transfected with 1 or 1.5 µg pAdApt35.LacZ. These latter dishes were used to monitor LacZ expression two days following transfection. After X-gal staining of these cultures transfection efficiency was estimated at approximately 40% with slightly more blue cells in the dish transfected

with 1.5 µg DNA. Selection medium was refreshed twice weekly in the remaining transfected dishes. Within two weeks following first addition of selection medium most cells in the negative control dish (transfected with 1.5 µg pAdApt35.LacZ) were dead. In the dishes transfected with pcDNA.nlsLacZ cell clones were becoming visible. Since the cells transfected with pLG35.55K seemed to be more resistant to G418, the concentration was raised to 0.75 mg/ml 3 weeks following transfection. Three days and seven days later a total of 196 cell clones were picked from the dishes transfected with pLG35.55K and seeded in separate wells of 96-well plates.

[0040] Cells remaining after colony picking of two 10 cm dishes of the transfection with 1 µg pLG35.55K DNA were trypsinised, pooled and expanded to give pool PERSSK(1.0) The same was done for two dishes of the 1.5 µg transfection. The PERSSK(1.0) cell pool was expanded and seeded in 4 T25 flasks at a density of 3.5x10⁶ cells/flask for transfection to test virus generation. In addition, 3 T25 flasks with parental PER.C6 cells were seeded at the same density. pAdApt35.eGFP (an adapter plasmid based on pAdApt35IP1 (described in WO 00/70071) but also containing the green fluorescent protein as marker gene, which was cloned into pAdApt35IP1 as HindIII-BamHI fragment derived from pIP-spAapt.eGFP (described in WO 02/24933)) was digested with PacI to liberate the adenoviral sequences from the plasmid backbone. pWE.Ad35.pIX-rITR (described in WO 00/70071) was digested with NotI to liberate the adenoviral sequences from the cosmid backbone. 2 flasks with PER.C6 cells and 2 flasks with PER55K(1.0) cells were transfected with 2 µg digested pAdApt35.eGFP and 6 µg digested pWE.Ad35.pIX-rITR each. One flask of each cell line was transfected with 8 µg pAdApt35.LacZ to monitor transfection efficiency. The remaining flask with PER55K(1.0) cells served as a negative control and was treated as the others but did not receive the transfection mixture. All transfections were performed with LipofectAmine (Invitrogen/Life Techn.) according to manufacturers instructions using for each transfection a total of 8 µg DNA and 40 µl LipofectAmine reagent. The transfection mixture was removed after 4 hrs incubation and fresh culture medium was added. Transfections were done the day after seeding of the cells and again two days later cells in the T25 flasks were transferred to a T80 flask except for the LacZ control transfections. These were stained with X-gal solution after mild fixation. After five hours incubation with staining solution, the percentage of blue cells was estimated at approximately 90% in both flasks showing that transfection went well for both cell lines. Four days following the passage to the T80 flasks the transfected PER55K(1.0) cultures showed starting CPE (cytopathogenic effect, indicative of virus replication) with approximately 100 events/flask. The untransfected PER55K(1.0) cells were grown confluent with no evidence of CPE. In the transfected PER.C6 cultures only three CPE events were visible in the confluent monolayer of cells. Again three days later, the transfected PER55K(1.0) cultures showed full CPE, with all cells rounded and detached in clumps. In contrast, in the PER.C6 cultures the few events of CPE had not progressed and cells were still in monolayer. This confirms earlier observations that generation of E1-deleted Ad35-based viruses on PER.C6 is very inefficient. Also the untransfected PER55K(1.0) cultures showed, as expected, a confluent monolayer with no CPE. The cells and medium in the PER55K(1.0) flasks with full CPE were harvested and subjected to two freeze/thaw cycles after which the cell debris was removed by centrifugation at 3000 rpm for 10 minutes in a table centrifuge. One of the resulting crude lysates was used to infect a fresh culture of PER55K(1.0) cells in a T175 flask (1.5 ml/flask). Cells and medium were harvested at full CPE four days later. This shows that infectious virus had formed in the initial transfections. GFP expression was confirmed by fluorescent microscopy of A549 cells infected with the crude lysate. The crude lysate was then used to analyse complementation of this E1-deleted Ad35.AdApt.eGFP virus in the individual clones as described below.

[0041] The supra described clones that were picked from the pLG35.55K transfected PER.C6 cells were expanded and were functionally tested for the ability to sustain replication of Ad35.AdApt.eGFP. Hereto, the clones were seeded at two densities in 6-well plates and one day later infected with 15 ml of the above described crude lysate. CPE was monitored the day after. Of the 146 clones tested in this way 19 gave full CPE at day 2 or 3 and 68 gave full CPE at day 5 or 6. The remaining clones had only partial CPE or showed a few non-progressing events. The latter were indistinguishable from PER.C6 cells that were taken along as a negative control.

[0042] Based on these results a selection of 24 clones was made that were further screened for the ability to generate recombinant E1-deleted viruses following transfection of the pAdApt35.GFP adapter plasmid and the large pWE.Ad35.pIX-rITR cosmid clone. Hereto, clones were plated in T25 flasks and transfected with 2 µg of the adapter and 6 µg of the backbone plasmid using LipofectAmine as described above. Two days following the transfection, cells were transferred to T80 flasks to prevent overconfluency of the cultures. Of the 24 clones 5 gave full CPE three days after passage to T80 and another 13 clones gave progressing to full CPE the day after. The remaining 6 clones showed no CPE or only starting. In comparison: routine generation of E1-deleted Ad5 vectors on PER.C6 cells generally results in full CPE four to six days after transfer to T80 flasks.

[0043] This shows that the new clones efficiently complement E1-deleted adenovirus vectors. One of the clones (clone #16) described above was used to generate and produce multiple batches of E1 and E1/E3 deleted Ad35 viruses containing different transgenes. Hereto, virus in crude lysates resulting from transfections as described above, but using different adapter plasmids, were plaque purified on the new cell line. Single plaques were tested for transgene activity and then amplified for medium scale production in 4-8 triple layer flasks (3x175 cm²/flask). Cells were harvested at full CPE and the virus was released and purified as routinely done for adenoviruses. The amount of virus particles was

determined by HPLC (Shabram et al., 1997). Table I presents the yields after downstream processing of medium scale productions of E1- and E1/E3-deleted Ad35 viruses on triple layer flasks with PER55K clone #16 cells. The amount of purified virus particles is comparable with the yields of Ad5-based vectors on PER.C6 cells.

[0044] We conclude that we have generated multiple cell lines that efficiently complement fully E1-deleted Ad35-based vectors. Thus, Ad35 E1B-55K expression in an Ad5 complementing cell line facilitates replication of Ad35 vectors.

Example 2. Generation of pWE.Ad35.pIX-rITRΔE3.

[0045] The early region-3 of human adenoviruses contains multiple coding regions for proteins that interfere with the host immune response to adenoviral infection. When adenoviral vectors are used as vaccine carrier such interference is unwanted. Therefore, we constructed an Ad35 backbone cosmid lacking the E3 region.

[0046] Hereto, construct pBr.Ad35.PRn (Fig. 11; described in example 13 in publication EP1054064) was digested with *Stu*I and *Mlu*I and the 17.3 kb vector fragment was purified from low melting point (LMP) gel using agarase enzyme (Roche) according to manufacturers instructions. Next, a PCR fragment was generated on pBr.Ad35.PRn using primers 35E3for and 35E3rev. For the amplification Pwo DNA polymerase (Roche) was used according to manufacturers instructions and program set at: 94°C for 2 minutes, 30 cycles of (94°C for 30 seconds, 58°C for 30 seconds and 72°C for 1 minute) and a final incubation at 68°C for 8 minutes. The 833 bp PCR product was purified using the QIAquick PCR purification kit (Qiagen) and digested with *Mlu*I and *Stu*I. The digested DNA was purified from gel using the QIAquick gel extraction kit (Qiagen). Both isolated fragments were ligated and transformed into DH5a competent cells (Invitrogen/Life Technologies) to give pBr.Ad35.PRnΔE3 (Fig. 12). The plasmid was checked by restriction analysis and sequencing of the PCR amplified insert. The E3 deletion was then cloned into the pWE.Ad35.pIX-rITR cosmid backbone. Hereto, pWE.Ad35.pIX-rITR was digested with *Pac*I and the DNA was purified by precipitation with isopropanol and washing with 70% EtOH. Following resuspension in milliQ water, the DNA was digested with *Swa*I and the 22.8 kb vector containing fragment was purified from LMP gel using agarase enzyme as above. Construct pBr.Ad35.PRnΔE3 was digested with *Pac*I and *Swa*I in the same manner and the 16.6 kb fragment was also isolated using agarase enzyme. Both isolated fragments were ligated using 0.5-0.6 μg of each fragment. Ligated fragments were then packaged using λ-phage packaging extracts (Stratagene) according to manufacturers instructions and mixed with STBL-2 cells. Bacteria were plated on LB+Amp plates and resulting colonies were analyzed for the presence of the correct construct. This gave construct pWE.Ad35.pIX-rITRΔE3 (Fig. 1). The E3 deletion extends from nucl. 27648 to 30320 of the Ad35 sequence (described in WO 00/70071) and thus spans a 2.6 kb region.

[0047] Cotransfection of *Not*I digested pWE.Ad35.pIX-rITRΔE3 and pIPsp-1 (New England Biolabs) digested pAdApt35.eGFP onto PER55-clone #16 cells (described supra) gave rise to GFP expressing Ad35-based viruses. Upon isolation of viral DNA from these viruses, PCR amplification of the E3 region showed that the viruses were deleted for 2.6 kb of E3 sequences as expected.

Example 3. Limits in packaging size E1-deleted Ad35-based vectors.

[0048]

Ad35-based E1-deleted and E1/E3-deleted vectors containing different inserts were generated by transfection of PER55K-clone#16 cells (see example 1) with

1.5 μg of an Ad35 adapter plasmid carrying a specific transgene digested with *Pac*I or pIPsp-1 enzyme to liberate the adenovirus insert from the plasmid vector sequences and,

4.5 μg of either pWE.Ad35.pIX-rITR digested with *Not*I or with pWE.Ad35.pIX-rITRΔE3 digested with *Not*I enzyme.

[0049] The right flank of the adapter plasmids and the left end of the backbone plasmid contain homologous sequences mediating recombination events that lead to a complete E1-deleted viral genome (as described in WO 00/70071).

[0050] Transfections were done with 30 μl Lipofectamine reagent (Invitrogen/Life Technologies) for each set of constructs according to manufacturers instructions. Transfection mixtures were added to PER55K clone 16 cells at 70% confluency in T25 flasks. The following combinations were transfected:

1. pAdApt35IP1 + pWE.Ad35.pIX-rITR
2. pAdApt35IP 1 + pWE.Ad35.pIX-rITRΔE3
3. pAdApt35eGFP + pWE.Ad35.pIX-rITR
4. pAdApt35eGFP + pWE.Ad35.pIX-rITRΔE3
5. pAdApt35Luc + pWE.Ad35.pIX-rITR
6. pAdApt35Luc + pWE.Ad35.pIX-rITRΔE3
7. pAdApt35LacZ + pWE.Ad35.pIX-rITR

8. pAdApt35LacZ + pWE.Ad35.pIX-rITRΔE3

[0051] Adapter plasmids were digested with pIPsp-1 enzyme to liberate the adenovirus sequences from the plasmid vector backbone. pWE.Ad35.pIX-rITR and pWE.Ad35.pIX-rITRΔE3 were digested with NotI prior to transfection for the same reason. Generation of the adapter plasmids and of the pWE.Ad35.pIX-rITR backbone cosmid is described previously in WO 00/70071. Generation of pWE.Ad35.pIX-rITRΔE3 is described supra.

[0052] Two days following transfection cells were passaged to T80 and further incubated until full CPE was obtained. Cells and medium were harvested 1-2 days after full CPE was noticed. The mixtures were subjected to one freeze/thaw cycle and spun down at 1500 rpm for 15 minutes to pellet cell debris, after which supernatants were collected. The crude lysates obtained in this way were used to isolate viral DNA. Hereto, 275 µl of crude lysate material was incubated with 10 µl 10mg/ml DNaseI at 37°C for 30 minutes. Subsequently, 6.0 µl 0.5 M EDTA (pH 8.0), 7.5 µl 20% SDS and 1.5 µl 20 mg/ml Proteinase K was added and mixed by vortexing. The mixture was then incubated at 50°C for 1 hour. Finally, the viral DNA was isolated using the GeneClean Spin Kit (Bio 101, Inc.). Following elution of the viral DNA in 20 µl milliQ H₂O, the transgene region was analysed by PCR amplification. Hereto, primers AdApt35CMVF and 35pIXR were used. The amplifications were done with 2 µl of the isolated viral DNA using Taq DNA polymerase (Invitrogen). The reaction mixtures contained 5 µl 10x buffer (Invitrogen), 2 µl 50mM MgCl₂, 5 µl 2mM dNTPs, 3 µl of each primer (10µM stock) and 2.5 units Taq enzyme in a total volume of 50 µl. The program was set at 94°C for 2 minutes followed by 30 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 4 minutes). Control reactions were done on 5 ng of adapter plasmids. After completion of the PCR, 5 µl of the reaction was loaded on gel for analysis. Figure 2 shows the results of the above mentioned transfections. The primers amplify sequences from the 5' end of the CMV promoter to the 5' end of the pIX coding region. As can be seen in Figure 2, viruses without transgene or with GFP insert show the expected band (compare with the plasmid controls; lanes PL for each virus). Smaller fragments are seen with the larger inserts, luciferase and LacZ, and these deletions become more prominent with larger total length of the virus (compare LacZ or Luc viruses with and without E3). Thus, increasing genome length corresponds with the occurrence of deletions in the transgene region. The fact that the total genome length (also indicated in Fig. 2) of Ad35.AdApt.eGFP and Ad35.AdApt.LacZΔE3, 33.7 and 33.4 kb respectively, is comparable while deletions are only found in the LacZ virus sample, indicates that either the sequence or the size of the insert in the former E1 region can also influence the occurrence of the deletions.

Example 4. Sequence comparison of the pIX gene region of adenovirus serotype 5 and 35.

[0053] The finding that with increasing genome length of recombinant Ad35 viruses, deletions occur in the transgene region could suggest, in analogy with the pIX-deficient Ad5 viruses (Ghosh-Choudhury et al., 1987), that there is a problem with the stability of the capsids. The fact that Ad35.E1B+.AdApt.Luc viruses (where E1A sequences are replaced by the AdApt.Luc cassette), with a total length of 36.7 kb can be made, indicates that the deletion of E1B plays a role. This might be either through a function of one of the E1B proteins itself or through a function of unknown regulatory sequences in this region having influence on expression of other adenoviral proteins. It has, to our knowledge, not been described that E1B proteins itself influence the packaging capacity of adenoviruses. However, it has been described that the E1B-21K protein non-specifically stabilizes transfected DNA (Herrman and Mathews, 1989) and that mutations in the 21 K protein result in degradation of cellular and viral DNA during infection (Pilder et al., 1984; White et al., 1984). Since the Ad5 E1B-21K protein is expressed in PER.C6 cells, these findings do not provide an explanation for our observations. The pIX gene is located directly 3' of the E1B-55K coding region. For Ad5 it is known that the pIX promoter and coding sequences are located within the E1B transcription region since pIX and E1B share the poly-adenylation signal. The minimal promoter sequences necessary for pIX expression have been studied in case of Ad5 (Babiss and Vales, 1991). It was shown that a promoter fragment containing the upstream Sp1 site and the TATA-box sequence was sufficient for pIX expression. The spacing between the Sp1 site and the TATA-box as well as the sequence of the TATA-box itself, were shown to influence the level of pIX expression. Whether the corresponding region in Ad35 is also sufficient to drive pIX expression to a level high enough for stable viruses is not known. Sequence comparison revealed that both the Sp1 site and the TATA sequence are different from those found in the Ad5 pIX promoter. Using sequence information available from Genbank, a comparison was made of the proximal pIX upstream sequences (i.e. between the stop codon of E1B-55K and the start codon of the pIX gene) of serotypes from different subgroups. The following adenoviruses with SEQ. ID. NOs. and Genbank reference sequences were used for the comparison: Ad2 (SEQ. ID. NO. 45; Genbank NC_001405), Ad5 (SEQ. ID. NO. 46; Genbank M73260), Ad12 (SEQ. ID. NO. 47; Genbank NC_001460), Ad9 (SEQ. ID. NO. 48; Genbank AF099665), Ad40 (SEQ. ID. NO. 49; Genbank L19443), Ad4 (SEQ. ID. NO. 50; NC_003266), Simian 25 (SEQ. ID. NO. 51; Genbank AF394196), Ad7 (SEQ. ID. NO. 54; Genbank AD7001). The Ad35 sequence (SEQ. ID. NO. 52) was as published in WO 00/70071. The Ad11 sequence (SEQ. ID. NO. 53) was not published before and is provided herein. Fig. 3A shows an alignment of the above mentioned sequences between the stop codon of the E1B-55K protein (first 3 nucleotides in all sequences) and the start codon of the pIX protein (last 3

nucleotides). The Sp1 site and the TATA sequence in Ad2 and Ad5 are boxed. In most cases there is insufficient homology to directly point the Sp1 and TATA boxes in the other sequences. Therefore, the consensus sequences for GC- and TATA-boxes as published by Bucher, P (1990) was used to identify the putative Sp1 and TATA-box in the various sequences. Fig. 3b shows the putative Sp1 and TATA-box sequences and the spacing between them. Ad12, Ad9 and Ad40, belonging to respectively subgroup A, D and F, have Sp1 and TATA sequences that fairly match the consensus sequence. However, the distance between the two boxes is smaller than for Ad5 and Ad2. This is not unusual since the Ad5 E1B promoter also contains an Sp1 box and a TATA sequence with a spacing of 11 nucleotides. However, a deletion of 9 nucleotides (of the 20) in the Ad5 pIX promoter sequence between the Spl- and TATA-boxes gave reduced pIX levels (Babiss and Vales, 1991). The subgroup B serotypes Ad35, Ad11 and Ad7 as well as subgroup E virus Ad4, have divergent TATA-box sequences and different spacing between the putative Sp1 sequence and the TATA-box. The proximal pIX region in human adenovirus type 4 is identical to that in the simian adenovirus 25 (CV68), a serotype that recently was proposed as therapeutic vector (Farina et al., 2001). Thus, also for replication-deficient vectors based on non-human adenoviruses pIX expression may be insufficient for stable capsids.

[0054] It may well be that pIX expression is regulated differently in Ad35 viruses and other human and non-human adenoviruses and that regulatory sequences, or even the promoter sequences itself, are located further upstream in the E1B sequences or even more upstream. Alternatively, it is also possible that, since pIX expression is activated by E1A proteins, high levels of pIX expression are obtained in the presence of E1A proteins belonging to the same serotype or subgroup.

[0055] We tested whether changing the endogenous proximal pIX upstream sequences into a heterologous promoter to increase pIX expression in the vector, leads to more stable viruses and a better packaging capacity (infra). Alternatively, the pIX function may be delivered in trans via the packaging cell line. As a non-limiting example we describe recombinant Ad35-based viruses that have a non-endogenous proximal pIX promoter as found in Ad5 viruses, and show that these viruses have a better stability than the unchanged recombinant vectors.

Example 5. Generation of adapter plasmids with an Ad5 pIX promoter

[0056] pAdApt535 is an Ad35 adapter plasmid having part of the Ad5 pIX promoter sequences but is otherwise identical to Ad35 adapter plasmid pAdApt35IP1 (see WO 00/70071). Its construction is described below:

[0057] A first PCR fragment was generated with primers SV40for and pIX5Rmfe. The reaction was done with Pwo DNA polymerase (Roche) according to manufacturers instructions but with 3% DMSO in the final mix. pAdApt, an adapter plasmid for Ad5 E1-deleted viruses (100 ng; see WO 00/70071) was taken as template. The program was set as follows: 2 minutes at 94°C and then 30 cycles of (94°C for 30 seconds (melting), 52°C for 30 seconds (annealing) and 72°C for 30 seconds (elongation)) followed by 8 minutes at 72 °C. The resulting PCR fragments contain the 3' end of the SV40 polyadenylation signal from pAdApt and the Ad5 pIX promoter region as present in Genbank Accession number M73260 from nucleotide 3511 to nucleotide 3586 and an MfeI site at the 3' end.

[0058] A second PCR fragment was generated as described above but with primers pIX35Fmfe and 35R4. 100 ng pAdApt35IP1 was taken as template, the annealing was set at 58°C for 30 seconds and the elongation of the PCR program was set at 72°C for 90 seconds. This PCR amplifies Ad35 sequences from nucleotide 3467 to nucleotide 4669 (sequence numbering as in WO 00/70071) and adds an MfeI site to the 5' end.

[0059] Both PCR fragments were then digested with MfeI and purified using the Qiagen PCR purification kit (Qiagen) according to manufacturers instructions. Concentration of the purified fragments was estimated by running a sample on agarose gel and approximate equimolar amounts of the two fragments were mixed in a ligation reaction containing 5 µg DNA, 4 µl 10x ligase buffer and 2 µl ligase enzyme (New England Biolabs) in a 40 µl volume. Following an incubation of > 2 hours at RT, the mixture was loaded on a 1.2% agarose gel in TAE and the DNA fragments of 1.4 kb length were isolated with the GeneClean II kit (Bio 101, Inc.) according to manufacturers instructions.

[0060] The DNA was eluted in 30 µl sterile H₂O and 1 µl was used in a PCR amplification reaction with primers SV40for and 35R4 as described above. The PCR was done as described above with an annealing temperature of 52°C and an elongation time at 90 seconds. The resulting product was isolated from gel using the Qiagen gel extraction kit and digested with AgeI and BglII. The resulting 0.86 kb band was isolated from gel using the GeneClean II kit according to manufacturers instructions.

[0061] pAdApt35.Luc (described in WO 00/70071) was also digested with BglII and AgeI and the 5.8 kb vector fragment was isolated from gel using the GeneClean II kit as above. This fragment was ligated with the isolated BglII-AgeI fragment described supra containing the Ad5-Ad35 chimeric pIX promoter, to give pAdApt535.Luc (Fig. 4).

[0062] Other adapter plasmids containing the Ad5 pIX promoter were then made as follows:

pAdApt535.Luc was digested with BglII and ApaI and the 1.2 kb insert was purified from gel using the GeneClean II kit according to manufacturers instructions, pAdApt35IP1 was also digested with BglII and ApaI and the 3.6 kb vector fragment was isolated as above. Ligation of both isolated fragments resulted in pAdApt535 (Figure 5). Next,

pAdApt535 was used to clone other marker genes like eGFP (derived from pAdApt35.eGFP) and LacZ (derived from pAdApt35.LacZ) into the multiple cloning site using standard cloning techniques giving rise to pAdApt535.eGFP and pAdApt535.LacZ.

Example 6. Generation of E1-deleted Ad35-based vectors with adapter plasmids containing the Ad5 pIX promoter.

[0063] Recombinant viruses were generated by transfection of adapter plasmids and Ad35 vector backbone cosmids on PER55K clone 16 cells as described above. Hereto, the following set of plasmids were used:

- T1. pAdApt535eGFP + pWE.Ad35.pIX-rITR
- T2. pAdApt535eGFP + pWE.Ad35.pIX-rITRAE3
- T3. pAdApt35Luc + pWE.Ad35.pIX-rITR
- T4. pAdApt535Luc + pWE.Ad35.pIX-rITR
- T5. pAdApt535Luc + pWE.Ad35.pIX-rITRAE3
- T6. pAdApt535LacZ + pWE.Ad35.pIX-rITR
- T7. pAdApt535LacZ + pWE.Ad35.pIX-rITRAE3
- T8. pAdApt35LacZ + pWE.Ad35.pIX-rITR
- T9. pAdApt35LacZ + pWE.Ad35.pIX-rITRAE3

[0064] AdApter plasmids were digested with PacI except pAdApt535.Luc and pAdApt35.Luc which were digested with pIPsp-1 enzyme and pWE.Ad35.pIX-rITR and pWE.Ad35.pIX-rITRAE3 were digested with NotI prior to transfection. 2 µg of each adapter plasmid and 6 µg of the backbone DNA were mixed with 40 µl Lipofectamine (Invitrogen/Life Technologies) according to manufacturers instructions and incubated with PER55K clone 16 cells in T25 flasks at 70% confluency. Transfection medium was removed after 4 hrs and cells were further incubated at 37°C/10% CO₂. Two days after transfection, cells were passaged to a T80 flask and scored for occurrence of cytopathogenic effect (CPE) the days after. Five days later all cultures showed progressing or full CPE except T6 (no CPE) and T8 (CPE events). Again two days later, T6 and T8 showed starting CPE and all others full CPE. All cultures were harvested by collecting medium and cells. The mixtures were stored at -20°C. Upon thawing of the samples, the mixtures were spun down at 1500 rpm for 15 minutes to pellet cell debris and supernatant were collected. Of some of the samples (the four LacZ expressing viruses, T6-T9) 2 ml was used to infect again PER55K clone 16 cells at 80% confluency in a T80 flask to further amplify the virus titre. Cells and medium were harvested upon progressing (T6+T8) or full CPE (T7+T9) and crude lysates were prepared as described above.

[0065] The crude lysates obtained in this way were used to isolate viral DNA. Hereto, 275 µl of crude lysate material was incubated with 10 µl 10mg/ml DNaseI at 37°C for 30 minutes. Subsequently, 6.0 µl 0.5 M EDTA (pH 8.0), 7.5 µl 20% SDS and 1.5 µl 20 mg/ml Proteinase K was added and mixed by vortexing. The mixture was then incubated at 50°C for 1 hour. Finally, the viral DNA was isolated using the GeneClean Spin Kit (Bio 101, Inc.). Viral DNA was eluted in 50 µl milliQ H₂O and 5 µl samples were used to analyse the transgene region. It should be noted that the pWE.Ad35.pIX-rITR+/-E3 backbone cosmids were unchanged and therefore still contain the Ad35 pIX promoter. Since this promoter is located at the very 5' end of the cosmid, the chances for a recombination event resulting in the wt Ad35 promoter were considered to be small. However, it could not be excluded in this set-up that viruses would be generated that still contain the Ad35 pIX promoter. Therefore, two specific PCR amplification were performed on each virus preparation: The first was done with primer set 1 (Ad35 specific): AdApt35CMVF and AdApt35pIXrev. This PCR specifically amplifies the transgene region in viruses containing the Ad35 pIX promoter. The PCR reaction was done on 5 µl of the isolated viral DNA samples with recombinant Taq polymerase (Invitrogen) according to manufacturers instructions but with using 4mM MgCl₂ and 4 units Taq enzyme in the reactions. The PCR program was set at 94°C for 2 minutes followed by 30 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 5 minutes) and ended with a final step of 8 minutes at 68°C.

[0066] The second was done with the primers AdApt35CMVF and pIX5Rmfe and thus specifically amplifies the transgene region in viruses containing the Ad5 pIX promoter (primer set 2).

[0067] PCR amplification was done on 5 µl of the isolated viral DNA using Pwo DNA polymerase (2.5 units/µl Genaxis) in 50 µl volume containing 0.3 µl of each primer (100 µM stock), 5 µl 2mM dNTP mixture, 5 µl 10x complete buffer (incl. Mg²⁺), 1.5 µl DMSO and 0.8 µl Pwo enzyme. The PCR program was set at 94°C for 2 minutes followed by 30 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 5 minutes) and ended with a final step of 8 minutes at 68°C. During PCR the heating and cooling ramps were set at 2 °C/second. Then, 5 µl loading buffer was added to the samples and 8 µl of the mixture was loaded on gel for analysis.

[0068] The E1 and E1/E3 deleted Ad35 viruses containing the Ad5 pIX promoter sequence and eGFP transgene (transfections T1 and T2) had PCR amplified bands at the expected height with no shorter fragments. Fig. 6a shows the results for the PCR amplifications on the E1-deleted Luciferase carrying viruses (transfections T3 and T4). Lanes

5-8 are the control PCRs on AdApt535Luc (lanes 5 and 6) and AdApt35Luc plasmids (lanes 7 and 8) with both primer sets. Lanes 1-4 are PCRs on the viral DNA isolates. Primer set 1 (specific for Ad35 pIX region) amplifies a band of the expected length and shows in addition shorter fragments on Ad35.AdApt35.Luc viruses (lane 4; compare also Fig. 2 Luciferase +E3). In contrast, primer set 2 (specific for the Ad5 pIX promoter) only shows a band of the expected length with no deletion fragments when viruses are made with the AdApt535.Luc plasmid (lane 1). From this we conclude that the insertion of Ad5 pIX promoter sequences increases the stability and the packaging capacity of Ad35-E1 deleted viruses. Figure 6b confirms these results for Ad35 E1/E3 deleted viruses carrying LacZ as transgene. Lanes 1-4 are the control PCRs on AdApt535.LacZ and AdApt35.LacZ plasmids with each primer set. Some background bands are seen especially with primer set 1 (lanes 2 and 4) but a strong specific band is also seen at the expected height for each primer set on the homologous samples (lanes 1 and 4). Viral DNA was isolated after transfection and after one amplification round as described above. Strikingly, primer set 2 generates the expected fragment on Ad35.AdApt535.LacZ viruses with no deletion fragments (lanes 5 and 9) whereas the sample with viruses containing the Ad35 pIX promoter sequence clearly shows deleted fragments in addition to a fragment of the correct length (visible after amplification (lane 11)).

[0069] Altogether, these results show that substitution of the Ad35-pIX promoter sequences for Ad5-pIX promoter sequences increase the stability of the transgene region in viruses with larger genomes. Stronger promoters or additional promoter elements may even enhance this effect.

Example 7. Generation of pWE.Ad35-3481.

[0070] As indicated above, the adenovirus insert in the cosmid pWE.Ad35.pIX-riTR contains the Ad35 pIX promoter at its 5' end. This could lead to re-insertion of the Ad35 pIX promoter into viruses generated with the pAdApt535-based adapter plasmids. Therefore, a new version of the Ad35 backbone cosmid is made that lacks pIX promoter sequences. Hereto, a PCR fragment was generated with the pIXcosF-2 and Adapt35-3 primers. The amplification was done with Pwo DNA polymerase (2.5 units/ μ l; Genaxis) in 50 μ l volume containing 3 μ l of each primer (10 μ M stock), 5 μ l 2mM dNTP mixture, 5 μ l 10x complete buffer (incl. Mg²⁺), 1.5 μ l DMSO, 0.5 μ l Pwo enzyme and 10 ng pAdApt35IP1 template. The PCR program was set at 94°C for 2 minutes followed by 5 cycles of (94°C for 30 seconds, 58°C for 30 seconds and 72°C for 1.5 minutes) and then 25 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1.5 minutes) and ended with a final step of 8 minutes at 68°C. The resulting 1.2 kb PCR product contains Ad35 sequences from nucleotide 3481 to nucleotide 4663 (numbering according to Ad35 sequence as published in WO 00/70071) with an AatII and NotI site attached to the 5' end. The PCR product was purified using the PCR purification kit (Qiagen) according to manufacturers instructions and cloned into the pPCR-Script Amp vector (Stratagene) according to manufacturers instructions. The sequence of the cloned fragment is then verified by sequencing and subsequently removed from the construct by digestion with AatII and AgeI. The resulting 780 bp fragment is purified from gel using the GeneClean spin kit (Bio101, Inc.) according to manufacturers instructions.

[0071] Construct pWE.Ad35 Δ NdeI (described infra) is also digested with AatII and AgeI and the resulting 12 kb vector fragment is isolated from gel using the GeneClean spin kit (Bio101, Inc.) according to manufacturers instructions. Ligation of both isolated fragments results in construct pWE.Ad35-3481 Δ NdeI.

[0072] The construction of construct pWE.Ad35 Δ NdeI is described in WO 00/70071 and contains Ad35 sequences from nucleotide 3401 to the NdeI site at nucleotide 6541 and Ad35 sequences from the NdeI site at nucleotide 33167 to the end of the right ITR whereby both Ad35 fragments are linked via the NdeI site (see also Figure 13 in WO 00/70071).

[0073] pWE.Ad35-3481 Δ NdeI is then linearised with NdeI, dephosphorylated with CIP enzyme (New England Biolabs) and purified from gel using the GeneClean spin kit (Bio101, Inc.) according to manufacturers instructions. This vector fragment is then ligated to a 26.6 kb NdeI fragment isolated from Ad35 wt DNA after which the mixture is used to package the cosmid using λ -phage packaging extracts (Stratagene) according to manufacturers instructions. The resulting mixture is used to transform STBL-2 bacteria (Invitrogen), giving rise to pWE.Ad35-3481.

Example 8. Construction of pIG35.55K.

[0074] Construct pIG35.55K contains the coding sequences of the Ad35 E1B-55K gene operatively linked to the human phosphoglycerate kinase promoter (hPGK) and the HBV poly-adenylation sequence. In addition, it contains the neomycine resistance gene operatively linked to the RSV promoter and HBV pA. The construction of pIG35.55K is described below.

[0075] Construct pIG270 (described in WO 00/70071) was digested with EcoRI, treated with Klenow enzyme and purified using a PCR purification kit (Qiagen) according to the manufacturers instructions. The recovered DNA was then digested with AgeI and the ~5 kb vector fragment was isolated from gel using the GeneClean kit (Bio101, Inc.) according to manufacturers instructions. Next, Ad35 E1B-55K sequences were amplified by PCR on pIG270 template DNA using the 35D21 and 35B3 primers. The PCR amplification was done with Pwo DNA polymerase (Roche) on 2 ng template DNA according to manufacturers instructions but with using DMSO at a final concentration of 3% in the PCR mixture.

The program was set at: 94°C for 2 minutes followed by 25 cycles of (94°C for 30 seconds, 56°C for 30 seconds and 72°C for 30 seconds) and ended by a final incubation of 72 °C for 10 minutes. The resulting PCR fragment was purified using the PCR purification kit (Qiagen) and digested with NcoI. Following Klenow treatment to fill in the protruding ends, the DNA was further digested with AgeI and again column purified. The thus treated PCR fragment was then cloned into the above prepared EcoRI/AgeI digested vector fragment to give pIG270.ΔE1AΔ21K. pIG270.ΔE1AΔ21K was digested with AvrII and XbaI and protruding ends were filled in using Klenow enzyme. The 2.9 kb fragment containing the PGK promoter and Ad35 E1B-55K sequences was isolated from gel as described above. Next, pRSVneo4 (construction described infra) was digested with BglII, blunted with Klenow enzyme, dephosphorylated and isolated from gel. The blunted AvrII/XbaI fragment from pIG270.ΔE1AΔ21K was then ligated into the above prepared pRSVneo4 vector fragment to give pIG35.55K.

[0076] pRSVneo4 was generated as follows: Construct pRSVhvbvNeo (described in WO 00/70071) was digested with ScaI and BamHI and protruding ends were filled in using Klenow enzyme. The 1070 bp fragment containing part of the Ampicillin gene and the RSV promoter was isolated from gel using the GeneClean kit (BIO 101, Inc.). Next, pRSVhvbvNeo was digested with ScaI and EcoRI, blunted with Klenow and the 3.2 kb fragment containing the neo gene, HBVpA, vector and part of the Ampicillin gene was isolated as above. The two fragments were then ligated to give pRSVneo4.

Example 9. Increased pIX expression mediated by the RSV promoter increases stability of Ad35 viruses.

[0077] As an example of a heterologous promoter driving expression of the pIX gene, the RSV promoter was inserted into the Ad35 adapter plasmids containing the LacZ or Luciferase reporter gene. The RSV promoter corresponds to an NruI/ApaI fragment obtainable from pRc-RSV (Invitrogen). Protruding ends were filled in using Klenow enzyme (New England Biolabs) according to manufacturers instructions. The 388 bp fragment containing the RSV promoter was isolated from agarose gel using the QIAquick Gel Extraction kit (Qiagen). Adapter plasmids pAdApt35.Luc and pAdApt35.LacZ were linearized with BglII followed by Klenow treatment to blunt the ends. BglII digests just behind the SV40 poly-adenylation sequence of the transgene expression cassette. For a description of pAdApt35-based adapter plasmids see WO 00/70071. The treated adapter plasmids were then dephosphorylated using Shrink Alkaline Phosphatase (SAP) according to manufacturers (Roche) instructions. The isolated RSV promoter fragment was then ligated with each of the treated vectors and transformed into DH5α competent bacteria (Invitrogen). Colonies were analyzed for forward oriented insertion of the RSV promoter relative to the pIX gene resulting in pAdApt35.Luc.rsv and pAdApt35.LacZ.rsv.

[0078] In addition, an adapter plasmid was generated from sequences that were isolated by PCR from an Ad35 recombinant virus that resulted after deletion of the transgene region. Analysis of a crude lysate preparation resulting from a transfection of pAdApt35.LacZ and the pWE.Ad35.pIX-rITR Ad35 backbone constructs and subsequent plaque purification showed that the virus had a deletion in the transgene region of approximately 2.8 kb. The 5' sequences from this virus were PCR amplified from isolated DNA using primers 35F1 and 35R4. The reaction was performed with Pwo polymerase (Roche) according to manufacturers instructions. Program settings were as follows: 94°C for 2' then 5 cycles of (94°C for 30 sec.; 48°C for 30 sec.; 72°C for 2.5 min.) followed by 25 cycles of (94°C for 30 sec.; 56°C for 30 sec.; 72°C for 2.5 min.), and ended by 8 min. at 68°C.

[0079] The resulting 2 kb fragment was purified by the PCR purification kit (Qiagen) and cloned into the pCR-Script-Amp vector (Stratagene) according to manufacturers instructions resulting in pCR.Ad3502.8kb. This plasmid was sequenced to determine the extent of the deletion. The deletion affected most of the CMV promoter, the transgene and SV40 polyA. This resulted in linking of the 5' 317 bp of the CMV promoter to the Ad35 sequences upstream of the pIX gene. This CMV fragment contains three GC-boxes and a 21-bp repeat (Boshart et al., 1985). Possibly, the remaining sequences of the CMV promoter could augment the pIX expression resulting in a more stable virus. An alternative possibility was that the virus being smaller, on it self resulted in increased stability. To investigate this, a complete expression cassette was cloned back in the following manner, and viruses with this new adapter plasmid were generated. The pCR-Script-based vector containing the amplified sequences (renamed in pCR.C4) had a unique AvrII site preceding the ΔCMV-pIX sequences. The vector was linearized with AvrII, blunted with Klenow enzyme and dephosphorylated using SAP enzyme (Roche) as described above. Adapter plasmids pAdApt535.LacZ (Example 5) and pAdApt.Luc (WO 00/70071) were digested with AvrII and BglII and DNA was treated with Klenow to fill protruding ends. The fragments corresponding to LacZ and Luciferase expression cassettes (CMV-TG-pA) were isolated from gel as above and ligated with the AvrII linearized pCR.C4 vector. Transformation in competent cells as above and selection of colonies that had the cassettes in the forward orientation relative to the left ITR, resulted in pCR.C4.LacZ and pCR.C4.Luc.

[0080] Ad35 viruses were generated as described in example 6 using the new adapter plasmids: pCR.C4.LacZ digested with PacI, pCR.C4.Luc digested with ApaI and

[0081] pAdApt35.LacZ.rsv and pAdApt35.Luc.rsv each digested with PI-PspI.

[0082] The adapter plasmids were cotransfected onto PER55K cells (WO 02/40665) with pWE.Ad35.pIX-rITR or pWE.Ad35.pIX-rITRΔE3 digested with NotI. In addition, adapter plasmid pBr.Ad35.ΔE1AΔ21K.Luc (construction de-

scribed below) was digested with PI-PspI and cotransfected with pWE.Ad35.pIX-rITR digested with NotI. Upon full cytopathogenic effect (CPE) cultures were harvested by one freeze/thaw cycle and centrifugated to remove cell debris. 300 μ l of the resulting cleared lysates were then used to re-infect PER55K cells seeded the day before in T80 flasks. Upon full CPE, crude lysates were prepared and used to infect A549 cells to test for transgene expression and to perform a plaque assay on PER55K cells.

[0083] A549 cells were seeded in 6-well plates at 5×10^5 cells/well and after 5 hours infected with 10, 1 or 0.1 μ l of each of the LacZ virus stocks and incubated for two days. A549 cells were then stained for LacZ activity and blue cells were counted. The percentage of blue cells is given in Table II.

[0084] LacZ expressing viruses are clearly more stable when the RSV promoter is driving expression of the pIX gene as compared to the deleted CMV promoter. These results are confirmed with the Luciferase viruses. To measure activity of the Luciferase viruses A549 cells were seeded in 24-well plates at 1×10^5 cells/well and infected with 10, 1, 0.1, or 0.01 μ l of the virus stocks and incubated. After two days, cells were washed with PBS twice and resuspended in 100 μ l lysis buffer (Promega) and stored at -20°C until use. Luciferase was measured using the Steady-Glo luciferase assay system (Promega) according to manufacturers instructions. Results are presented in Table III.

[0085] In example 3 we described that fully E1-deleted Ad35 viruses containing the E3 region and an AdApt.Luc or AdApt.LacZ expression cassette were not stable. Apparently, in the new described constructs the deleted CMV promoter in front of pIX did not prevent the deletion of the transgene region. With the RSV promoter driving the pIX gene however, we now are able to generate viruses of more than wild type length. The Ad35.AdApt.Luc.rsv and Ad35.AdApt.LacZ.rsv are 35 kb and 36.5 kb respectively (see also figure 2). Ad35. Δ E1A Δ 21K.Luc (36.4 kb) also showed high transgene activity.

[0086] We next tested whether viruses would be intact after a plaque purification. Hereto, PER55K cells were seeded in 6-well plates at 0.9×10^6 cells/well and infected with different 10-fold dilutions of the Ad35.AdApt.LacZ crude lysates. Dilutions from 10⁻⁵ to 10⁻⁸ were plated and the next day an agar overlay was added. Hereto, cells were first washed with PBS and then 3 ml of a pre-warmed agar solution prepared by mixing 2xMEM (GibcoBRL; 9.14 ml), FBS (Gibco; 0.36 ml), MgCl (4.9 M; 0.037 ml) with agarose (SeaPlaque GTG; 2.5% in H₂O, 7.2 ml), was added. After solidification plates were further incubated at 37°C/ 5% CO₂. Four days later plaques were visible and LacZ staining solution was added to the wells on top of the agar and allowed to drain. All viruses showed clear, separate plaques in the range of 10⁻⁷ to 10⁻⁹ but only in case of the viruses with the RSV promoter driving the pIX gene all plaques stained blue. In both cases where the deleted CMV promoter drives pIX at least part of the plaques did not stain. This clearly shows that the packagable genome size/stability is increased in viruses that have the RSV promoter regulating pIX.

This invention for the first time provides a stable recombinant adenovirus derived from or based upon an adenovirus serotype 35 lacking expression of a functional E1B gene. Such an adenovirus has at least a deletion in the E1-region. In particular embodiments provided by the invention, said stable recombinant adenoviruses have foreign insert sequences of more than 4.2 kb, and a packaged genome size of more than 33.4 kb, using methods according to the invention. It is therefore an object of the present invention to provide a stable recombinant adenovirus that: a) harbours a foreign nucleic acid sequence of more than 4.2 kb, and/or b) has a packaged genome size of more than 33.4 kb. In particular embodiments, the invention provides an Ad35 or Ad11 based recombinant adenovirus that: a) harbours a foreign nucleic acid sequence of at least 4.6 kb, and/or b) has a packaged genome size of more than 33.8 kb. Alternatively or in addition thereto, said packaged genome sizes are at least 34.6, 35.0, 36.1 and 36.5 kb, respectively. The foreign sequences in these embodiments may include a heterologous promoter driving expression of pIX. In another aspect, said stable recombinant adenovirus is of serotype 11. A stable adenovirus according to this aspect of the invention can be passaged on a packaging cell to provide a batch of the recombinant adenoviruses, with less than 10%, preferably less than 5%, preferably none of separate clones giving rise to deletions in the foreign sequences in the recombinant adenovirus, as can be measured e.g. by the PCR method exemplified in Example 3.

[0087] pBr.Ad35. Δ E1A Δ 21K.Luc (see above) was made as follows. Construct pBr.Ad35. Δ E1A Δ 21K (WO 02/40665) was digested with HpaI, dephosphorylated with CIP (New England Biolabs) and the 5 kb vector fragment was isolated from gel. Construct pBr.Ad35. Δ E1A.Luc was also digested with HpaI and the 3.3 kb insert was isolated from gel and ligated with the isolated vector fragment. Following transformation into competent STBL-2 cells (Invitrogen), a colony was selected with the insert in the correct orientation. This gave construct pBr.Ad35. Δ E1A Δ 21K.Luc. pBr.Ad35. Δ E1A.Luc (also called pBr.Ad35.E1B+.Luc, because it still contains the E1B region) was made by inserting the AdApt.Luc cassette, taken from pAdApt.Luc after AvrII and BglII digestion and blunting with Klenow enzyme, into the vector fragment pBr.Ad35.leftITR-pIX (WO 02/40665) digested with SnaBI and HindIII and blunted with Klenow. Colonies with the expression cassette in the forward orientation were selected, giving pBr.Ad35. Δ E1A.Luc.

Example 10. Identification of pIX regulatory sequences.

[0088] The previous examples show that Ad35 recombinant viruses in which the coding regions for E1A and E1B are completely removed become progressively more unstable if the genome size is increased. We show in this application that addition of a heterologous promoter driving pIX expression can overcome the instability. In WO 02/40665 and supra

we disclosed that Ad35 viruses that retain the complete E1B-55K coding sequence can be produced on PER.C6 and are stable. The same is true for viruses that retain the full E1B coding sequence (WO 00/70071; Abrahamsen et al., 1997). Together these results raise the possibility that expression of the pIX gene is regulated differently in subgroup B viruses as compared to the pIX gene in subgroup C. Since the viruses that retain the E1B-55K gene driven by the E1B promoter are stable (see above), pIX regulatory sequences will probably be located in this region. To investigate this we generate a series of constructs that retain different lengths of the 3' end of the 55K sequence. Hereto, pBr.Ad35 Δ SM.AdAptLacZ is first generated as follows. Construct pBr.Ad35.1ITR-pIX (described in WO 00/70071) is digested with SnaBI and MfeI, blunted with Klenow and de-phosphorylated with SAP enzyme (Roche). The 4.4 kb vector fragment is then isolated from agarose gel. Construct pAdApt.LacZ (An Ad5-based adapter plasmid pAdApt with LacZ transgene insert; WO 99/55132) is digested with AvrII and BglII (and, optionally, Sall to increase the difference in fragment size) and blunted with Klenow enzyme. The 4.2 kb CMV.LacZ.pA insert is then isolated from gel. Both isolated fragments are then ligated to give pBr.Ad35 Δ SM.AdAptLacZ (Figure7). The orientation can be checked by restriction digestion since ligation in the correct orientation restores both the AvrII site and the MfeI site. Construct pBr.Ad35 Δ SM.AdAptLacZ retains the 0.6 kb 3'E1B-55K sequences (wt Ad35 nucl 2804-3400) in the wt position relative to the pIX gene. Previously, we have shown that these 55K sequences do not lead to expression of a functional E1B-55K protein since propagation on PER.C6 cells appeared not possible (pBr.Ad35 Δ SM; WO 02/40665). Starting from pBr.Ad35 Δ SM.AdAptLacZ different deletions can be made of the 680 bp (0.7 kb) E1B-55K region by digestion with MfeI (isoschizomer of MunI) and either StuI, NsiI or BglII followed by blunting of the protruding ends using Klenow or T4 DNA polymerase in case of 5' or 3' overhang respectively. Religation of the digested DNA gives functional adapter plasmids that are then used to generate recombinant viruses on PER55K cells by co-transfection with pWE.Ad35.pIX-rITR as described above. Additional constructs are made by using enzymes DraIII, Bsu36I, BssHII or BamHI, and digest the vector partially (the LacZ gene also contains a recognition site for these enzymes) using methods known in the art, followed by selection of the correct clone. The stability is tested as described above for the Ad35.AdApt.LacZ.rsv construct. Constructs that are stable (i.e. do not acquire deletions in the transgene region) contain proper regulatory regions for pIX expression. In addition, it is possible to directly test promoter activity in a given sequence by inserting the sequence upstream of a reporter gene. pGL3basic (Promega) is such a reporter gene construct. The region between MunI and the start of the pIX gene was amplified using primer set Ad3555KmfeF and Ad35pIXNcoR. This PCR (2 minutes 94°C; then 30 cycles of [30 seconds 94 °C, 30 seconds 59°C, 60 seconds 72°C]; followed by 8 minutes 68°C; enzyme: Pwo (Genexis) according to manufacturer's instructions, with additional 3% DMSO) amplified Ad35 sequences from 2804 to 3491 (numbering as in wt Ad35) thereby changing the sequence around the start codon of pIX into an NcoI site and introducing an HindIII site at the 5' end. This amplified fragment is digested with HindIII and NcoI and cloned into pGL3basic digested with the same enzymes generating pGL3-MN. pGL3-MN is then used to delete sequences upstream of the Luciferase coding region by combining HindIII digestion with e.g. PacI, NsiI, StuI, Bsu36I, BssHII or BglII, followed by blunting of the protruding ends and religation. Promoter activity is tested by transient transfection of the obtained constructs into PER.C6 cells using lipofectamine reagent according to manufacturers instructions. Luciferase activity is analysed two days after transfection using Steady-Glo luciferase assay system (Promega) according to manufacturers instructions. Alternatively, into the pGL3basic vector different regions are inserted, which regions are generated by PCR amplification using a 5'(forward) primer directed to a specific sequence in the Ad35 E1B-55K region and having a HindIII site attached at the 5' end combined with the Nco-pIXrev primer. In this way one is not limited to the presence of a unique restriction site for cloning.

[0089] The location of the pIX promoter was further investigated by using software to find putative promoter sequences (Reese and Eeckman, 1995). Figure 8 shows the promoter scores (minimum set at 0.65) for the E1B promoter directly linked to the 55K coding sequence (as in pBr.Ad35. Δ E1A Δ 21K). The regions marked A corresponds to the E1B promoter and regions B and C locate within the 55K coding region. The pIX upstream region is not recognized as a promoter sequence. Region C has the highest score (0.96) of the three (even higher than the known E1B promoter) and may therefore comprise sequences that influence pIX expression. To locate and identify a possible pIX promoter experimentally, a series of small fragments corresponding to different (overlapping) parts of the 3'-end of the 55K coding sequence are generated. Figure 9 schematically depicts these fragments and their location relative to the putative promoter region and the pIX gene. The fragments are generated by restriction digestion using the indicated enzymes. Fragments are blunted with Klenow (5' protruding ends) or T4 DNA polymerase (3' protruding ends) and cloned into the NcoI site of the pGL3basic vector (Promega) also blunted by Klenow treatment and de-phosphorylated by SAP treatment (Roche). Following transformation into competent bacteria obtained plasmids are checked for the orientation of the insert by restriction digestion. Promoter activity is then analysed by transient transfection of the obtained luciferase constructs into PER.C6 cells using lipofectamine reagent according to manufacturers instructions. Empty pGL3basic plasmid serves as a negative control. Additional controls are made by cloning i) a BglII-MfeI fragment from pAdApt535 containing the Ad5 pIX promoter, ii) a 388 bp Nrul-ApaLI RSV promoter fragment (described above), or iii) the Ad35 pIX upstream region as a PCR fragment into the blunted NcoI site of pGL3basic as described above. The Ad35 upstream pIX region is amplified on pAdApt35IP1 using primers SV40-for and 5'-phosphorylated Ad35pIXrev. Following amplification the

DNA is digested with BglII and treated with Klenow.

[0090] Constructs are also transfected into human cells not containing adenovirus E1 (e.g. A549, Hela) to investigate the dependency on E1A expression.

[0091] The fragments are also cloned into an adapter plasmid pBr.Ad35ΔSM.AdAptLacZ (see above) to be able to generate recombinant viruses and study viral genome stability. Hereto, construct pBr.Ad35ΔSM.AdAptLacZ is digested with MfeI and BglII, blunted with Klenow enzyme and dephosphorylated. After gel isolation of the vector fragment, DNA can be ligated with the fragments described above (see Fig. 9) to give rise to a set of adapter plasmids that have varying lengths of 55K fragments upstream of the pIX gene. Viruses can be generated with the construct pWE.Ad35.pIX-rITR as described above. Control transfections are done with the pBr.Ad35ΔSM.AdAptLacZ, pAdApt35.LacZ and pAdApt35.LacZ.rsv constructs. Upon appearance of full CPE, cells and medium are harvested by one freeze/thaw cycle and used to re-infect fresh PER55K cells. Cells and medium are again harvested at full CPE, crude lysates are prepared and used to perform a plaque assay. After appearance of plaques, X-gal staining solution is added to check for LacZ expression.

[0092] The results of the above experiments aid in finding the position of pIX regulatory sequences in the Ad35 E1B-55K region.

[0093] As yet another alternative, pIX gene expression may be driven by the E1B promoter as a heterologous promoter for the generation of recombinant viruses. Hereto, pAdApt535.LacZ is digested with BglII and MfeI followed by Klenow treatment to blunt ends and dephosphorylation. The thus treated 4.8 kb vector fragment is then isolated from gel. The E1B promoter region is isolated as a PCR fragment using pBr.Ad35.leftITR-pIX as target DNA and the Epr-F and Epr-R primers, whereby both primers are phosphorylated. PCR is done with Pwo DNA polymerase (Genaxis/Inno-train Diagnostik GmbH) according to manufacturers instructions. The resulting 151 bp fragment is then cloned into the isolated vector to give pAdApt35Epr.LacZ

[0094] This plasmid is then used to generate Ad35-based viruses and test stability as described before.

[0095] To identify the different transcripts that contain pIX sequences, RNA is isolated from infected cells and pIX containing RNAs are identified by hybridisation with a labelled specific probe. Hereto, PER55K cells are infected at a multiplicity of infection of 10 and 50 with the following viruses: wtAd35, Ad35.E1B.AdApt.Luc, Ad35ΔE3.AdApt.Luc, Ad35ΔE3.AdApt535.Luc, Ad35.AdApt.Luc.rsv. Infected cells are harvested after 8 hrs (wtAd35 also after 2 and 18 hrs) and RNA is isolated using TRIzol Reagent (Invitrogen). This RNA is size fractionated on an 1.5% agarose gel, transferred to a Northern blot and hybridised to a 32P-labeled probe derived from the pIX coding region. Procedures are known in the art (described in Molecular Cloning: A laboratory manual, by Sambrook and Russell, 2001 or earlier versions). The length of the RNA can be determined if known RNA size markers are included and will give an indication of the RNA species that contain pIX sequences. To identify the mRNAs that start in the E1B promoter, the blot can be stripped and re-hybridised with a 5' 21K probe. pIX-containing transcripts that do not hybridise to the E1B-21K probe are likely generated by a promoter different from the E1B promoter.

[0096] Due to possible (and expected) splicing events it is still difficult to precisely determine transcription start sites via this method. This can be achieved as follows. The isolated RNA is reverse transcribed into cDNA and the cDNA is used to specifically amplify 5' ends of pIX containing RNAs using the GeneRacer System (Invitrogen) according to manufacturers instructions with the reverse primers directed to pIX coding sequences: pIXrev and the nested primer pIXrev-N2. Cloning and sequencing of the amplified fragments gives the location of the transcription start sites and 5' sequences of mRNAs that contain pIX sequences. In this way the possible pIX coding mRNAs are identified. The correlation between the levels of pIX expression and stability of the corresponding recombinant adenoviruses can thus also be determined.

Example 11. E1B and pIX sequences from group B adenoviruses.

[0097] Above examples use the Ad35 virus as an example. Other members of the subgroup B that have considerable homology to each other are could have comparable pIX regulation.

[0098] To investigate this, we aligned E1B and pIX sequences of subgroup B members. The sequence of Ad7 (SEQ. ID. NO. 57) is available via Genbank Accession number X03000. The sequence of Ad11 (SEQ. ID. NO. 56) was revealed by shotgun sequencing of DNA isolated from Ad11p wt viruses performed by Lark Technologies (UK) similar as described (WO 00/70071) for the Ad35 sequence (SEQ. ID. NO. 55). Ad11 and Ad35 are highly homologous to each other (overall 98.1% similarity), and the main differences are located in hexon and fiber knob.

The Ad11 sequence is also disclosed in WO 02/053759.

The sequence between the poly-adenylation site (pA) of E1A and the pA downstream of the pIX gene is used in the alignment (Fig. 10). Ad35 has an overall similarity (in this region) of 98.4% to Ad11 and 82.9 % to Ad7. This makes it very likely that pIX expression is regulated in the same way in these viruses.

[0099] Hence, the methods and means according to the invention as exemplified in the previous examples can be used accordingly to increase the stability and/or insert capacity of other recombinant adenoviruses of subgroup B, herein

exemplified by Ad11 and Ad7.

Example 17. E1-deleted Ad35 viruses with a heterologous promoter driving pIX expression.

[0100] To investigate the effect of a heterologous promoter sequence activating the pIX gene in full E1-deleted viruses, a series of adapter plasmids was used to generate recombinant Ad35 viruses. Hereto, pAdApt35LacZ, pAdApt35.LacZ.rsv (example 9), pAdApt535.LacZ (example 5) and pAdApt35BLacZ (containing the Ad35 E1B promoter sequence in front of the pIX gene; described below) were digested with pIPsp-1 and used to generate viruses with NotI digested cosmid pWE/Ad35-3481 and pWE/Ad35-3481ΔE3 (example 7) as described in example 2 (and in WO 00/70071). In addition, viruses were generated with adapter plasmid pBr.Ad35ΔSM.AdAptLacZ (Figure 7; example 10). This adapter plasmid is deleted for E1A and a large part of the E1B sequences. It retains 0,6 kb of the 3' E1B-55K sequence and also has wt sequences between the stop codon of 55K and the start codon of pIX.

Upon full CPE, the cells and medium were harvested, freeze/thawed and centrifuged to remove the cell debris. The supernatant (cleared lysates) of each of the transfections was then used to perform a plaque assay as described in example 9. Cleared lysates were diluted serially tenfold and 10⁻⁵ to 10⁻⁹ dilutions were plated.

One week after addition of the agar overlay, plaques became visible and were stained with X-gal to monitor LacZ activity. Table VI summarizes the results of these experiments. All Ad35 viruses having additional or other sequences than just the endogenous proximal pIX upstream sequence regulating pIX perform better and have a higher number of expressing plaques in our assay as compared to the E1-deleted Ad35.AdApt.LacZ viruses. Note that the total genome length of the Ad35ASM.LacZ viruses (106% compared to wt Ad35) exceeds the maximum packable length as determined for Ad5 viruses (105%). This may influence the results obtained for this virus. The Ad35.AdApt.LacZ.rsv (105%) are also at the border of the theoretical packagable size. Altogether the results show that a heterologous promoter driving pIX expression improves the maximum tolerated packaging size and the stability stability of E1-deleted Ad35 viruses. The same is true for viruses that have a longer endogenous proximal sequence (Ad35ASM.LacZ) suggesting that the additional (E1B 55K) sequences herein contain regulatory elements for pIX expression. pAdapt35BLacZ is an Ad35 adapter plasmid with the Ad35 E1B promoter sequence regulating the pIX gene.

Adapter plasmid pAdApt35BLacZ was generated as follows:

The E1B promoter fragment was amplified using the primers 35E1Blong and Ad35E1bpromrev. Both primers were phosphorylated. The reaction was done with Pwo DNA polymerase (Inno-train, Diagnostic GmbH) according to manufacturer instructions. pBr.Ad35.leftITR-pIX was used as template DNA, (25 ng, described in WO 02/40665). The program was set as follows: 2 minutes at 94°C and then 30 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute) and ended by 10 minutes at 72°C. The cooling/heating slope was set at 2°C/sec. This PCR results in amplification of the potential E1B promoter of Ad35 of 125 nucleotides. Construct pAdapt535.LacZ (example 5) was then digested with MfeI and BglII. After digestion the vector was treated with Klenow enzyme to create blunt ends. A dephosphorylation step was done using SAP (Roche). The thus treated 8 kb vector fragment was then isolated from gel. The E1B promoter region was also isolated from gel. These two fragments were ligated and transformed into DH5α-T1r competent cells (Invitrogen). The correct orientation of the E1B promoter in the resulting plasmid was confirmed by digesting with HpaI and ApaLI. After selection of the correct clone the inserted E1B promoter sequence was also verified by sequencing.

Example 18. The promoter of the pIX gene is located in the 3' end of the E1B-55K coding sequence in Ad35 and Ad11 viruses.

[0101] Based on the results described *supra* we expected that the pIX promoter in subgroup B viruses would be located in the E1B-55K coding region. To investigate this directly, we set out to identify the pIX mRNA cap site as described in example 10. Hereto, wtAd35, wtAd11 and Ad35.E1B⁺.AdApt.Luc viruses were used to infect PER55K clone 16 cells at an MOI of 50 VP/cell. As a control wtAd5 was taken along since the promoter and mRNA start site of this virus is known. RNA was isolated from the infected cultures at 16-18 hrs post-infection using TRIzol agent (Invitrogen) as described by the manufacturer. At the end of the procedure, the isolated RNA was stored in 100% formamide. The GeneRacer Kit (Invitrogen) was used to amplify the 5' end of pIX transcripts, in order to locate the start of transcription. Before starting GeneRacer protocol, 5 μg RNA was purified from the formamide by sodium acetate precipitation as described in the GeneRacer protocol. Purified RNA was treated according to manufacturer's Protocol for amplification of the 5' end of the pIX mRNA. After phosphatase treatment and subsequent removal of the cap structure with tobacco acid pyrophosphatase and ligation of the Generacer RNA oligo, SuperScript[™] II Reverse Transcriptase from the kit was used for cDNA synthesis. cDNA was synthesized by reverse transcription using a gene specific (reverse) primer for pIX. For Ad35 (wt and E1B⁺Luc virus) and wtAd11 primer pIXrev was used, for Ad5 the primer pIXrev-Ad5 was used. The resulting cDNA (1 μl of unknown concentration) was used as a template for PCR to generate dsDNA. This PCR was done using Pwo DNA polymerase (Roche) according to manufacturers instructions, and with addition of DMSO (Sigma; 3% v/v). The amplification was done with the GeneRacer 5' primer from the kit which

is specific for the oligonucleotide ligated to the 5' end of the mRNA, and the gene specific reverse primers, as mentioned above.

Reaction conditions were as follows: denaturation at 94°C for 2 minutes, followed by 30 cycles of (94°C for 30 seconds, 64°C for 30 seconds, 72°C for 2 minutes) and finished by elongation at 68°C for 8 minutes. The resulting DNA fragments were size separated by electrophoresis on a 1.0% agarose gel. For Ad5 a 480 bp fragment and for Ad35 (both viruses) and Ad11 a 200 bp fragment was obtained. Ad11 also showed a 2 kb fragment. All fragments were excised and purified from agarose gel. The purified DNA fragments were cloned into the pCR4Blunt-TOPO® vector (Invitrogen). The vectors were sequenced using commercial M13 Forward and Reverse primers. The resulting sequences were aligned against wildtype sequences to locate the start of pIX transcription. The 200 bp band isolated from Ad35 and Ad11 cDNA preparations constituted the genuine pIX mRNA, the 2 kb fragment isolated from Ad11 turned out to originate from the E1B promoter. Fig. 14 shows an alignment of the Ad35 (SEQ. ID. NO. 59) and Ad11 (SEQ. ID. NO. 58) cDNA sequences with the wt Ad35 sequence (SEQ. ID. NO. 60). The alignment reveals the location of a spliced intron sequence in the pIX mRNA. In Fig. 15 the location of the identified cap site and splice sites is schematically shown in the E1B-pIX region of Ad35. For Ad5 the expected pIX mRNA (Babiss and Vales, 1991) was identified with the cap site located at position 3580 (not shown; numbering as in genbank accession no. M73260). For Ad35 the cap site was located in the 3' end of the E1H-55K gene at position 3339 on an A residue (Ad35 sequence WO 00/70071). In Ad11 the cap site was similarly found on a T residue (position 3339 in Genbank Acc No. AY163756). Interestingly, the sequence between the stop codon of the 55K gene and the start codon of the pIX, where in Ad5 viruses the promoter for pIX is located, is spliced out of the mRNA in Ad35 and Ad11 viruses. These results provide strong evidence that in Ad35 and Ad11 pIX gene expression is regulated from a promoter located in the 3' end of the 55K gene.

Example 19: E1-deleted Ad35 viruses that retain a short stretch of 3' E1B-55K sequence have a larger packaging capacity.

[0102] With the identification of the pIX mRNA cap site it becomes possible to include the natural Ad35 promoter for correct pIX expression and also limit as much as possible the E1B-55K sequences in the viral vector. Here we show, as a non-limiting example, the construction of an Ad35 adapter plasmid that retains 166 bp of the 3' end of the 55K coding sequence (pAdApt35Bsu.Luc) and the generation of an E1-deleted Ad35Luc virus with increased stability and/or packaging capacity. This 166 bp sequence does not code a functional 55K gene product but contains the pIX mRNA cap site identified in the previous example in its natural position relative to the pIX coding sequence. Construct pAdApt35Bsu.Luc was generated as follows:

First a PCR fragment was generated using 40ng pBr.Ad35.leftITR-pIX as target DNA (described in WO 02/40665) and primers Bsu55KF and Age-pIXR. The PCR was performed with Pwo DNA polymerase (Genaxis) according to manufacturer instructions. In addition, 3% v/v DMSO (Sigma) was used. The program was set as follows: 2 minutes at 94°C, then 30 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1.5 minute) and ended by 8 minutes at 68°C. The resulting 1.2 kb product was cloned directly into the pCR4Blunt-TOPO vector (Invitrogen) according to the manufacturer's protocol, resulting in pCR4Blunt-TOPO.Bsu-Age. The construct was checked by digestion with PvuII (New England Biolabs). The Bsu-Age fragment was isolated from the pCR4Blunt-TOPO.Bsu-Age plasmid by digestion with Bsu36I (New England Biolabs) and treated with Klenow enzyme (New England Biolabs) to blunt ends. The DNA was then purified using the PCR purification kit (Qiagen) and was digested with AgeI (New England Biolabs). The 1 kb fragment was isolated from gel using the Gene clean II kit (Bio101, Inc.). In parallel, construct pAdApt35.Luc (described in WO 00/70071) was digested with BglII and treated with Klenow enzyme. The DNA was purified using the PCR purification kit (Qiagen). The purified DNA was digested with AgeI (New England Biolabs) and dephosphorylated with SAP (Roche). The 5.8-Kb fragment was isolated from gel with the Gene clean II kit (Bio101). The two fragments were mixed in equimolar amounts in a ligation reaction and transformed into T1 resistant EM DH10B cells (Invitrogen). This resulted in plasmid pAdApt35Bsu.Luc.

To generate E1-deleted viruses pAdApt35Bsu.Luc was digested with pIPsp-I and cotransfected onto PER55K clone 16 cells with NotI digested pWE.Ad35-3481 (example 7) and with pWE.Ad35-3481ΔE3 as described before. pWE.Ad35-3481ΔE3 contains the same E3 deletion as described for pWEAd35.pIX-rITRΔE3 (example 2) and was generated according to the method described in example 7 using construct pWE.Ad35-3481 ΔNdeI and a 26,6 kb NdeI fragment from pWE.Ad35.pIX-rITRΔE3.

In addition, E1-deleted Ad35 viruses were generated that contained the E4-Orf6 and E4-Orf6/7 sequences from Ad5 in the viral backbone replacing the native Ad35 sequences (see WO 03/104467 for the generation of such viruses on unmodified PER.C6 cells). In the current example pAdApt35Bsu.Luc digested with pIPsp-I is cotransfected with NotI/EcoRV digested pWEAd35.pIX-EcoRV and with PacI/NotI digested pBr.Ad35.PR5Orf6 (with and without E3 region). All transfections gave rise to full CPE within a week following transfection and cells and medium were harvested as described

before. Viruses were then plaque purified and viral stocks amplified on the appropriate complementation cells and originating from single plaques were analysed by PCR for integrity of the transgene region. Transgene PCRs were done as described in example 3 using primers AdApt35CMVF and pIXrevN2. Fig. 16 shows an example of the PCR results on plaques originating from Ad35Bsu.Luc and from Ad35Bsu.Luc.5ORf6 viruses.

Irrespective of the presence of the E3 region or of the E4-Orf6 sequence in the viral backbone, all tested plaques (5-10 for each virus) contained an intact transgene. One exception occurred in one of the plaques from Ad35Bsu.Luc viruses that showed a faint band at approximately 1,6 kb (Fig. 16, lane 12) probably originating from minor amount of viruses with a deletion.

The faint band at approximately 500 bp that occurs in all virus samples, is a background band of the primers on the viral backbone. The observation that E3-containing Ad35 viruses with a luciferase expression cassette proved stable following plaque purification is in contrast to previous results with Ad35.AdApt.Luc viruses that are fully E1-deleted and do not contain the 166 bp 3' 55K coding sequence. Using standard pAdApt35.Luc plasmids, we were not able to generate plaque-purified viruses containing the E3 region. Thus with incorporation of the extra 55K sequences in the backbone we can now make viruses of more than 34.6 kb total length without severe instability. This closely matches the length of a wt Ad35 virus. If an E3-deleted backbone were used, the capacity for foreign sequences theoretically would be over 5 kb. Obviously, it is possible to incorporate more E1B-55K sequences than in the current example and/or to combine the 3' 55K sequences with heterologous enhancer sequences without departing from the invention disclosed herein.

TABLES

[0103]

Table I: Yields of E1- and E1/E3- deleted Ad35 viruses on clone #16 cells produced on triple layer flasks.

Virus	Scale (T175 ¹¹¹ flasks)	Total # of Virus Particles after DSP	VP/cell
Ad35.AdApt.eGFP	4	7.5x10 ¹¹	2500
Ad35.ΔE3.AdApt.empty	8	2x10 ¹²	3300
Ad35.ΔE3.AdApt.LacZ	8	3.8x10 ¹¹	600
Ad35.ΔE3.AdApt.MV-F	4	8.8x10 ¹¹	2900
Ad35.ΔE3.AdApt.MV-H	8	2.6x10 ¹²	4250

Table II: Transgene (LacZ) activity test on A549 using crude lysates from second passage virus. % blue cells is given for each amount of virus used for infection.

Virus	10 μl	1 μl	0.1 μl
Ad35.AdApt.LacZ.rsv	95	15	<1
Ad35.ΔE3.AdApt.LacZ.rsv	90	10	<1
Ad35.AdApt.LacZ.C4	2	<0.1	0
Ad35.ΔE3.AdApt.LacZ.C4	15	<1	<0.1

Table III: Transgene (Luciferase) activity test on A549 using crude lysates from second passage virus. Activity is expressed in relative light units (RLU).

Virus	10 μl	1 μl	0.1 μl	0.01 μl
Ad35.AdApt.Luc.rsv	845453	27940	178	26
Ad35.ΔE3.AdApt.Luc.rsv	258269	2217	46	6
Ad35.AdApt.Luc.C4	6130	175	18	33
Ad35.ΔE3.AdApt.Luc.C4	814642	6278	147	23
Ad35. ΔE1AΔ21K.Luc	1514698	50196	503	57

Table IV: Primer sequences.

name	sequence	SEQ. ID. NO.
35E3for	5'-AATGACTAATGCAGGTGCGC-3'	19
35E3rev	5'-CGACGCGTTGTAGTCGTTGAGCTTCTAG-3'	20
AdApt35CMVF	5'-GTAGGTGTCAGCCTAGGTGGTC-3'	21
35pIXR	5'-TCATGTCAGCTGCAAGACAG-3'	22
SV40for	5'-CAATGTATCTTATCATGTCTAG-3'	23
pIX5Rmfe	5'-CTCTCTCAATTGCAGATACAAAACCTACATAAGACC-3'	24
pIX35Fmfe	5'-CTCTCTCAATTGTCTGTCTTGCAGCTGACATG-3'	25
AdApt35pIXrev	5'-CAATCTGTCCATCTGAAAATCC-3'	26
pIXcosF-2	5'- CTGCTGGACGTCGCGGCCGCGACATGAGTGGAAATGCTT C-3'	27
Adapt35-3	5'-TGCAAATCTGTGAGGGGAAC-3'	28
35D21	5'-TTA GAT CCA TGG ATC CCG CAG ACT C-3'	29
35B3	5'-CCT CAG CCC CAT TTC CAG-3'	30
35F1	5'- CGGAATTCTTAATTAATCGACATCATCAATAATATACCT TATAG-3'	31
35R4	5'- CGGAATTCTTCTTAATTAAGGGAAATGCAAATCTGTGAG G-3'	32
Ad3555KMfeF	5'-AACCAAGCTTCAATTGTCTCTGAA-3'	33
Ad35pIXNcoR	5'-CCACCCATGGCAGCTGCAAGACAG-3'	34
Ad35pIXrev	5'-TCAGCTGCAAGACAGAAAAAAC-3'	35
Epr-F	5'-GTGTTTACTTAAGGTGACGTC-3'	36
Epr-R	5'-GAAAGCCAGCTCCTATGAGC-3'	37
pIXrev	5'-GGCGGGTTGAACGGGTCTTCCA-3'	38
pIXrev-N2	5'-GATGGGAGACGCCCTGTCAGATAAGG-3'	39
35E1Blong	5'-AAGGTGACGTCAATATTTGTGTG-3'	40
Ad35E1bpromrev	5'-ATGAAAGCCAGCTCCTATGAG-3'	41
pIXrev-Ad5	5'-AGGGGAGGAAGCCTTCAGG-3'	42
Bsu55KF	5'-AGG TGG GCG TAG AGG AAT G-3'	43
Age-pIXR	5'-CAA GAC GGG ATC TTG GCG G-3'	44

Table VI: Percentages of LacZ positive plaques of Ad35 viruses having different promoter sequences driving pIX expression. (NP= no plaques visible)

Virus name	% of blue plaques		virus length (incl. E3 region)
	with E3 region	w/o E3 region	
Ad35.AdApt.LacZ	0%	50%	36,1 kb
Ad535.AdApt.LacZ	NP	100%	36,1 kb
Ad35.AdAptB.LacZ	5%	80%	36,2 kb
Ad35.AdApt.LacZ.rsv	90%	100%	36,5 kb
Ad35ΔSM.LacZ	50%	100%	36,7 kb

REFERENCES

[0104]

- Abrahamsen K, Kong H-L, Mastrangeli A, Brough D, Lizonova A, Crystal R and Falck-Pedersen E. (1997) Construction of an adenovirus type 7a E1A- vector. *J Virol* 11:8946-8951.
- Babiss, L.E. and Vales, L.D. (1991). Promoter of the adenoviral polypeptide IX gene: Similarity to E1B and inactivation by substitution of the simian virus TATA element. *J. Virol.* 65(2), p598-605.
- Bett, A.J., Prevec, L. and Graham, F.L. (1993). Packaging capacity and stability of human adenovirus type 5 vectors. *J. Virol.* 67(10), p5911-5921.
- Boshart, M., Weber, F., Jahn, G., Dorsch-Hasler, K., Fleckenstein B. and Schaffner W. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 41, 521-530.
- Caravokyri, C. and Leppard, K.N. (1995). Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. *J. Virol.* 69(11), p6627-6633.
- Fallaux, F.J., Kranenburg, O., Cramer, S.J., Houweling, A., van Ormondt, H., Hoebe, R.C. and van der Eb, A.J. (1996). Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. *Hum. Gene Ther.* 7, p 215-222.
- Fallaux, F.J., Bout, A., van der Velde, I., van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., van Ormondt, H., van der Eb, A.J., Valerio, D. and Hoebe, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. *Hum. Gene Ther.* 9, p 1909-1917.
- Farina, S.F., Gao, G.P., Xiang, Z.Q., Rux, J.J., Burnett, R.M., Alvira, M.R., Marsh, J., Ertl, H.C. and Wilson, J.M. (2001). Replication-defective vector based on a chimpanzee adenovirus. *J. Virol.* 75(23), p11603-11613.
- Francki, R.I.B., Fauquet, C.M., Knudson, L. and Brown, F. (1991). Classification and nomenclature of viruses. Fifth report of the international committee on taxonomy of viruses. *Arch. Virol. Suppl.* 2, p 140-144.
- Furcinitti, P.S., van Oostrom, J. and Burnett R.M. (1989). Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. *EMBO J.* 8(12), p3563-3570.
- Graham, F.O., Smiley, J., Russell, W. and Nairn, R. (1970). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen. Virol.* 36, p59-72.
- Ghosh-Choudhury, G., Haj-Ahmad, Y. and Graham, F.L. (1987). Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. *EMBO J.* 6(6), p1733-1739.
- Hehir, K.M., Armentano, D., Cardoza, L.M., Choquette, T.L., Berthelette, P.B., White, G.A., Couture, L.A., Everton, M.B., Keegan, J., Martin, J.M., Pratt, D.A., Smith, M.P., Smith, A.E. and Wadsworth, S.C. (1996). Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. *J. Virol.* 70(12), p8459-8467.
- Herrman, C.H. and Mathews, M.B. (1989). The adenovirus E1B 19-kilodalton protein stimulates gene expression by increasing DNA levels. *Mol. Cell. Biol.* 9, p5412-5423.
- Lutz, P., Rosa-Calatrava, M. and Keding, C. (1997). The product of the adenovirus intermediate gene IX is a transcriptional activator. *J. Virol.* 71(7), p5102-5109.
- Pilder, S., Logan, J. and Shenk, T. (1984). Deletion of the gene encoding the adenovirus type 5 early region 1B 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. *J. Virol.* 52(2), p664-671.
- Pilder, S., Moore, M., Logan, J. and Shenk, T. (1986). The adenovirus E1B 55K transforming polypeptide modulates

transport or cytoplasmic stabilization of viral and host cell mRNAs. *Mol. Cell. Biol.* 6, p470-476.

Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S. and White, E. (1992). The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. *Proc. Natl. Acad. Sci. USA* Vol. 89, pp 7742-7746.

Reese, M.G. and Eeckman, F.H. (1995). Novel neural network algorithms for improved eukaryotic promoter site recognition. Talk and Abstract from The seventh international genome sequencing and analysis conference. Hyatt Regency, Hilton Head Island, South Carolina, Sept 16-20, 1995. (http://www.fruitfly.org/seq_tools/promoter.html). Robert, J.-J., Gauffeny, I., Maccario, J., Jullien, C., Benoit, P., Vigne, E., Crouzet, J., Perricaudet, M. and Yeh, P. (2001). Degenerated pIX-IVa2 adenoviral vector sequences lowers reacquisition of the E1 genes during virus amplification in 293 cells. *Gene Ther.* 8, p1713-1720.

Russell, W.C. (2000). Update on adenoviruses and its vectors. *J. Gen. Virol.* 81, pp 2573-2604.

Sambrook, J. and Russell, D. *Molecular Cloning: A laboratory manual*. Third Edition. Cold Spring Harbor Press (2001). ISBN 0-87969-576-5.

Shabram, P.W., Giroux, D.D., Goudreau, A.M., Gregory, R.J., Horn, M.T., Huyghe, B.G., Liu, X., Nunnally, M.H., Sugarman, B.J. and Sutjipto, S. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. *Hum. Gene Ther.* 8(4): 453-465.

Shenk, T. (1996). *Adenoviridae: The viruses and their replication*. In *Virology*, eds. Fields, B.N., Knipe, D.M. and Howley, P.M. (Lippincott-Raven, New York), Vol. 2, pp 2111-2148.

White, E., Grodzicker, T. and Stillman, B.W. (1984). Mutations in the gene encoding the adenovirus early region 1B 19,000 molecular-weight tumor antigen cause degradation of chromosomal DNA. *J. Virol.* 52(2), p410-419.

Yew, P.R. and Berk, A.J. (1992). Inhibition of p53 transactivation required for transformation by adenovirus early region 1B protein. *Nature* 357, pp 82-85.

SEQUENCE LISTING

[0105]

<110> Crucell Holland B.V.

vogels, Ronald

Havenga, Menzo J.E.

zuijdgeest, David A.T.M.

<120> stable adenoviral vectors and methods for propagation thereof

<130> 0076WO00ORD

<150> EP02102631.5

<151> 2002-11-25

<150> PCT/NL02/00281

<151> 2002-04-25

<150> PCT/NL02/00656

<151> 2002-10-15

<160> 65

<170> PatentIn version 3.2

<210> 19

<211> 20

<212> DNA

<213> Artificial

<220>

<223> primer 35E3for

<400> 19

aatgactaat gcaggtgcgc 20

<210> 20

<211> 28

<212> DNA

<213> Artificial

<220>

<223> primer 35E3rev

<400> 20

cgaccggtg tagtcgtga gcttctag 28

<210> 21

<211> 22
 <212> DNA
 <213> Artificial
 <220>
 5 <223> primer AdApt35CMVF
 <400> 21
 gtaggtgtca gcctaggtgg tc 22
 <210> 22
 <211> 20
 10 <212> DNA
 <213> Artificial
 <220>
 <223> primer 35pIXR
 <400> 22
 15 tcatgtcagc tgcaagacag 20
 <210> 23
 <211> 22
 <212> DNA
 <213> Artificial
 20 <220>
 <223> primer sv40for
 <400> 23
 caatgtatct tatcatgtct ag 22
 <210> 24
 25 <211> 35
 <212> DNA
 <213> Artificial
 <220>
 <223> primer pIX5Rmfe
 30 <400> 24
 ctctctcaat tgcaagataca aaactacata agacc 35
 <210> 25
 <211> 32
 <212> DNA
 35 <213> Artificial
 <220>
 <223> primer pIX35Fmfe
 <400> 25
 ctctctcaat tgtctgtctt gcagctgaca tg 32
 40 <210> 26
 <211> 22
 <212> DNA
 <213> Artificial
 <220>
 45 <223> primer AdApt35pIXr
 <400> 26
 caatctgtcc atctgaaaat cc 22
 <210> 27
 <211> 40
 50 <212> DNA
 <213> Artificial
 <220>
 <223> primer pIXcosF-2
 <400> 27
 55 ctgctggacg tcgcgccgc gacatgagtg gaaatgcttc 40
 <210> 28
 <211> 20
 <212> DNA

<213> Artificial
 <220>
 <223> primer Adapt35-3
 <400> 28
 5 tgcaaatctg tgaggggaac 20
 <210> 29
 <211> 25
 <212> DNA
 <213> Artificial
 10 <220>
 <223> primer 35D21
 <400> 29
 ttagatccat ggatcccgca gactc 25
 <210> 30
 15 <211> 18
 <212> DNA
 <213> Artificial
 <220>
 <223> primer 35B3
 20 <400> 30
 cctcagcccc attccag 18
 <210> 31
 <211> 44
 <212> DNA
 25 <213> Artificial
 <220>
 <223> primer 35F1
 <400> 31
 cggaattctt aattaatcga catcatcaat aatatacctt atag 44
 30 <210> 32
 <211> 40
 <212> DNA
 <213> Artificial
 <220>
 35 <223> primer 35R4
 <400> 32
 cggaattctt ctaattaag ggaaatgcaa atctgtgagg 40
 <210> 33
 <211> 24
 40 <212> DNA
 <213> Artificial
 <220>
 <223> primer Ad3555KMfeF
 <400> 33
 45 aaccaagctt caattgtctc tgaa 24
 <210> 34
 <211> 24
 <212> DNA
 <213> Artificial
 50 <220>
 <223> primer Ad35pIXNCOR
 <400> 34
 ccacccatgg cagctgcaag acag 24
 <210> 35
 55 <211> 22
 <212> DNA
 <213> Artificial
 <220>

<223> primer Ad35pIXrev
 <400> 35
 tcagctgcaa gacagaaaaa ac 22
 <210> 36
 5 <211> 21
 <212> DNA
 <213> Artificial
 <220>
 <223> primer Epr-F
 10 <400> 36
 gtgtttactt aaggtgacgt c 21
 <210> 37
 <211> 20
 <212> DNA
 15 <213> Artificial
 <220>
 <223> primer Epr-R
 <400> 37
 gaaagccagc tcctatgagc 20
 20 <210> 38
 <211> 22
 <212> DNA
 <213> Artificial
 <220>
 25 <223> primer pIXrev
 <400> 38
 ggcgggtga acgggtcttc ca 22
 <210> 39
 <211> 26
 30 <212> DNA
 <213> Artificial
 <220>
 <223> primer plxrev-N2
 <400> 39
 35 gatgggagac gccctgtcag ataagg 26
 <210> 40
 <211> 23
 <212> DNA
 <213> Artificial
 40 <220>
 <223> primer 35E1Blong
 <400> 40
 aaggtgacgt caatattgt gtg 23
 <210> 41
 45 <211> 21
 <212> DNA
 <213> Artificial
 <220>
 <223> primer Ad35E1bpromrev
 50 <400> 41
 atgaaagcca gtcctatga g 21
 <210> 42
 <211> 19
 <212> DNA
 55 <213> Artificial
 <220>
 <223> primer plxrev-Ad5
 <400> 42

aggggaggaa gccttcagg 19
 <210> 43
 <211> 19
 <212> DNA
 5 <213> Artificial
 <220>
 <223> primer Bsu55KF
 <400> 43
 aggtgggcgt agaggaatg 19
 10 <210> 44
 <211> 19
 <212> DNA
 <213> Artificial
 <220>
 15 <223> primer Age-pIXR
 <400> 44
 caagacggga tcttggcgg 19
 <210> 45
 <211> 102
 20 <212> DNA
 <213> Adenovirus type 2
 <220>
 <221> misc_feature
 <223> Ad2 proximal pIX upstream sequence
 25 <220>
 <221> E1B 55K stopcodon
 <222> (1)..(3)
 <220>
 <221> sp1 site
 30 <222> (18)..(24)
 <220>
 <221> TATA_signal
 <222> (45)..(51)
 <220>
 35 <221> pIX startcodon
 <222> (99)..(102)
 <400> 45

 40 **tgagggtactg aaatgtgtgg gcgtggccta aggggtgggaa agaatatata aggtgggggt 60**
ctcatgtagt tttgtatctg ttttgcagca gccgccgcca tg 102

 <210> 46
 45 <211> 105
 <212> DNA
 <213> Adenovirus type 5
 <220>
 <221> misc_feature
 50 <223> Ad5 proximal pIX upstream sequence
 <220>
 <221> E1B 55K stopcodon
 <222> (1)..(3)
 <220>
 55 <221> Sp1 site
 <222> (18)..(24)
 <220>
 <221> TATA_signal

<222> (45)..(51)
 <220>
 <221> pIX startcodon
 <222> (103)..(105)
 <400> 46

5

tgagggtactg aaatgtgtgg gcgtggctta aggggtgggaa agaatatata aggtgggggt 60

cttatgtagt tttgtatctg ttttgcagca gccgccgccg ccatg 105

10

<210> 47
 <211> 84
 <212> DNA
 <213> Adenovirus type 12
 <220>
 <221> misc_feature
 <223> Ad12 proximal pIX upstream sequence
 <220>
 <221> E1B 55K stopcodon
 <222> (1)..(3)
 <220>
 <221> pIX startcodon
 <222> (81)..(84)
 <400> 47

15

20

25

tgaggtaagt ggggtggagct aggtgggatt ataaaaggct ggaagtcaac taaaaattgt 60

ttttgttctt ttaacagcac gatg 84

30

<210> 48
 <211> 93
 <212> DNA
 <213> Adenovirus type 9
 <220>
 <221> misc_feature
 <223> Ad9 proximal pIX upstream sequence
 <220>
 <221> E1B 55K stopcodon
 <222> (1)..(3)
 <220>
 <221> pIX startcodon
 <222> (91)..(93)
 <400> 48

35

40

45

tagaggtagg tcgagtgagt agtgggctg gctaagggtga ctataaaggc ggggtgtctta 60

cgagggtctt tttgcttttc tgcagacatc atg 93

50

<210> 49
 <211> 73
 <212> DNA
 <213> Adenovirus type 40
 <220>
 <221> misc_feature
 <223> Ad40 proximal pIX upstream sequence

55

	<220>		
	<221> E1B 55K stopcodon		
	<222> (1)..(3)		
	<220>		
5	<221> pIX startcodon		
	<222> (71)..(73)		
	<400> 49		
10	taagggtaag gggcggagcc tattacaggt ataaaggttg gggtagagta aaaaaaaggg	60	
	aagttacaaa atg	73	
15	<210> 50		
	<211> 90		
	<212> DNA		
	<213> Adenovirus type 4		
	<220>		
	<221> misc_feature		
20	<223> Ad4 proximal pIX upstream sequence		
	<220>		
	<221> E1B 55K stopcodon		
	<222> (1)..(3)		
	<220>		
25	<221> pIX startcodon		
	<222> (88)..(90)		
	<400> 50		
30	tagagtgagt agtgttctgg ggcgggggag gacctgcatg agggccagaa taactgaaat	60	
	ctgtgctttt ctgtgtgttg cagcagcatg	90	
35	<210> 51		
	<211> 90		
	<212> DNA		
	<213> simian Adenovirus type 25		
	<220>		
	<221> misc_feature		
40	<223> sAd25 proximal pIX upstream sequence		
	<220>		
	<221> E1B 55K stopcodon		
	<222> (1)..(3)		
	<220>		
45	<221> pIX startcodon		
	<222> (88)..(90)		
	<400> 51		
50	tagagtgagt agtgttctgg ggcgggggag gacctgcatg agggccagaa taactgaaat	60	
	ctgtgctttt ctgtgtgttg cagcagcatg	90	
55	<210> 52		
	<211> 89		
	<212> DNA		
	<213> Adenovirus type 35		
	<220>		

<221> misc_feature
 <223> Ad35 proximal pIX upstream sequence
 <220>
 <221> E1B 55K stopcodon
 5 <222> (1)..(3)
 <220>
 <221> pIX startcodon
 <222> (87)..(89)
 <400> 52
 10

taagggtgagt attgggaaaa ctttggggtg ggattttcag atggacagat tgagtaaaaa 60
tttgtttttt ctgtcttgca gctgacatg 89
 15

<210> 53
 <211> 89
 <212> DNA
 <213> Adenovirus type 11
 20 <220>
 <221> misc_feature
 <223> Ad11 proximal pIX upstream sequence
 <220>
 <221> E1B 55K stopcodon
 25 <222> (1)..(3)
 <220>
 <221> pIX stopcodon
 <222> (87)..(89)
 <400> 53
 30

taagggtgagt attgggaaaa ctttggggtg ggattttcag atggacagat tgagtaaaaa 60
tttgtttttt ctgtcttgca gctgtcatg 89
 35

<210> 54
 <211> 100
 <212> DNA
 <213> Adenovirus type 7
 40 <220>
 <221> misc_feature
 <223> Ad7 proximal pIX upstream sequence
 <220>
 <221> E1B 55K stopcodon
 45 <222> (1)..(3)
 <220>
 <221> pIX startcodon
 <222> (98)..(100)
 <400> 54
 50

taaagtaagt agtgggggca aaatgtggat ggggactttc aggttggtaa ggtggacaaa 60
ttgggtaaat tttgttaatt tctgtcttgc agctgcatg 100
 55

<210> 55
 <211> 2430
 <212> DNA

EP 1 497 440 B1

<213> Adenovirus type 35
 <220>
 <221> misc_feature
 <223> Ad35 E1B-pIX region
 <400> 55

5
 aataaaaaata tgttaactgt tcactgggtt ttattgcttt ttgggcgggg actcaggtat 60
 ataagtagaa gcagacctgt gtggttagct cataggagct ggctttcatc catggagggtt 120
 10 tgggccattt tggaagacct taggaagact aggcaactgt tagagagcgc ttccggacgga 180
 gtctccggtt tttggagatt ctggttcgct agtgaattag ctagggtagt ttttaggata 240

15

20

25

30

35

40

45

50

55

	aaacaggact ataaacaaga atttgaaaag ttgttggttag attgcccagg actttttgaa	300
	gctcttaatt tgggccatca gggtcacttt aaagaaaaag ttttatcagt tttagacttt	360
5	tcaacccag gtagaactgc tgctgctgtg gcttttctta cttttatatt agataaatgg	420
	atccccgaga ctcatattcag caggggatac gttttggatt tcatagccac agcattgtgg	480
	agaacatgga aggttcgcaa gatgaggaca atcttaggtt actggccagt gcagcctttg	540
10	ggtgtagcgg gaatcctgag gcatccaccg gtcatgccag cggttctgga ggaggaacag	600
	caagaggaca acccgagagc cggcctggac cctccagtgg aggaggcgga gtagctgact	660
	tgtctcctga actgcaacgg gtgcttactg gatctacgtc cactggacgg gataggggcg	720
15	ttaagaggga gagggcatcc agtggtagt atgctagatc tgagttggct ttaagtttaa	780
	tgagtcgcag acgtcctgaa accatttggt ggcatgaggt tcagaaagag ggaagggatg	840
	aagtttctgt attgcaggag aaatattcac tggaacaggt gaaaacatgt tggttggagc	900
20	cagaggatga ttgggcggtg gccattaaaa attatgccaa gatagctttg aggcctgata	960
	aacagtataa gatcagtaga cggattaata tccggaatgc ttgttacata tctggaaatg	1020
	gggctgaggt ggtaatagat actcaagaca agacagttat tagatgctgc atgatggata	1080
25	tgtggcctgg agtagtcggt atggaagcag tcacttttgt aaatgttaag tttaggggag	1140
	atggttataa tggaatagtg tttatggcca ataccaaact tatattgcat ggttgtagct	1200
	tttttggttt caacaatacc tgtgtagatg cctggggaca ggtagtgta cgggggtgta	1260
30	gtttctatgc gtgttggtt gccacagctg gcagaaccaa gagtcaattg tctctgaaga	1320
	aatgcatatt ccaaagatgt aacctgggca ttctgaatga aggcgaagca agggctcgtc	1380
	actgcgcttc tacagatact ggatgtttta ttttaattaa gggaaatgcc agcgtaaagc	1440
35	ataacatgat ttgtggtgct tccgatgaga ggccttatca aatgctcact tgtgctggtg	1500
	ggcattgtaa tatgctggct actgtgcata ttgtttccca tcaacgcaa aaatggcctg	1560
	tttttgatca caatgtgttg accaagtgca ccatgcatgc aggtgggctg agaggaatgt	1620
	ttatgcctta ccagtgtaac atgaatcatg tgaaagtgtt gttggaacca gatgcctttt	1680
40	ccagaatgag cctaacagga atctttgaca tgaacacgca aatctggaag atcctgaggt	1740
	atgatgatac gagatcgagg gtgcgcgcat gcgaatgcgg aggcaagcat gccaggttcc	1800
	agccggtgtg tgtagatgtg accgaagatc tcagaccgga tcatttggtt attgcccgca	1860
45	ctggagcaga gttcggatcc agtggagaag aaactgacta aggtgagtat tgggaaaact	1920
	ttgggggtggg attttcagat ggacagattg agtaaaaatt tgtttttct gtcttgacgc	1980
	tgacatgagt ggaaatgctt cttttaaggg gggagtcttc agcccttatc tgacagggcg	2040
50	tctcccatcc tgggcaggag ttcgtcagaa tgttatggga tctactgtgg atggaagacc	2100
	cgttcaaccc gccaatctt caacgctgac ctatgctact ttaagttctt cacctttgga	2160
	cgcagctgca gccgctgccg ccgcctctgt cgccgctaac actgtgcttg gaatgggtta	2220
55	ctatggaagc atcgtggcta attccacttc ctctaataac ctttctacac tgactcagga	2280

caagttactt gtccttttgg cccagctgga ggctttgacc caacgtctgg gtgaactttc 2340
 tcagcaggtg gccgagttgc gagtacaaac tgagtctgct gtcggcacgg caaagtctaa 2400
 5 ataaaaaaaa ttccagaatc aatgaataaa 2430

<210> 56
 <211> 2429
 10 <212> DNA
 <213> Adenovirus type 11
 <220>
 <221> misc_feature
 <223> Ad11 E1B-pIX region
 15 <400> 56

aataaaaaata tgtaactgt tcaactggtt ttattgcttt ttgggcgggg actcaggtat 60
 ataagtagaa gcagacctgt gtggttagct cataggagct ggctttcatc catggagggt 120
 20 tgggccatth ttgaagacct taggaagact aggcaactgt tagagaacgc ttcggacgga 180
 gtctccggtt tttggagatt ctggttcgct agtgaattag ctagggtagt ttttaggata 240
 aaacaggact ataaacaaga atttgaaaag ttgttggttag attgcccagg actttttgaa 300
 25 gctcttaatt tgggccatca ggttcacttt aaagaaaaag ttttatcagt ttttagacttt 360
 tcaacccag gtagaactgc tgctgctgtg gcttttctta cttttatatt agataaatgg 420
 atcccgaga ctcatctcag caggggatac gttttggatt tcatagccac agcattgttg 480
 30 agaacatgga aggttcgcaa gatgaggaca atcttaggtt actggccagt gcagcctttg 540
 ggtgtagcgg gaatcctgag gcatccaccg gtcatgccag cggttctgga ggaggaacag 600
 caagaggaca acccgagagc cggcctggac cctccagtgg aggaggcgga gtagctgact 660
 35 tgtctcctga actgcaacgg gtgcttactg gatctacgtc cactggacgg gataggggag 720
 ttaagagggg gagggcatct agtggtactg atgctagatc tgagttaggt ttaagtttaa 780
 tgagtcgag acgtcctgaa accatttggt ggcatgaggt tcagaaagag ggaagggatg 840
 aagtttctgt attgcaggag aaatattcac tggaacaggt gaaaacatgt tggttggagc 900
 40 ctgaggatga ttgggaggtg gccattaaaa attatgccaa gatagctttg aggcctgata 960
 aacagtataa gattactaga cggattaata tccggaatgc ttgttacata tctggaaatg 1020
 gggctgaggt ggtaatagat actcaagaca aggcagttat tagatgctgc atgatggata 1080
 45 tgtggcctgg ggtagtcggt atggaagcag taacttttgt aaatgttaag tttaggggag 1140
 atggttataa tggaatagtg tttatggcca ataccaaact tatattgcat ggtttagct 1200
 tttttggttt caacaatacc tgtgtagatg cctggggaca ggttagtgta cggggatgta 1260
 50 gtttctatgc gtgttggtt gccacagctg gcagaaccaa gagtcaattg tctctgaaga 1320
 aatgcatatt tcaaagatgt aacctgggca ttctgaatga aggcgaagca agggctccgcc 1380
 actgcgcttc tacagatact ggatgtttta ttttgattaa gggaaatgcc agcgtaaagc 1440
 55 ataacatgat ttgcggtgct tccgatgaga ggccttatca aatgctcact tgtgctggtg 1500

ggcattgtaa tatgctggct actgtgcata ttgtttccca tcaacgcaaa aaatggcctg 1560
 tttttgatca caatgtgatg acgaagtgtg ccatgcatgc aggtgggCGT agaggaatgt 1620
 5 ttatgcctta ccagtgtaac atgaatcatg tgaagtggtt gttggaacca gatgcctttt 1680
 ccagaatgag cctaacagga atttttgaca tgaacatgca aatctggaag atcctgaggt 1740
 atgatgatac gagatcgagg gtacgcgcac gcgaatgcgg aggcaagcat gccaggttcc 1800
 10 agccgggtgtg tgtagatgtg actgaagatc tcagaccgga tcatttggtt attgcccgca 1860
 ctggagcaga gttcggatcc agtggagaag aaactgacta aggtgagtat tgggaaaact 1920
 ttgggggtggg attttcagat ggacagattg agtaaaaatt tgttttttct gtcttgcagc 1980
 15 tgtcatgagt ggaaacgctt cttttaaggg gggagtcttc agcccttatc tgacagggcg 2040
 tctcccatcc tgggcaggag ttcgtcagaa tgttatggga tctactgtgg atggaagacc 2100
 cgtccaaccg gccaatctt caacgctgac ctatgctact ttaagttctt cacctttgga 2160
 20 cgcagctgca gctgccgccg ccgcttctgt tgccgctaac actgtgcttg gaatgggtta 2220
 ctatggaagc atcatggcta attccacttc ctctaataac ctttctacc tgactcagga 2280
 caagttactt gtccttttgg ccagctgga ggctttgacc caacgtctgg gtgaactttc 2340
 25 tcagcaggtg gtcgagttgc gagtacaaac tgagtctgct gtcggcacgg caaagtctaa 2400
 ataaaaaat ccagaatca atgaataaa 2429

30 <210> 57
 <211> 2426
 <212> DNA
 <213> Adenovirus type 7
 <220>
 <221> misc_feature
 35 <223> Ad7 E1B-pIX region
 <400> 57

aataaaatta tgtcagctgc tgagtgtttt attacttctt ggggtggggc ttggatatat 60
 40 aagtaggagc agatctgtgt ggttagctca cagcaacttg ctgccatcca tggaggtttg 120
 ggctatcttg gaagacctca gacagactag gctactacta gaaaacgcct cggacggagt 180
 ctctggcctt tggagattct ggttcgggtg tgatctagct aggctagtgt ttaggataaa 240
 45 acaggactac agggagaagt ttgaaaagtt attggacgac attccaggac tttttgaagc 300
 tcttaacttg ggccatcagg ctcatcttaa ggagaagggt ttatcagttt tagatttttc 360
 tactcctggg agaactgctg ctgctgtagc ttttcttact tttatattgg ataaatggat 420
 50 ccgcaaaact cacttcagca agggatacgt tttggatttc atagcagcag ctttgtggag 480
 aacatggaag gctcgcagga tgaggacaat cttagattac tggccagtgc agcctctggg 540
 agtagcaggg atactgagac acccaccgac catgccagcg gttctgcagg aggagcagca 600
 55 ggaggacaat ccgagagccg gcctggaccc tccggtggag gagtagctga cctgtttcct 660
 gaactgcgac ggggtgcttac taggtctacg accagtggac agaacagggg aattaagagg 720

	gagaggaatc ctagtgggaa taattcaaga accgagttgg ctttaagttt aatgagccgc	780
	aggcgtcctg aaactgtttg gtggcatgag gttcagagcg aaggcagggg tgaagtttca	840
5	atattgcagg agaaatattc actagaacaa cttaagacct gttggttga acctgaggat	900
	gattgggagg tggccattag gaattatgct aagatatctc tgaggcctga taaacaatat	960
	agaattacta agaagattaa tattagaaat gcatgctaca tatcagggaa tggggcagag	1020
10	gttataatag atacacaaga taaagcagct tttagatgtt gtatgatggg tatgtggcca	1080
	ggggttgtcg gcatggaagc aataacactt atgaatatta ggttttagagg ggatgggtat	1140
	aatggcattg tatttatggc taacactaag ctgattctac atggtttag tagtttttggg	1200
15	tttaataata cgtgtgtaga agcttggggg caagttagtg tgaggggttg tagtttttat	1260
	gcatgctgga ttgcaacatc aggtagggtg aagagtcagt tgtctgtgaa gaaatgcatg	1320
	tttgagagat gtaatcttgg catactgaat gaagggtgaag caagggtccg ccatgcgca	1380
20	gctacagaaa ctgcctgctt cattctaata aagggaatg ccagtgtgaa gcataatatg	1440
	atctgtggac attcggatga gaggccttat cagatgctaa cctgcgctgg tggacattgc	1500
	aatattcttg ctaccgtgca tatcgtttca catgcacgca agaaatggcc tgtatttgaa	1560
25	cataatgtga ttaccaagtg caccatgcat ataggtggtc gcaggggaat gtttatgcct	1620
	taccagtgtg acatgaatca tgtgaaggta atgttggaa cagatgcctt ttccagagtg	1680
	agcgtaacag gaatctttga tatgaatatt caactatgga agatcctgag atatgatgac	1740
30	actaaaccaa ggggtgcgcg atgcgaatgc ggaggcaagc atgctagatt ccagccggtg	1800
	tgctgtggatg tgactgaaga cctgaggccc gatcatttgg tgcttgctg cactggagcg	1860
	gagttcggtt ctagtgggtg agaaactgac taaagtaagt agtgggggca aaatgtggat	1920
35	ggggactttc aggttggtaa ggtggacaaa ttgggttaaatt tttgttaatt tctgtcttgc	1980
	agctgccatg agtgggaagcg cttcttttga ggggggagta tttagccctt atctgacggg	2040
	caggctccca ccatgggcag gagttcgtca gaatgtcatg ggatccactg tggatgggag	2100
	accggtccag cccgccaaatt cctcaacgct gacctatgcc actttgagtt cgtcaccatt	2160
40	ggatgcagct gcagccgccg ccgctactgc tgccgccaac accatccttg gaatgggcta	2220
	ttacggaagc attgttgcca attccagttc ctctaataat ccttcaaccc tggctgagga	2280
	caagctactt gttctcttgg ctgagctcga ggccttaacc caacgcttag gcgaactgtc	2340
45	taagcaggtg gcccagttgc gtgagcaaac tgagtctgct gttgccacag caaagtctaa	2400
	ataaagatct caaatcaata aataaa	2426

50	<210> 58
	<211> 240
	<212> DNA
	<213> Adenovirus type 11
	<220>
55	<221> misc_feature
	<223> Ad11 pIX cDNA sequence
	<400> 58

cgactggagc acgaggacac tgacatggac tgaaggagta gaaatcattt ggttattgcc 60
 cgcactggag cagagttcgg atccagtgga gaagaaactg actaagctgt catgagtgga 120
 5 aacgcttctt ttaagggggg agtcttcagc ccttatctga cagggcgtct cccatcctgg 180
 gcaggagttc gtcagaatgt tatgggatct actgtggatg gaacacccgt tcaacccgcc 240

10 <210> 59
 <211> 227
 <212> DNA
 <213> Adenovirus type 35
 <220>
 <221> misc_feature
 15 <223> Ad35 pIX cDNA sequence
 <400> 59

ggacactgac atggactgaa ggagtagaaa atcatttgggt tattgcccgc actggagcag 60
 20 agttcggatc cagtggagaa gaaactgact aagctgacat gagtggaaat gcttctttta 120
 aggggggagt cttcagccct tatctgacag ggcgtctccc atcctgggca ggagttcgtc 180
 agaatgttat gggatctact gtggatggaa gacccgttca acccgcc 227

25 <210> 60
 <211> 289
 <212> DNA
 30 <213> Adenovirus type 35
 <220>
 <221> misc_feature
 <223> wild-type Ad35 sequence nt 3339-3628
 <220>
 35 <221> Intron
 <222> (62)..(138)
 <220>
 <221> startcodon pIX
 <222> (146)..(148)
 40 <400> 60

atcatttgggt tattgcccgc actggagcag agttcggatc cagtggagaa gaaactgact 60
 45 aaggtgagta ttgggaaaac tttgggggtgg gattttcaga tggacagatt gagtaaaaat 120
 ttgttttttc tgtcttgacg ctgacatgag tggaaatgct tcttttaagg ggggagtcct 180
 cagcccttat ctgacagggc gtctcccatc ctgggcagga gttcgtcaga atgttatggg 240
 atctactgtg gatggaagac ccgttcaacc cgccaattct tcaacgctg 289

50

Claims

55 1. A recombinant subgroup B adenovirus having a deletion in the E1-region and which adenovirus does not encode a functional E1B 55K gene product, said adenovirus comprising:

(i) the adenovirus sequence located between the stop codon of the E1B 55K coding sequence and the start

codon of the pIX coding sequence; and

(ii) a functional pIX coding sequence under the control of a sequence having promoter activity, wherein said sequence having promoter activity consists of up to 0.7 kb of the adenovirus sequences that are directly upstream of the pIX start codon, said sequence comprising the minimally required sequence for promoter activity which is present within the last 166 bp of the E1B 55K coding sequence.

2. A recombinant adenovirus according to claim 1, wherein said sequence having promoter activity contains up to 600 nucleotides of the adenovirus sequences that are directly upstream of the pIX coding sequence.

3. A recombinant adenovirus according to claim 1, wherein said sequence having promoter activity contains up to 300 nucleotides of the adenovirus sequences that are directly upstream of the pIX coding sequence.

4. A recombinant adenovirus according to claim 1, wherein said sequence having promoter activity contains up to 250 nucleotides of the adenovirus sequences that are directly upstream of the pIX coding sequence.

5. A recombinant subgroup B adenovirus comprising a functional pIX coding sequence and having a deletion in the E1-region, wherein the pIX coding sequence is under control of a heterologous promoter for driving expression in a given packaging cell.

6. A recombinant adenovirus according to claim 5, wherein said heterologous promoter comprises a nucleic acid sequence chosen from the group consisting of a non-endogenous proximal pIX promoter, a viral promoter, a cellular promoter, a synthetic promoter and a hybrid promoter.

7. A recombinant adenovirus according to claim 6, wherein said heterologous promoter is chosen from the group consisting of sequences that are at least in part derived from the Ad5 proximal pIX promoter, a Rous Sarcoma Virus promoter and an adenovirus E1B promoter.

8. A recombinant adenovirus according to any one of claims 1-7, wherein said adenovirus is derived from an adenovirus serotype 35 or an adenovirus serotype 11.

9. A recombinant adenovirus according to any one of claims 1-8, **characterized in that** it further comprises a sequence encoding a functional E4-orf6 protein derived from an adenovirus of subgroup C.

10. An isolated nucleic acid that upon introduction into a suitable packaging cell constitutes the genome of a recombinant adenovirus according to any one of claims 2-9.

11. A method for increasing the stability and/or the packaging capacity of a recombinant subgroup B adenovirus having a deletion in the E1-region, comprising the step of expressing the elements necessary for production and assembly of said recombinant adenovirus into virus particles in a packaging cell, **characterized in that** the following elements are retained or reintroduced in said adenovirus:

(i) the adenovirus sequence located between the stop codon of the E1B 55K coding sequence and the start codon of the pIX coding sequence; and

(ii) a functional pIX coding sequence under the control of a sequence having promoter activity, wherein said sequence having promoter activity consists of up to 0.7 kb of the adenovirus sequences that are directly upstream of the pIX start codon, said sequence comprising the minimally required sequence for promoter activity which is present within the last 166 bp of the E1B 55K coding sequence.

12. A method according to claim 11, wherein said sequence having promoter activity contains up to 600 nucleotides of the adenovirus sequences that are directly upstream of the pIX coding sequence.

13. A method according to claim 11, wherein said sequence having promoter activity contains up to 300 nucleotides of the adenovirus sequences that are directly upstream of the pIX coding sequence.

14. A method according to claim 11, wherein said sequence having promoter activity contains up to 250 nucleotides of the adenovirus sequences that are directly upstream of the pIX coding sequence.

15. A method for increasing the stability and/or the packaging capacity of a recombinant subgroup B adenovirus having

a deletion in the E 1-region, comprising the step of expressing the elements necessary for production and assembly of said recombinant adenovirus into virus particles in a packaging cell, wherein the pIX coding sequences are under control of a heterologous promoter.

- 5 16. A method according to any one of claims 11-15, wherein said recombinant adenovirus is derived from an adenovirus serotype 35 or an adenovirus serotype 11.
17. A method according to any one of claims 15-16, wherein said heterologous promoter is chosen from the group consisting of a non-endogenous proximal pIX promoter, a viral promoter, a cellular promoter, a synthetic promoter
10 and a hybrid promoter.
18. A method according to claim 17, wherein said heterologous promoter is chosen from the group consisting of the Ad5 proximal pIX promoter, a Rous Sarcoma Virus promoter, an adenovirus E1B promoter.
- 15 19. A recombinant adenovirus packaging cell comprising a recombinant adenovirus according to any one of claims 1-9.

Patentansprüche

- 20 1. Rekombinantes Adenovirus der Untergruppe B mit einer Deletion in der E1-Region und wobei das Adenovirus nicht für ein funktionelles E1B 55K-Genprodukt codiert, wobei das Adenovirus umfasst:

(i) die Adenovirussequenz, die zwischen dem Stoppcodon der E1B 55K codierenden Sequenz und dem Start-
codon der pIX codierenden Sequenz lokalisiert ist; und
25 (ii) eine funktionelle pIX codierende Sequenz unter der Kontrolle einer Sequenz mit Promotoraktivität, wobei die Sequenz mit Promotoraktivität aus bis zu 0,7 kb der Adenovirussequenzen besteht, die sich direkt stromaufwärts des pIX-Startcodons befinden, wobei die Sequenz die erforderliche Minimalsequenz für die Promotoraktivität umfasst, welche in den letzten 166 Basenpaaren der E1B 55K codierenden Sequenz vorkommt.
- 30 2. Rekombinantes Adenovirus nach Anspruch 1, wobei die Sequenz mit Promotoraktivität bis zu 600 Nucleotide der Adenovirussequenzen direkt stromaufwärts der pIX codierenden Sequenz enthält.
3. Rekombinantes Adenovirus nach Anspruch 1, wobei die Sequenz mit Promotoraktivität bis zu 300 Nucleotide der Adenovirussequenzen direkt stromaufwärts der pIX codierenden Sequenz enthält.
- 35 4. Rekombinantes Adenovirus nach Anspruch 1, wobei die Sequenz mit Promotoraktivität bis zu 250 Nucleotide der Adenovirussequenzen direkt stromaufwärts der pIX codierenden Sequenz enthält.
- 40 5. Rekombinantes Adenovirus der Untergruppe B, das eine funktionelle pIX codierende Sequenz und eine Deletion in der E1-Region umfasst, wobei die pIX codierende Sequenz unter der Kontrolle eines heterologen Promotors ist, der die Expression in einer gegebenen Verpackungszelle steuert.
- 45 6. Rekombinantes Adenovirus nach Anspruch 5, wobei der heterologe Promotor eine Nucleinsäuresequenz umfasst, die ausgewählt ist aus der Gruppe bestehend aus einem nichtendogenen proximalen pIX-Promotor, einem viralen Promotor, einem zellulären Promotor, einem synthetischen Promotor und einem Hybridpromotor.
7. Rekombinantes Adenovirus nach Anspruch 6, wobei der heterologe Promotor ausgewählt ist aus der Gruppe bestehend aus Sequenzen, die mindestens zum Teil vom Ad5-proximalen pIX-Promotor, einem Rous Sarcomavirus-Promotor und einem Adenovirus-E1B-Promotor abgeleitet sind.
- 50 8. Rekombinantes Adenovirus nach einem der Ansprüche 1 bis 7, wobei das Adenovirus von einem Adenovirus-Serotyp 35 oder einem Adenovirus-Serotyp 11 abgeleitet ist.
- 55 9. Rekombinantes Adenovirus nach einem der Ansprüche 1 bis 8, **dadurch gekennzeichnet, dass** es des weiteren eine Sequenz enthält, die ein funktionelles E4-orf6-Protein codiert, das von einem Adenovirus der Untergruppe C abgeleitet ist.
10. Isolierte Nucleinsäure, die nach Einführen in eine geeignete Verpackungszelle das Genom eines rekombinanten

Adenoviruses nach einem der Ansprüche 2 bis 9 darstellt.

11. Verfahren zum Erhöhen der Stabilität und/oder der Verpackungskapazität eines rekombinanten Adenoviruses der Untergruppe B mit einer Deletion in der E1-Region, umfassend den Schritt der Expression der Elemente, die für die Produktion und den Zusammenbau des rekombinanten Adenoviruses in Viruspartikel in der Verpackungszelle notwendig sind, **dadurch gekennzeichnet, dass** die folgenden Elemente beibehalten oder wieder in das Adenovirus eingeführt werden:

(i) die Adenovirussequenz, die zwischen dem Stoppcodon der E1B 55K codierenden Sequenz und dem Startcodon der pIX codierenden Sequenz lokalisiert ist; und

(ii) eine funktionelle pIX codierende Sequenz unter der Kontrolle einer Sequenz mit Promotoraktivität, wobei die Sequenz mit Promotoraktivität aus bis zu 0,7 kb der Adenovirussequenzen besteht, die sich direkt stromaufwärts des pIX-Startcodons befinden, wobei die Sequenz die erforderliche Minimalsequenz für die Promotoraktivität umfasst, welche in den letzten 166 Basenpaaren der E1B 55K codierenden Sequenz vorkommt.

12. Verfahren nach Anspruch 11, wobei die Sequenz mit Promotoraktivität bis zu 600 Nucleotide der Adenovirussequenzen direkt stromaufwärts der pIX codierenden Sequenz enthält.

13. Verfahren nach Anspruch 11, wobei die Sequenz mit Promotoraktivität bis zu 300 Nucleotide der Adenovirussequenzen direkt stromaufwärts der pIX codierenden Sequenz enthält.

14. Verfahren nach Anspruch 11, wobei die Sequenz mit Promotoraktivität bis zu 250 Nucleotide der Adenovirussequenzen direkt stromaufwärts der pIX codierenden Sequenz enthält.

15. Verfahren zum Erhöhen der Stabilität und/oder der Verpackungskapazität eines rekombinanten Adenoviruses der Untergruppe B mit einer Deletion in der E1-Region, umfassend den Schritt der Expression der Elemente, die für die Produktion und den Zusammenbau des rekombinanten Adenoviruses in Viruspartikel in der Verpackungszelle notwendig sind, wobei die pIX codierenden Sequenzen unter der Kontrolle eines heterologen Promotors sind.

16. Verfahren nach einem der Ansprüche 11 bis 15, wobei das rekombinante Adenovirus von einem Adenovirus-Serotyp 35 oder einem Adenovirus-Serotyp 11 abgeleitet ist.

17. Verfahren nach einem der Ansprüche 15 und 16, wobei der heterologe Promotor ausgewählt ist aus der Gruppe bestehend aus einem nichtendogenen proximalen pIX-Promotor, einem viralen Promotor, einem zellulären Promotor, einem synthetischen Promotor und einem Hybridpromotor.

18. Verfahren nach Anspruch 17, wobei der heterologe Promotor ausgewählt ist aus der Gruppe bestehend aus dem Ad5-proximalen pIX-Promotor, einem Rous Sarcomavirus-Promotor und einem Adenovirus E1B-Promotor.

19. Rekombinante Adenovirus-Verpackungszelle, umfassend ein rekombinantes Adenovirus nach einem der Ansprüche 1 bis 9.

Revendications

1. Adénovirus du sous-groupe B recombinant ayant une délétion dans la région E1 et lequel adénovirus ne code pas pour un produit de gène E1B 55K fonctionnel, ledit adénovirus comprenant :

(i) la séquence d'adénovirus localisée entre le codon d'arrêt de la séquence codant pour E1B 55K et le codon d'initiation de la séquence codant pour pIX ; et

(ii) une séquence codant pour pIX fonctionnelle sous le contrôle d'une séquence ayant une activité promotrice, dans laquelle ladite séquence ayant une activité promotrice est constituée de jusqu'à 0,7 kb des séquences d'adénovirus qui sont directement en amont du codon d'initiation de pIX, ladite séquence comprenant la séquence requise au minimum pour une activité promotrice qui est présente au sein des 166 dernières pb de la séquence codant pour E1B 55K.

2. Adénovirus recombinant selon la revendication 1, dans lequel ladite séquence ayant une activité promotrice contient jusqu'à 600 nucléotides des séquences d'adénovirus qui sont directement en amont de la séquence codant pour pIX.

3. Adénovirus recombinant selon la revendication 1, dans lequel ladite séquence ayant une activité promotrice contient jusqu'à 300 nucléotides des séquences d'adénovirus qui sont directement en amont de la séquence codant pour pIX.
- 5 4. Adénovirus recombinant selon la revendication 1, dans lequel ladite séquence ayant une activité promotrice contient jusqu'à 250 nucléotides des séquences d'adénovirus qui sont directement en amont de la séquence codant pour pIX.
- 10 5. Adénovirus du sous-groupe B recombinant comprenant une séquence codant pour pIX fonctionnelle et ayant une délétion dans la région E1, dans lequel la séquence codant pour pIX est sous le contrôle d'un promoteur hétérologue afin de diriger l'expression dans une cellule d'empaquetage donnée.
- 15 6. Adénovirus recombinant selon la revendication 5, dans lequel ledit promoteur hétérologue comprend une séquence d'acide nucléique choisie dans le groupe constitué par un promoteur de pIX proximal non endogène, un promoteur viral, un promoteur cellulaire, un promoteur synthétique et un promoteur hybride.
- 20 7. Adénovirus recombinant selon la revendication 6, dans lequel ledit promoteur hétérologue est choisi dans le groupe constitué de séquences qui sont au moins en partie dérivées du promoteur de pIX proximal d'un Ad5, d'un promoteur du virus du Sarcome de Rous, et d'un promoteur de E1B d'adénovirus.
- 25 8. Adénovirus recombinant selon l'une quelconque des revendications 1 à 7, dans lequel ledit adénovirus est dérivé d'un adénovirus de sérotype 35 ou d'un adénovirus de sérotype 11.
- 30 9. Adénovirus recombinant selon l'une quelconque des revendications 1 à 8, **caractérisé en ce qu'il** comprend en outre une séquence codant pour une protéine E4-orf6 fonctionnelle dérivée d'un adénovirus du sous-groupe C.
- 35 10. Acide nucléique isolé qui lors de l'introduction dans une cellule d'empaquetage appropriée constitue le génome d'un adénovirus recombinant selon l'une quelconque des revendications 2 à 9.
- 40 11. Procédé pour augmenter la stabilité et/ou la capacité d'empaquetage d'un adénovirus du sous-groupe B recombinant ayant une délétion dans la région E1, comprenant l'étape d'expression des éléments nécessaires à la production et l'assemblage dudit adénovirus recombinant en particules virales dans une cellule d'empaquetage, **caractérisé en ce que** les éléments suivants sont conservés ou réintroduits dans ledit adénovirus :
 - (i) la séquence d'adénovirus localisée entre le codon d'arrêt de la séquence codant pour E1B 55K et le codon d'initiation de la séquence codant pour pIX ; et
 - 35 (ii) une séquence codant pour pIX fonctionnelle sous le contrôle d'une séquence ayant une activité promotrice, dans laquelle ladite séquence ayant une activité promotrice est constituée de jusqu'à 0,7 kb des séquences d'adénovirus qui sont directement en amont du codon d'initiation de pIX, ladite séquence comprenant la séquence requise au minimum pour une activité promotrice qui est présente au sein des 166 dernières pb de la séquence codant pour E1B 55K.
- 45 12. Procédé selon la revendication 11, dans lequel ladite séquence ayant une activité promotrice contient jusqu'à 600 nucléotides des séquences d'adénovirus qui sont directement en amont de la séquence codant pour pIX.
- 50 13. Procédé selon la revendication 11, dans lequel ladite séquence ayant une activité promotrice contient jusqu'à 300 nucléotides des séquences d'adénovirus qui sont directement en amont de la séquence codant pour pIX.
- 55 14. Procédé selon la revendication 11, dans lequel ladite séquence ayant une activité promotrice contient jusqu'à 250 nucléotides des séquences d'adénovirus qui sont directement en amont de la séquence codant pour pIX.
15. Procédé pour augmenter la stabilité et/ou la capacité d'empaquetage d'un adénovirus du sous-groupe B recombinant ayant une délétion dans la région E1, comprenant l'étape d'expression des éléments nécessaires à la production et l'assemblage dudit adénovirus recombinant en particules virales dans une cellule d'empaquetage, dans lequel les séquences codant pour pIX sont sous le contrôle d'un promoteur hétérologue.
16. Procédé selon l'une quelconque des revendications 11 à 15, dans lequel ledit adénovirus recombinant est dérivé d'un adénovirus de sérotype 35 ou d'un adénovirus de sérotype 11.
17. Procédé selon l'une quelconque des revendications 15 à 16, dans lequel ledit promoteur hétérologue est choisi

EP 1 497 440 B1

dans le groupe constitué d'un promoteur de pIX proximal non endogène, d'un promoteur viral, d'un promoteur cellulaire, d'un promoteur synthétique et d'un promoteur hybride.

5 18. Procédé selon la revendication 17, dans lequel ledit promoteur hétérologue est choisi dans le groupe constitué du promoteur de pIX proximal d'un Ad5, d'un promoteur du virus du Sarcome de Rous, et d'un promoteur de E1B d'adénovirus.

10 19. Cellule d'empaquetage d'un adénovirus recombinant comprenant un adénovirus recombinant selon l'une quelconque des revendications 1 à 9.

10

15

20

25

30

35

40

45

50

55

Fig. 1




Fig. 2

Transgene PCR on Ad35 E1- and E1/E3-deleted viruses




Fig. 3A

Alignment of pIX proximal regions

```

1  TGAGGTTACTGAAATGTGTGGGCGTGGCTTAAGGGTGGGAAAGAAATATATAAGGTGGGGGT Ad2.SEQ
1  TGAGGTTACTGAAATGTGTGGGCGTGGCTTAAGGGTGGGAAAGAAATATATAAGGTGGGGGT Ad5.SEQ
1  TGAGG---TAAAGTGGGTGGAGCTA-----GGTGGGATTATAAAA--GGC-TGGAAGT Ad12.SEQ
1  TAGAGG--TAGGTCGAGTGAGTAGTGGGCGTGGCTAAGGT-GACTATA-AAGGCGGGTGT Ad9.SEQ
1  TAAGGG--TAAG-----GGGCGGAGCCTATTAC--AGGTATAAAGGTTGGGGT-AGAGT Ad40.SEQ
1  TAGAG---TGAGTAGTG-----TTCTG-GGGCGGGGGA---GGACCTGCATGAGGGC Ad4.SEQ
1  TAGAG---TGAGTAGTG-----TTCTG-GGGCGGGGGA---GGACCTGCATGAGGGC S25.SEQ
1  TAAGG---TGAGTATTGGGA--AAACTTTG-GGGTGGGATTTTCAGAT-----GGA Ad35.SEQ
1  TAAGG---TGAGTATTGGGA--AAACTTTG-GGGTGGGATTTTCAGAT-----GGA Ad11.SEQ
1  TAAAG---TAAGTAGTGGGGGCAAAATGTG-GATGGGGACTTTTCAGGTTGGTAAGGTGGA Ad7.SEQ

61 CTCATGTAGTTTTGTATCTGTTTTGCAGCA-GCCGCCGCC---ATG Ad2.SEQ
61 CTTATGTAGTTTTGTATCTGTTTTGCAGCA-GCCGCCGCCGCCATG Ad5.SEQ
47 CA-----ACTAAAAATTGT-TTTTGTCT-TTTAACAGC-ACGATG Ad12.SEQ
57 CTTACGAGGGTCTT--TTTGCTTTTCTGCA-GA-----CATCATG Ad9.SEQ
50 AAAAAAAGGGAAG-----TTACAA-----AATG Ad40.SEQ
46 CAGAATAACTGAAATCTGTGCTTTTCTGTGTGTGTCAGCAG-CATG Ad4.SEQ
46 CAGAATAACTGAAATCTGTGCTTTTCTGTGTGTGTCAGCAG-CATG S25.SEQ
46 CAGATTGAGTAAAAATT-TGTTT-TTCTGTCTTGCAGCTGACATG Ad35.SEQ
46 CAGATTGAGTAAAAATT-TGTTT-TTCTGTCTTGCAGCTGTCATG Ad11.SEQ
57 CAAATTGGGTAAAT-TT-TGTTAATTTCTGTCTTGCAGCTGCCATG Ad7.SEQ

```

Fig. 3B

: Comparison of putative pIX promoter regions


	stop 55k			Start pIX coding
Ad5:	3509	GGGCGT	20 nucl.....	TATATAA 3609
Ad12:	3295	GGGTGG	11 nucl	ATTATAA 3374
Ad9:	3361	GGGCGT	12 nucl	TATAAAG 3449
Ad40:	3149	GGGCGG	13 nucl	TATAAAG 3217
Ad4:	3404	GGGCGG	23 nucl	AATAACT 3489
		GGGAGG	17 nucl	AATAACT
Ad35:	3400	GGGTGG	27 nucl	AATTTGT 3484
Ad11:	3399	GGGTGG	27 nucl	AATTTGT 3483
Ad7:	3385	GGGACT	30 nucl	AATTTTG 3480
				
		Consensus SP1 site G/a G G C/t/a G/a G/t		

Fig. 4




Fig. 5




Fig. 6A

Transgene PCR on Ad35 E1deleted viruses




Fig. 6B

Transgene PCR on Ad35 E1/E3 deleted viruses




Fig. 7




Fig. 8




Fig. 9




Fig. 10

Alignment Report of Align.E1B-pIX.35-11-7.MEG, using Clustal method with Weighted residue weight table.

Friday 4 October 2002 9:32

```

1  AATAAAATATGTTAACTGTTCACTGGTTTTTATTGCTTTTGGGCGGGG Ad35.E1B-pIX.SEQ
1  AATAAAATATGTTAACTGTTCACTGGTTTTTATTGCTTTTGGGCGGGG Ad11.E1B-pIX.SEQ
1  AATAAAATATGTTAACTGTTCACTGGTTTTTATTGCTTTTGGGCGGGG Ad7.E1B-pIX.SEQ

51  ACTCAGGTATATAAGTAGAAGCAGACCTGTGTGGTTAGCTCATAGGAGCT Ad35.E1B-pIX.SEQ
51  ACTCAGGTATATAAGTAGAAGCAGACCTGTGTGGTTAGCTCATAGGAGCT Ad11.E1B-pIX.SEQ
49  TCTTGGAATATAAGTAGAAGCAGACCTGTGTGGTTAGCTCATAGGAGCT Ad7.E1B-pIX.SEQ

101 GGCTTTTCATCCATGGAGGTTTGGGCCATTTTGGGAAGACCTTAGGAAGACT Ad35.E1B-pIX.SEQ
101 GGCTTTTCATCCATGGAGGTTTGGGCCATTTTGGGAAGACCTTAGGAAGACT Ad11.E1B-pIX.SEQ
99  TGCCTGCATCCATGGAGGTTTGGGCCATTTTGGGAAGACCTTAGGAAGACT Ad7.E1B-pIX.SEQ

151 AGGCAACTGTTAGAGAGCGCTTCGGACGGAGTCTCCGGTTTTTGGAGATT Ad35.E1B-pIX.SEQ
151 AGGCAACTGTTAGAGAGCGCTTCGGACGGAGTCTCCGGTTTTTGGAGATT Ad11.E1B-pIX.SEQ
149 AGGCTACTTACTAGAGAGCGCTTCGGACGGAGTCTCCGGTTTTTGGAGATT Ad7.E1B-pIX.SEQ

201 CTGGTTCGCTAGTGAATTAGCTAGGGTAGTTTTTAGGATAAAACAGGACT Ad35.E1B-pIX.SEQ
201 CTGGTTCGCTAGTGAATTAGCTAGGGTAGTTTTTAGGATAAAACAGGACT Ad11.E1B-pIX.SEQ
199 CTGGTTCGCTAGTGAATTAGCTAGGGTAGTTTTTAGGATAAAACAGGACT Ad7.E1B-pIX.SEQ

251 AATAACAAGAAATTTGAAAAGTTGTTGGTAGATTGCCCAGGACTTTTTGAA Ad35.E1B-pIX.SEQ
251 AATAACAAGAAATTTGAAAAGTTGTTGGTAGATTGCCCAGGACTTTTTGAA Ad11.E1B-pIX.SEQ
249 AATGAGGAAAGAAATTTGAAAAGTTGTTGGTAGATTGCCCAGGACTTTTTGAA Ad7.E1B-pIX.SEQ

301 GCTCTTAATTTGGGCCATCAGGTTCACTTTAAAGAAAAAGTTTTATCAGT Ad35.E1B-pIX.SEQ
301 GCTCTTAATTTGGGCCATCAGGTTCACTTTAAAGAAAAAGTTTTATCAGT Ad11.E1B-pIX.SEQ
299 GCTCTTAATTTGGGCCATCAGGTTCACTTTAAAGAAAAAGTTTTATCAGT Ad7.E1B-pIX.SEQ

351 TTTAGACTTTTCAACCCAGGTAGAACTGCTGCTGCTGGCTTTTCTTA Ad35.E1B-pIX.SEQ
351 TTTAGACTTTTCAACCCAGGTAGAACTGCTGCTGCTGGCTTTTCTTA Ad11.E1B-pIX.SEQ
349 TTTAGACTTTTCAACCCAGGTAGAACTGCTGCTGCTGGCTTTTCTTA Ad7.E1B-pIX.SEQ

401 CTTTTATATTAGATAAAATGGATCCCGCAGACTCATTTTCAAGCAGGGGATAC Ad35.E1B-pIX.SEQ
401 CTTTTATATTAGATAAAATGGATCCCGCAGACTCATTTTCAAGCAGGGGATAC Ad11.E1B-pIX.SEQ
399 CTTTTATATTAGATAAAATGGATCCCGCAGACTCATTTTCAAGCAGGGGATAC Ad7.E1B-pIX.SEQ

451 GTTTTGGATTTCATAGCCACAGCATTTGTGGAGAACATGGAAGGTTTCGCAA Ad35.E1B-pIX.SEQ
451 GTTTTGGATTTCATAGCCACAGCATTTGTGGAGAACATGGAAGGTTTCGCAA Ad11.E1B-pIX.SEQ
449 GTTTTGGATTTCATAGCCACAGCATTTGTGGAGAACATGGAAGGTTTCGCAA Ad7.E1B-pIX.SEQ

501 GATGAGGACAATCTTAGGTTACTGGCCAGTGCAGCCTTTGGGTGTAGCGG Ad35.E1B-pIX.SEQ
501 GATGAGGACAATCTTAGGTTACTGGCCAGTGCAGCCTTTGGGTGTAGCGG Ad11.E1B-pIX.SEQ
499 GATGAGGACAATCTTAGGTTACTGGCCAGTGCAGCCTTTGGGTGTAGCGG Ad7.E1B-pIX.SEQ

```

Fig. 10, Cont'd

551 GAATCCTGAGGCATCCACCGGTTCATGCCAGCGGTTCTGGAGGAGGGAACAG Ad35.E1B-pIX.SEQ
 551 GAATCCTGAGGCATCCACCGGTTCATGCCAGCGGTTCTGGAGGAGGGAACAG Ad11.E1B-pIX.SEQ
 549 G[G]A[T]A[CT]GAG[A]C[A]C[CC]ACCG[A]C[AT]GCCAGCGGTTCTG[C]A[G]GAGGA[G]CAG Ad7.E1B-pIX.SEQ

 601 CAAGAGGACAACCCGAGAGCCGGCCTGGACCTTCCAGTGGAGGAGGCGGA Ad35.E1B-pIX.SEQ
 601 CAAGAGGACAACCCGAGAGCCGGCCTGGACCTTCCAGTGGAGGAGGCGGA Ad11.E1B-pIX.SEQ
 599 CA[G]GAGGACA[A]T[C]CGAGAGCCGGCCTGGACCTTCC[G]GTGGAGGA G[-----] Ad7.E1B-pIX.SEQ

 651 GTAGCTGACTTGTCTCCTGAACTGCAACGGGTGCTTACTGGATCTACGTC Ad35.E1B-pIX.SEQ
 651 GTAGCTGACTTGTCTCCTGAACTGCAACGGGTGCTTACTGGATCTACGTC Ad11.E1B-pIX.SEQ
 644 [-]TAGCTGAC[C]TGT[T]TCCTGAACTGC[G]ACGGGTGCTTACT[A]G[G]TCTACG[A]C Ad7.E1B-pIX.SEQ

 701 CACTGGACGGGATAGGGGCGTTAAAGAGGGAGAGGGCATCCAGTGGTACTG Ad35.E1B-pIX.SEQ
 701 CACTGGACGGGATAGGGGCGTTAAAGAGGGAGAGGGCATCT[TA]GTGGTACTG Ad11.E1B-pIX.SEQ
 693 CA[G]TGGAC[A]G[A]A[C]AGGGG[A]TTAAAGAGGGAGAGG[AATC]CTAGTGG[G]A[A]T[A] Ad7.E1B-pIX.SEQ

 751 ATGCTAGATCTGAGTTGGCTTTAAAGTTTAAATGAGTGCAGACGTCCTGAA Ad35.E1B-pIX.SEQ
 751 ATGCTAGATCTGAGTTGGCTTTAAAGTTTAAATGAGTGCAGACGTCCTGAA Ad11.E1B-pIX.SEQ
 743 AT[T]C[A]AGA[A]C[C]GAGTTGGCTTTAAAGTTTAAATGAG[C]CGCAG[G]CGTCCTGAA Ad7.E1B-pIX.SEQ

 801 ACCATTTGGTGGCATGAGGTTCAGAAAGAGGGAAGGGATGAAGTTTCTGT Ad35.E1B-pIX.SEQ
 801 ACCATTTGGTGGCATGAGGTTCAGAAAGAGGGAAGGGATGAAGTTTCTGT Ad11.E1B-pIX.SEQ
 793 AC[T]GTTTGGTGGCATGAGGTTCAGAA[G]G[A]G[G]CAGGGATGAAGTTTCT[A]A Ad7.E1B-pIX.SEQ

 851 ATTGCAGGAGAAAATATTCACCTGGAACAGGTGAAAACATGTTGGTTGGAGC Ad35.E1B-pIX.SEQ
 851 ATTGCAGGAGAAAATATTCACCTGGAACAGGTGAAAACATGTTGGTTGGAGC Ad11.E1B-pIX.SEQ
 843 ATTGCAGGAGAAAATATTCACCT[A]GAACA[A]C[T]TAA[G]A[C]CTGTTGGTTGG[A]C Ad7.E1B-pIX.SEQ

 901 CAGAGGATGATTGGGCGGTGGCCATTAAAAATTATGCCAAGATAGCTTTG Ad35.E1B-pIX.SEQ
 901 C[T]GAGGATGATTGGG[A]GGTGGCCATTAAAAATTATGCCAAGATAGCTTTG Ad11.E1B-pIX.SEQ
 893 C[T]GAGGATGATTGGG[A]GGTGGCCATTAA[G]GAATTATGCT[TA]AGATA[T]CT[C]TG Ad7.E1B-pIX.SEQ

 951 AGGCCTGATAAACAGTATAAGATCAGTAGACGGATTAAATATCCGGAATGC Ad35.E1B-pIX.SEQ
 951 AGGCCTGATAAACAGTATAAGAT[T]A[C]TAGACGGATTAAATATCCGGAATGC Ad11.E1B-pIX.SEQ
 943 AGGCCTGATAAACAA[A]TATA[G]AAT[T]A[C]TA[A]GAAGATTAAATAT[T]A[G]AATGC Ad7.E1B-pIX.SEQ

 1001 TTGTTACATATCTGGAAAATGGGGCTGAGGTGGTAAATAGATACTCAAGACA Ad35.E1B-pIX.SEQ
 1001 TTGTTACATATCTGGAAAATGGGGCTGAGGTGGTAAATAGATACTCAAGACA Ad11.E1B-pIX.SEQ
 993 [A]T[G]TACATATC[A]GG[G]AATGGGGC[A]GAGGT[T]A[T]AAATAGATAC[A]CAAG[A]T Ad7.E1B-pIX.SEQ

 1051 AGACAGTTATTAGATGCTGCATGATGGATATGTGGCCTGGAGTAGTCGGT Ad35.E1B-pIX.SEQ
 1051 AG[G]CAGTTATTAGATGCTGCATGATGGATATGTGGCCTGG[G]GTAGTCGGT Ad11.E1B-pIX.SEQ
 1043 A[A]GCA[G]C[T]TTTAGATG[T]G[T]ATGATGG[G]TATGTGGC[A]G[G]GT[T]GTCG[G]C Ad7.E1B-pIX.SEQ

Fig. 10, Cont'd

1101 ATGGAAGCAGTCAC TTTTGTAAATGTTAAGTTTAGGGGAGATGGTTATAA Ad35.E1B-pIX.SEQ
 1101 ATGGAAGCAGTAACTTTTGTAAATGTTAAGTTTAGGGGAGATGGTTATAA Ad11.E1B-pIX.SEQ
 1093 ATGGAAGCAATAACACTTATGAATATTAGGTTTAGAGGGGATGGTTATAA Ad7.E1B-pIX.SEQ

 1151 TGGAAATAGTGTTTATGGCCAAATACCAAACCTTATATTGCATGGTTGTAGCT Ad35.E1B-pIX.SEQ
 1151 TGGAAATAGTGTTTATGGCCAAATACCAAACCTTATATTGCATGGTTGTAGCT Ad11.E1B-pIX.SEQ
 1143 TGGCATGTATTTTATGGCTAAACAATAGCTGATTTTATCATGGTTGTAGCT Ad7.E1B-pIX.SEQ

 1201 TTTTTGGTTTCAACAATACCTGTGTAGATGCCCTGGGGACAGGTTAGTGTA Ad35.E1B-pIX.SEQ
 1201 TTTTTGGTTTCAACAATACCTGTGTAGATGCCCTGGGGACAGGTTAGTGTA Ad11.E1B-pIX.SEQ
 1193 TTTTTGGGTTTAAATAATACTGTGTAGAAAGCTTGGGGGCAAGTTAGTGTA Ad7.E1B-pIX.SEQ

 1251 CGGGGGTGTTAGTTTCTATGCGTGTGGATTGCCACAGCTGGCAGAAACCAA Ad35.E1B-pIX.SEQ
 1251 CGGGGATGTAGTTTCTATGCGTGTGGATTGCCACAGCTGGCAGAAACCAA Ad11.E1B-pIX.SEQ
 1243 AGGGGTGTGTAGTTTCTATGCACTGGATTGCAACATCAGGTAGGGTGA Ad7.E1B-pIX.SEQ

 1301 GAGTCAATTGTCTCTGAAGAAATGCATATTCCAAAGATGTAACTGGGCA Ad35.E1B-pIX.SEQ
 1301 GAGTCAATTGTCTCTGAAGAAATGCATATTTCAAAGATGTAACTGGGCA Ad11.E1B-pIX.SEQ
 1293 GAGTCAATTGTCTCTGAAGAAATGCATGTTTGAAGATGTAACTTGGCA Ad7.E1B-pIX.SEQ

 1351 TTCTGAATGAAGGCCGAAGCAAGGGTCCGTCACCTGCGCTTCTACAGATACT Ad35.E1B-pIX.SEQ
 1351 TTCTGAATGAAGGCCGAAGCAAGGGTCCGCTCACCTGCGCTTCTACAGATACT Ad11.E1B-pIX.SEQ
 1343 TACTGAATGAAGGTTGAAGCAAGGGTCCGCTCACCTGCGCTACAGATACT Ad7.E1B-pIX.SEQ

 1401 GGATGTTTTATTTTAAATTAAGGGAAATGCCAGCGTAAAGCATAACATGAT Ad35.E1B-pIX.SEQ
 1401 GGATGTTTTATTTTGAATTAAGGGAAATGCCAGCGTAAAGCATAACATGAT Ad11.E1B-pIX.SEQ
 1393 GCGTGTCTTCTAATTAATTAAGGGAAATGCCAGTGTGAAGCATAATATGAT Ad7.E1B-pIX.SEQ

 1451 TTGTGGTGCTTCCGATGAGAGGCCCTTATCAAATGCTCACTTGTGCTGGTG Ad35.E1B-pIX.SEQ
 1451 TTGCGGTGCTTCCGATGAGAGGCCCTTATCAAATGCTCACTTGTGCTGGTG Ad11.E1B-pIX.SEQ
 1443 CTGTGGGACATTCGATGAGAGGCCCTTATCAATGCTAATCTGCGCTGGTG Ad7.E1B-pIX.SEQ

 1501 GGCATTGTAAATATGCTGGCTACTGTGCATATTGTTTCCCATCAACGC AAA Ad35.E1B-pIX.SEQ
 1501 GGCATTGTAAATATGCTGGCTACTGTGCATATTGTTTCCCATCAACGC AAA Ad11.E1B-pIX.SEQ
 1493 GACATTGCATAATATCTTGCTACTCGTGCTATCTGTTTCACTGACGC AAA Ad7.E1B-pIX.SEQ

 1551 AAAATGGCCTGTTTTTGTATCACAAATGTGTTGACCAAGTGCAACCATGCATGC Ad35.E1B-pIX.SEQ
 1551 AAAATGGCCTGTTTTTGTATCACAAATGTGTTGACCAAGTGTTACCATGCATGC Ad11.E1B-pIX.SEQ
 1543 AAAATGGCCTGTATTTGAACAATAATGTGTTTACCAAGTGCAACCATGCAT Ad7.E1B-pIX.SEQ

 1601 AGGTGGGCGTAGAGGAATGTTTATGCCTTACCAGTGTAACATGAATCATG Ad35.E1B-pIX.SEQ
 1601 AGGTGGGCGTAGAGGAATGTTTATGCCTTACCAGTGTAACATGAATCATG Ad11.E1B-pIX.SEQ
 1593 AGGTGGTCGACGGGAATGTTTATGCCTTACCAGTGTAACATGAATCATG Ad7.E1B-pIX.SEQ

Fig. 10, Cont'd

1651 T G A A A G T G T T G T T G G A A C C A G A T G C C T T T T C C A G A A T G A G C C T A A C A G G A Ad35.E1B-pIX.SEQ
 1651 T G A A A G T G T T G T T G G A A C C A G A T G C C T T T T C C A G A A T G A G C C T A A C A G G A Ad11.E1B-pIX.SEQ
 1643 T G A A G G T A T G T T G G A A C C A G A T G C C T T T T C C A G A G T G A G C T A A C A G G A Ad7.E1B-pIX.SEQ

 1701 A T C T T T G A C A T G A A C A C G C A A A T C T G G A A G A T C C T G A G G T A T G A T G A T A C Ad35.E1B-pIX.SEQ
 1701 A T T T T G A C A T G A A C A T G C A A A T C T G G A A G A T C C T G A G G T A T G A T G A T A C Ad11.E1B-pIX.SEQ
 1693 A T C T T T G A T A T G A A T A T T C A A C T A T G G A A G A T C C T G A G A T A T G A T G A C A C Ad7.E1B-pIX.SEQ

 1751 G A G A T C G A G G G T G C G C G C A T G C G A A T G C G G A G G C A A G C A T G C C A G G T T C C Ad35.E1B-pIX.SEQ
 1751 G A G A T C G A G G G T A C G C G C A T G C G A A T G C G G A G G C A A G C A T G C C A G G T T C C Ad11.E1B-pIX.SEQ
 1743 T A A A C A A G G G T G C G C G C A T G C G A A T G C G G A G G C A A G C A T G C T A G A T T C C Ad7.E1B-pIX.SEQ

 1801 A G C C G G T G T G T G T A G A T G T G A C C G A A G A T C T C A G A C C G G A T C A T T T G G T T Ad35.E1B-pIX.SEQ
 1801 A G C C G G T G T G T G T A G A T G T G A C T G A A G A T C T C A G A C C G G A T C A T T T G G T T Ad11.E1B-pIX.SEQ
 1793 A G C C G G T G T G C T G T G A T G T G A C T G A A G A C C T G A G C C C G A T C A T T T G G T G Ad7.E1B-pIX.SEQ

 1851 A T T G C C C G C A C T G G A G C A G A G T T C G G A T C C A G T G G A G A A G A A A C T G A C T A Ad35.E1B-pIX.SEQ
 1851 A T T G C C C G C A C T G G A G C A G A G T T C G G A T C C A G T G G A G A A G A A A C T G A C T A Ad11.E1B-pIX.SEQ
 1843 C T T G C C T G C A C T G G A G C G G A G T T C G G T T C T A G T G G T G A A G A A A C T G A C T A Ad7.E1B-pIX.SEQ

 1901 A G G T G A G T A T T G G G A - - A A A C T T T G G G G T G G G A T T T T C A G - - - - - A Ad35.E1B-pIX.SEQ
 1901 A G G T G A G T A T T G G G A - - A A A C T T T G G G G T G G G A T T T T C A G - - - - - A Ad11.E1B-pIX.SEQ
 1893 A A G T A A G T A G T G G G G G C A A A A T G T G A T G G G A C T T T T C A G G T T G G T A A G G Ad7.E1B-pIX.SEQ

 1940 T G G A C A G A T T G A G T A A A A A T T T G T T T T T C T G T C T T G C A G C T G A C A T G A G Ad35.E1B-pIX.SEQ
 1940 T G G A C A G A T T G A G T A A A A A T T T G T T T T T C T G T C T T G C A G C T G T C A T G A G Ad11.E1B-pIX.SEQ
 1943 T G G A C A A A T T G G T A A A T T T G T T A A T T T C T G T C T T G C A G C T G C A T G A G Ad7.E1B-pIX.SEQ

 1990 T G G A A A T G C T T C T T T T A A G G G G G G A G T C T T C A G C C C T T A T C T G A C A G G G C Ad35.E1B-pIX.SEQ
 1990 T G G A A A C G C T T C T T T T A A G G G G G G A G T C T T C A G C C C T T A T C T G A C A G G G C Ad11.E1B-pIX.SEQ
 1993 T G G A A G C T T C T T T T G A G G G G G G A G T A T T T A G C C C T T A T C T G A C G G G C A Ad7.E1B-pIX.SEQ

 2040 G T C T C C C A T C C T G G G C A G G A G T T C G T C A G A A T G T T A T G G G A T C T A C T G T G Ad35.E1B-pIX.SEQ
 2040 G T C T C C C A T C C T G G G C A G G A G T T C G T C A G A A T G T T A T G G G A T C T A C T G T G Ad11.E1B-pIX.SEQ
 2043 G C T C C C A C C A T G G G C A G G A G T T C G T C A G A A T G T C A T G G G A T C A C T G T G Ad7.E1B-pIX.SEQ

 2090 G A T G G A A G A C C C G T T C A A C C C G C C A A T T C T T C A A C G C T G A C C T A T G C T A C Ad35.E1B-pIX.SEQ
 2090 G A T G G A A G A C C C G T T C A A C C C G C C A A T T C T T C A A C G C T G A C C T A T G C T A C Ad11.E1B-pIX.SEQ
 2093 G A T G G A G A C C C G T C A A C C C G C C A A T T C T C A A C G C T G A C C T A T G C C A C Ad7.E1B-pIX.SEQ

 2140 T T T A A G T T C T T C A C C T T T G G A C G C A G C T G C A G C C G C T G C C G C C G C C T C T G Ad35.E1B-pIX.SEQ
 2140 T T T A A G T T C T T C A C C T T T G G A C G C A G C T G C A G C T G C C G C C G C C T T C T G Ad11.E1B-pIX.SEQ
 2143 T T T G A G T T C G T C A C C A T T G G A T G C A G C T G C A G C C G C C G C C G C C T A C - - - T G Ad7.E1B-pIX.SEQ

Fig. 10, Cont'd

```

2190 TCGCCGCTAACACTGTGCTTGGGAATGGGTTACTATGGGAAGCATCGTGGCT Ad35.E1B-pIX.SEQ
2190 TTTGCCGCTAACACTGTGCTTGGGAATGGGTTACTATGGGAAGCATCA TGGCT Ad11.E1B-pIX.SEQ
2190 CTGCCGC[A]AACAC[CA]T[C]CTTGGGAATGGG[CTA]TTA[CGGAAGCAT]TG TGC Ad7.E1B-pIX.SEQ

2240 AATTCCACTTCCTCTAATAAACCCCTTCTACACTGACTCAGGACAAGTTACT Ad35.E1B-pIX.SEQ
2240 AATTCCACTTCCTCTAATAAACCCCTTCTAC[CTGACTCAGGACAAGTTACT Ad11.E1B-pIX.SEQ
2240 AATTCCA[G]TTCCTCTAATAAA[T]CCTTCA[AC]CTG[CT]GAGGACAAG[CT]ACT Ad7.E1B-pIX.SEQ

2290 TGTCCTTTTTGGCCCGAGCTGGAGGCTTTGACCCAACGTCCTGGGTGAAC TTT Ad35.E1B-pIX.SEQ
2290 TGTCCTTTTTGGCCCGAGCTGGAGGCTTTGACCCAACGTCCTGGGTGAAC TTT Ad11.E1B-pIX.SEQ
2290 TGT[T]CT[CT]TTGGC[T]CAGCT[C]GAGGC[CT]T[A]ACCCAACG[CT]T[A]G[C]GAAC T[GT] Ad7.E1B-pIX.SEQ

2340 CTCAGCAGGTGGCCGAGTTGCGAGTACAAACTGAGTCTGCTGTCTGGCACG Ad35.E1B-pIX.SEQ
2340 CTCAGCAGGTGG[T]CGAGTTGCGAGTACAAACTGAGTCTGCTGTCTGGCACG Ad11.E1B-pIX.SEQ
2340 CT[A]AGCAGGTGGCC[C]AGTTGCG[TG][AG]CAAACTGAGTCTGCTGT[TG][C]ACA[A] Ad7.E1B-pIX.SEQ

2390 GCAAAGTCTAAATAAAAAAATTCAGAAATCAATGAATAAA Ad35.E1B-pIX.SEQ
2390 GCAAAGTCTAAATAAAAAA[T]T[CC]CAGAAATCAATGAATAAA Ad11.E1B-pIX.SEQ
2390 GCAAAGTCTAAATAAA[G]A[---]T[C]TCA[---]AATCAAT[A]AATAAA Ad7.E1B-pIX.SEQ

```

Decoration 'Decoration #1': Box residues that differ from Ad35.E1B-pIX.SEQ.

Fig. 11




Fig. 12





FIG. 13 Generation of E1-deleted Ad35 vectors via double homologous recombination in PER.C6 cells



Transfection of three
Plasmids in PER.C6




Fig. 14




Fig. 15





Fig. 16



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5994128 A [0005] [0034] [0034]
- WO 0070071 A [0007] [0007] [0023] [0026] [0033] [0035] [0035] [0039] [0040] [0040] [0046] [0049] [0051] [0053] [0056] [0057] [0058] [0061] [0070] [0072] [0072] [0075] [0076] [0077] [0079] [0088] [0088] [0098] [0100] [0101] [0102]
- WO 0224730 A [0007] [0033] [0035]
- EP 0350125 W, Crucell Holland B.V. [0008]
- WO 03104467 A [0008] [0102]
- WO 0240665 A [0026] [0082] [0087] [0087] [0088] [0088] [0100] [0102]
- EP 0978566 A [0033] [0033]
- EP 96022940 A [0034]
- WO 0138362 A [0035]
- WO 9938362 A [0035]
- WO 9955132 A [0039] [0088]
- WO 0224933 A [0040]
- EP 1054064 A [0046]
- WO 02053759 A [0098]
- EP 02102631 A [0105]
- NL 0200281 W [0105]
- NL 0200656 W [0105]

Non-patent literature cited in the description

- **ABRAHAMSEN K ; KONG H-L ; MASTRANGELI A ; BROUGH D ; LIZONOVA A ; CRYSTAL R ; FALCK-PEDERSEN E.** Construction of an adenovirus type 7a E1A- vector. *J Virol*, 1997, vol. 11, 8946-8951 [0104]
- **BABISS, L.E. ; VALES, L.D.** Promoter of the adenoviral polypeptide IX gene: Similarity to E1B and inactivation by substitution of the simian virus TATA element. *J. Virol.*, 1991, vol. 65 (2), 598-605 [0104]
- **BETT, A.J. ; PREVEC, L. ; GRAHAM, F.L.** Packaging capacity and stability of human adenovirus type 5 vectors. *J. Virol.*, 1993, vol. 67 (10), 5911-5921 [0104]
- **BOSHART, M. ; WEBER, F. ; JAHN, G. ; DORSCH-HASLER, K. ; FLECKENSTEIN B. ; SCHAFFNER W.** A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell*, 1985, vol. 41, 521-530 [0104]
- **CARAVOKYRI, C. ; LEPPARD, K.N.** Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. *J. Virol.*, 1995, vol. 69 (11), 6627-6633 [0104]
- **FALLAUX, F.J. ; KRANENBURG, O. ; CRAMER, S.J. ; HOUWELING, A. ; VAN ORMONDT, H. ; HOEBEN, R.C. ; VAN DER EB, A.J.** Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. *Hum. Gene Ther.*, 1996, vol. 7, 215-222 [0104]
- **FALLAUX, F.J. ; BOUT, A. ; VAN DER VELDE, I. ; VAN DEN WOLLENBERG, D.J. ; HEHIR, K.M. ; KEEGAN, J. ; AUGER, C. ; CRAMER, S.J. ; VAN ORMONDT, H. ; VAN DER EB, A.J.** New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. *Hum. Gene Ther.*, 1998, vol. 9, 1909-1917 [0104]
- **FARINA, S.F. ; GAO, G.P. ; XIANG, Z.Q. ; RUX, J.J. ; BURNETT, R.M. ; ALVIRA, M.R. ; MARSH, J. ; ERTL, H.C. ; WILSON, J.M.** Replication-defective vector based on a chimpanzee adenovirus. *J. Virol.*, 2001, vol. 75 (23), 11603-11613 [0104]
- **FRANCKI, R.I.B. ; FAUQUET, C.M. ; KNUDSON, L. ; BROWN, F.** Classification and nomenclature of viruses. Fifth report of the international committee on taxonomy of viruses. *Arch. Virol. Suppl.*, 1991, vol. 2, 140-144 [0104]
- **FURCINITTI, P.S. ; VAN OOSTROM, J. ; BURNETT R.M.** Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. *EMBO J.*, 1989, vol. 8 (12), 3563-3570 [0104]
- **GRAHAM, F.O. ; SMILEY, J. ; RUSSELL, W. ; NAIRN, R.** Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen. Virol.*, 1970, vol. 36, 59-72 [0104]
- **GHOSH-CHOUDHURY, G. ; HAJ-AHMAD, Y. ; GRAHAM, F.L.** Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. *EMBO J.*, 1987, vol. 6 (6), 1733-1739 [0104]

- **HEHIR, K.M. ; ARMENTANO, D. ; CARDOZA, L.M. ; CHOQUETTE, T.L. ; BERTHELETTE, P.B. ; WHITE, G.A. ; COUTURE, L.A. ; EVERTON, M.B. ; KEEGAN, J. ; MARTIN, J.M.** Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. *J. Virol.*, 1996, vol. 70 (12), 8459-8467 [0104]
- **HERRMAN, C.H. ; MATHEWS, M.B.** The adenovirus E1B 19-kilodalton protein stimulates gene expression by increasing DNA levels. *Mol. Cell. Biol.*, 1989, vol. 9, 5412-5423 [0104]
- **LUTZ, P. ; ROSA-CALATRAVA, M. ; KEDINGER, C.** The product of the adenovirus intermediate gene IX is a transcriptional activator. *J. Virol.*, 1997, vol. 71 (7), 5102-5109 [0104]
- **PILDER, S. ; LOGAN, J. ; SHENK, T.** Deletion of the gene encoding the adenovirus type 5 early region 1B 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. *J. Virol.*, 1984, vol. 52 (2), 664-671 [0104]
- **PILDER, S. ; MOORE, M. ; LOGAN, J. ; SHENK, T.** The adenovirus E1B 55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. *Mol. Cell. Biol.*, 1986, vol. 6, 470-476 [0104]
- **RAO, L. ; DEBBAS, M. ; SABBATINI, P. ; HOCKENBERY, D. ; KORSMEYER, S. ; WHITE, E.** The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 7742-7746 [0104]
- **REESE, M.G. ; EECKMAN, F.H.** Novel neural network algorithms for improved eukaryotic promoter site recognition. Talk and Abstract from The seventh international genome sequencing and analysis conference. *Hyatt Regency*, 16 September 1995, http://www.fruitfly.org/seq_tools/promoter.html [0104]
- **ROBERT, J.-J. ; GAUFFENY, I. ; MACCARIO, J. ; JULLIEN, C. ; BENOIT, P. ; VIGNE, E. ; CROUZET, J. ; PERRICAUDET, M. ; YEH, P.** Degenerated pIX-IVa2 adenoviral vector sequences lowers reacquisition of the E1 genes during virus amplification in 293 cells. *Gene Ther.*, 2001, vol. 8, 1713-1720 [0104]
- **RUSSELL, W.C.** Update on adenoviruses and its vectors. *J. Gen. Virol.*, 2000, vol. 81, 2573-2604 [0104]
- **SAMBROOK, J. ; RUSSELL, D.** Molecular Cloning: A laboratory manual. Cold Spring Harbor Press, 2001 [0104]
- **SHABRAM, P.W. ; GIROUX, D.D. ; GOUDREAU, A.M. ; GREGORY, R.J. ; HORN, M.T. ; HUYGHE, B.G. ; LIU, X. ; NUNNALLY, M.H. ; SUGARMAN, B.J. ; SUTJIPTO, S.** Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. *Hum. Gene Ther.*, 1997, vol. 8 (4), 453-465 [0104]
- **Adenoviridae: The viruses and their replication. SHENK, T.** Virology. Lippincott-Raven, 1996, vol. 2, 2111-2148 [0104]
- **WHITE, E. ; GRODZICKER, T. ; STILLMAN, B.W.** Mutations in the gene encoding the adenovirus early region 1B 19,000 molecular-weight tumor antigen cause degradation of chromosomal DNA. *J. Virol.*, 1984, vol. 52 (2), 410-419 [0104]
- **YEW, P.R. ; BERK, A.J.** Inhibition of p53 transactivation required for transformation by adenovirus early region 1B protein. *Nature*, 1992, vol. 357, 82-85 [0104]